Bicyclic therapeutic compounds and methods of use in the treatment of cancer - Patents.com
Bicyclic compounds targeting YAP/TAZ-TEAD interactions and KRAS signaling provide a solution to overcome resistance in cancer treatments, effectively inhibiting cancer cell growth and modulating TEAD activity.
Patent Information
- Application Number
- JP2024531256
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-05-19
- Filing Date
- 2022-11-21
- Publication Date
- 2024-11-26
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current treatments for cancers associated with dysregulation of the Hippo signaling pathway, particularly those involving YAP/TAZ and TEAD, face challenges due to resistance mechanisms when targeting Ras, necessitating improved inhibitors for effective cancer therapy.
Development of bicyclic therapeutic compounds that inhibit YAP/TAZ-TEAD protein-protein interactions and KRAS signaling, potentially combined with KRAS inhibitors, to target and modulate TEAD activity, thereby treating cancers with altered Hippo pathway function.
These compounds demonstrate significant inhibition of cancer cell growth, including resistance to KRAS inhibitors, by effectively targeting YAP/TAZ-TEAD interactions, offering a novel approach to cancer therapy.
Smart Images

Figure 2024543912000001_ABST
Abstract
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to and the benefit of U.S. Provisional Patent Application No. 63 / 283,119, filed November 24, 2021, and U.S. Provisional Patent Application No. 63 / 344,027, filed May 19, 2022, the disclosures of which are incorporated herein by reference in their entireties. Electronic sequence listing submission
[0002] The contents of the electronic sequence listing (file name: 146392059040SeqList.xml, creation date: November 17, 2022, size: 20,029 bytes) are incorporated herein by reference in their entirety. [Technical Field]
[0003] The present disclosure relates to compounds useful as inhibitors of TEAD, useful for therapy and / or prophylaxis in mammals, particularly useful for treating cancer. [Background technology]
[0004] The Hippo pathway is a signaling pathway that regulates cell proliferation and cell death and determines organ size. It is believed to play a role as a tumor suppressor in mammals, and disorders of this pathway are often detected in human cancers. This pathway is involved in and / or can regulate the self-renewal and differentiation of stem and progenitor cells. Additionally, the Hippo pathway may be involved in wound healing and tissue regeneration. Furthermore, the Hippo pathway interacts with other signaling pathways, such as Wnt, Notch, Hedgehog, and MAPK / ERK, which may affect a wide variety of biological events. It is believed that dysfunction of the Hippo pathway could be involved in many human diseases in addition to cancer. For reviews, see, e.g., Halder et al., 2011, Development 138:9-22; Zhao et al., 2011, Nature Cell Biology 13:877-883; Bao et al., 2011, J. Biochem. 149:361-379; Zhao at al., 2010, J. Cell Sci. 123:4001-4006.
[0005] The Hippo signaling pathway is conserved from Drosophila to mammals (Vassilev et al., Genes and Development, 2001, 15, 1229-1241; Zeng and Hong, Cancer Cell, 2008, 13, 188-192). The core of the pathway consists of a cascade of kinases (Hippo-MST1-2 is upstream of Lats1-2 and NDRI-2) that lead to the phosphorylation of two transcriptional coactivators, YAP (Yes-Associated Protein) and TAZ (transcriptional coactivator with a PDZ-binding motif or tafazzin; Zhao et al., Cancer Res., 2009, 69, 1089-1098; Lei et al., Mol. Cell. Biol., 2008, 28, 2426-2436).
[0006] The Hippo signaling pathway is involved in cancer development because it regulates animal development, organ size control, and stem cell regulation (reviewed in Harvey et al., Nat. Rev. Cancer, 2013, 13, 246-257; Zhao et al., Genes Dev., 2010, 24, 862-874). In vitro, overexpression of YAP or TAZ in breast epithelial cells induces cell transformation through the interaction of both proteins with the TEAD family of transcription factors. Elevated YAP / TAZ transcriptional activity has been shown to induce oncogenic properties, such as epithelial-mesenchymal transition, and confer stem cell properties to breast cancer cells. In vivo, overexpression of YAP or gene knockout of its upstream regulators MST1-2 in mouse liver leads to the development of hepatocellular carcinoma (HCC). Furthermore, when the tumor suppressor NF2 is inactivated in mouse liver, HCC development can be completely blocked by co-inactivation of YAP.
[0007] Deregulation of the Hippo tumor suppressor pathway has been shown to be a key factor in lung cancer (NSCLC; Zhou et al., Oncogene, 2011, 30, 2181-2186; Wang et al., Cancer Sci., 2010, 101, 1279-1285), breast cancer (Chan et al., Cancer Res., 2008, 68, 2592-2598; Lamar et al., Proc. Natl. Acad. Sci, USA, 2012; 109, E2441-E2250; Wang et al., Eur. J. Cancer, 2012, 48, 1227-1234), and head and neck cancer (Gasparotto et al., Oncotarget., 2011, 2, 1165-1175; Steinmann et al. al.,Oncol.Rep.,2009,22,1519-1526), colon cancer (Angela et al.,Hum. Pathol.,2008,39,1582-1589;Yuen et al.,PLoS One,2013,8,e54211;Avruch et al.,Cell Cycle,2012,11,1090-1096), ovarian cancer (Angela et al.,Hum. Pathol.,2008,39,1582-1589;Chad et al.,Cancer Res.,2010,70,8517-8525;Hall et al.,Cancer Res.,2010,70,8517-8525), liver cancer (Jie et al. al.,Gastroenterol.Res.Pract.,2013,2013,187070;Ahn et al.,Mol.Cancer.Res.,2013,11,748-758;Liu et al.,Expert.Opin.Ther.Targets,2012,16,243-247), brain cancer (Orr et al.,J Neuropathol.Exp.Neurol.2011,70,568-577;Baia et al.,Mol.Cancer Res.,2012,10,904-913;Striedinger et al.,Neoplasia,2008,10,1204-1212) and prostate cancer (Zhao et al.,Genes Dev.,2012,26,54-68;Zhao et al.,Genes Dev.,2007,21,2747-2761), mesothelioma (Fujii et al.,J.Exp.Med.,2012,209,479-494; Mizuno et al.,Oncogene,2012,31,5117-5122; Sekido Y.,Pathol.Int.,2011,61,331-344), sarcoma (Seidel et al.,Mol.Carcinog.,2007,46,865-871), and leukemia (Jimenez-Velasco et al.,Leukemia,2005,19,2347-2350).
[0008] Two of the core components of the mammalian Hippo pathway are the nuclear Dbf2-related (NDR) family protein kinases Lats1 and Lats2, which are homologous to the Drosophila Warts (Wts) kinase. Lats1 / 2 proteins are activated by association with the scaffolding protein Mob1A / B (Mps1 binder kinase activator-like 1A and 1B), which is homologous to the Drosophila Mats protein. Lats1 / 2 proteins are also activated by phosphorylation by the STE20 family protein kinases Mst1 and Mst2, which are homologous to Drosophila Hippo. Lats1 / 2 kinases phosphorylate the downstream effectors YAP (Yes-associated protein) and TAZ (transcriptional coactivator with PDZ-binding motifs; WWTR1), which are homologous to Drosophila Yorkie. Phosphorylation of YAP and TAZ by Lats1 / 2 is a key event in the Hippo signaling pathway. Lats1 / 2 phosphorylates YAP at multiple sites, with Ser127 phosphorylation being critical for YAP inhibition. YAP phosphorylation creates a protein-binding motif for 14-3-3 family proteins, and binding of 14-3-3 proteins leads to cytoplasmic retention and / or sequestration of YAP. Similarly, Lats1 / 2 phosphorylates TAZ at multiple sites, with Ser89 phosphorylation being critical for TAZ inhibition. TAZ phosphorylation leads to cytoplasmic retention and / or sequestration of TAZ. Furthermore, phosphorylation of YAP and TAZ is thought to destabilize these proteins by activating phosphorylation-dependent degradation catalyzed by YAP or TAZ ubiquitination. Therefore, when the Hippo pathway is "on," YAP and / or TAZ are phosphorylated, inactive, and generally trapped in the cytoplasm. In contrast, when the Hippo pathway is "off," YAP and / or TAZ are unphosphorylated, active, and generally found in the nucleus.
[0009] Unphosphorylated, active YAP translocates into the cell nucleus, where its primary target transcription factors are the four proteins in the TEAD domain-containing family (TEAD1-TEAD4, collectively referred to as "TEAD"). YAP, together with other transcription factors such as Smad1, RUNX, ErbB4, and p73, has been shown to induce the expression of various genes, including connective tissue growth factor (CTGF), Gli2, Birc5, Birc2, fibroblast growth factor 1 (FGF1), and amphiregulin (AREG). Similar to YAP, unphosphorylated TAZ translocates into the cell nucleus, where it interacts with multiple DNA-binding transcription factors, including peroxisome proliferator-activated receptor γ (PPARγ), thyroid transcription factor-1 (TTF-1), Pax3, TBX5, RUNX, TEAD1, and Smad2 / 3 / 4. Many of the genes activated by the YAP / TAZ-transcription factor complex mediate cell survival and proliferation. Therefore, under some conditions, YAP and / or TAZ act as oncogenes and the Hippo signaling pathway acts as a tumor suppressor. Therefore, pharmacological targeting of the Hippo cascade via inhibition of TEADs may be an important approach for the treatment of cancers with functional alterations of this pathway.
[0010] Ras is a small GTP-binding protein that functions as a nucleotide-dependent switch in central growth signaling pathways. In response to extracellular signals, Ras undergoes GDP-bound (Ras) exchange, catalyzed by guanine nucleotide exchange factors (GEFs), particularly the SOS1 protein. GDP ) state to GTP-bound (Ras GTP ) state. Active Ras GTP Ras mediates its diverse growth-stimulatory functions through direct interaction with effectors, including Raf, PI3K, and the Ral guanine nucleotide dissociation stimulator. The intrinsic GTPase activity of Ras then hydrolyzes GTP to GDP, terminating Ras signaling. Ras GTPase activity can be further accelerated by interaction with GTPase-activating proteins (GAPs), including the neurofibromin 1 tumor suppressor.
[0011] Mutant Ras has reduced GTPase activity, which sustains the activated form of Ras, thereby promoting Ras-dependent signaling and cancer cell survival or proliferation. Mutations in Ras that affect its ability to interact with GAPs or convert GTP back to GDP result in sustained activation of the protein, resulting in sustained signals that promote continued growth and division. Because these signals lead to cell growth and division, overactive RAS signaling can ultimately lead to cancer. Mutations in any one of the three major RAS isoforms (H-Ras, N-Ras, or K-Ras) are common events in human tumorigenesis. Of the three Ras isoforms (K, N, and H), K-Ras is the most frequently mutated.
[0012] The most common K-Ras (or KRAS) mutations are found at residues G12 and G13 in the P-loop and at residue Q61. G12C is a frequently observed mutation in the K-Ras gene (glycine-12 to cysteine). G12C is a single point mutation with a glycine to cysteine substitution at codon 12. This substitution promotes an activated state of KRAS and amplifies the signaling pathway that leads to oncogenesis (see, e.g., Hallin et al. (Cancer Discov, 2020, 10(1):54-71), Skoulidis et al. (N. Engl. J. Med., 2021, 384(25):2371-2381), and Hong et al. (N. Engl. J. Med., 2020, 383(13):1207-1217)). G12D, G12V, and G13D are other common mutations. Ras mutations in cancer are associated with poor prognosis.
[0013] Inactivation of oncogenic Ras in mice results in tumor regression. Therefore, Ras is widely considered an exceptionally important oncological target. However, treatment with Ras inhibitors (e.g., KRAS) can result in resistance due to bypass of the KRAS / MAPK pathway and activation of the Hippo pathway.
[0014] Thus, there is a need for therapies that improve the ability of inhibitors of Ras (e.g., KRAS) and inhibitors of YAP, TAZ, TEAD and / or YAP:TEAD protein-protein interactions to treat various diseases, disorders and conditions, including cancer. Summary of the Invention
[0015] In some embodiments, the compound of formula (II-AB'): TIFF2024543912000002.tif27170, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein: L' is *-N(R 3 )-L-** or TIFF2024543912000003.tif22170In the formula, * indicates the point of attachment to Z, and ** indicates TIFF2024543912000004.tif27170X 1 is C or N, and X 1 is R 1 and together with the atom to which they are attached, a 5- to 6-membered heteroaryl, a 5- to 6-membered heterocyclyl, a phenyl, or C fused to ring A 5-6 Forming a cycloalkyl; X 1 and R 1 5- to 6-membered heteroaryl, 5- to 6-membered heterocyclyl, phenyl, and C 5-6 Cycloalkyl may each independently be one or more R t and optionally substituted with R t independently, in each occurrence, halo, C 1-15 Alkyl, HaloC 1-15 Alkyl, C 6-20Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e selected from the group consisting of: In the formula, R d and R e are each independently H or C 1-6 alkyl, and R d or R e C 1-6 The alkyl is optionally substituted with one or more substituents selected from halo, oxo, —OH and —CN; X 2 is N or CR s where R s H, halo, C 1-15 Alkyl, Hydroxyl C 1-6 Alkynyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3- to 15-membered heterocyclyl, -OH, -CN, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -S(O)NHR d , -SO2NR d R e , -NR d SO2R e , and -NR d R e Selected from; In the formula, R s C 1-15 Alkyl and C 1-15 The alkoxy may each independently be one or more R t1wherein R t1 is independently in each occurrence halo, oxo, —OH, —CN, 5- to 6-membered heteroaryl, or —NR d R e where R d and R e are each independently H or C 1-6 alkyl, where R d or R e C 1-6 The alkyl is optionally substituted with one or more substituents selected from halo, oxo, —OH, and —CN; and In the formula, R s C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 The cycloalkyl and 3- to 15-membered heterocyclyl each independently represent one or more R t2 wherein R t2 is independently in each occurrence halo, oxo, —OH, —CN, and C 1-6 alkyl; and In the formula, R d and R e are each independently H or C 1-6 alkyl, and R d or R e C 1-6 The alkyl is optionally substituted with one or more substituents selected from halo, oxo, —OH and —CN; X 3 is N or CH; B is i) phenyl or 5- to 6-membered heteroaryl; the phenyl and 5- to 6-membered heteroaryl of B are each independently one or more R 2 is replaced by In the formula, R 2 independently, in each occurrence, halo;S(R y ) 5, wherein each R y is halo; or C optionally substituted with one or more halo 1-6 is alkoxy; or ii) Halo C 1-3alkyl-substituted -O-phenyl (provided that B is haloC 1-3 When L' is -O-phenyl substituted with alkyl, L' is -N(R 3 )-L-**, Z is -C(O)CHCH2, and X 1 is C and X 2 is CR s and X 3 is CH); or iii) C 1-3 Is it an alkyl-substituted bicyclopentane (provided B is C)? 1-3 If it is an alkyl-substituted bicyclopentane, L' is *-N(R 3 )-L-**, provided that Z is —C(O)CHCH2; or iv) ethynyl or haloC 1-3 alkyl-substituted phenyl (provided that B is ethynyl or haloC 1-3 When L' is phenyl substituted with alkyl, L' is -N(R 3 )-L-**, Z is -C(O)CHCH2, and R s is C substituted with one or more -OH 1-3 provided that it is alkyl); or v) Halo C 1-3 Alkyl or haloC 1-3 alkoxy-substituted piperidine, provided that B is haloC 1-3 Alkyl or haloC 1-3 When L' is an alkoxy-substituted piperidine, L' is -N(R 3 )-L-** and Z is -C(O)CHCH2); R 3 is H or C 1-6 is alkyl; Z is -OH, -NR d R e , C 1-6 Alkoxy, -C(O)R a , or -S(O)R b and In the formula, R d and R e are each independently H or C1-6 alkyl, and R d or R e C 1-6 The alkyl is optionally substituted with one or more substituents selected from halo, oxo, —OH and —CN; R a and R b are each independently: i) deuterium, C 1-6 Alkyl, Hydroxyl C 1-6 Alkyl, halo and haloC 1-6 C optionally substituted with one or more substituents selected from alkyl 2-6 alkenyl; ii) C optionally substituted with one or more halo 1-6 alkyl; or iii) cyclobutenyl or bicyclobutanyl; L is methylene or ethylene, and the methylene of L is one C 1-6 optionally substituted with alkyl; Y is CH or C(CN), and n and m are each independently 1 or 2; However, subject to the following conditions: i)i-1)X 1 R 1 and together with the atom to which they are attached form a phenyl, i-2) X 2 or X 3 is N, B in formula (II-AB') is phenyl, and R 2 Halo C 1-6 being alkoxyl; and ii) when n=1 and m=2, or when n=2 and m=1, B is phenyl substituted with halomethyloxyl; and iii) The compound of formula (II-AB') is not any of the following: N-((8-(4-fluorophenyl)imidazo[1,2-a]pyrazin-6-yl)methyl)acrylamide; N-((8-(4-(trifluoromethoxy)phenyl)imidazo[1,2-a]pyrazin-6-yl)methyl)acrylamide; N-((7-fluoro-4-(4-(trifluoromethoxy)phenyl)quinazolin-2-yl)methyl)acrylamide; N-((8-(4-(difluoromethoxy)phenyl)imidazo[1,2-a]pyrazin-6-yl)methyl)acrylamide; 1-(4-(4-(4-methoxyphenyl)-1-methyl-1H-imidazo[4,5-c]pyridin-6-yl)piperidin-1-yl)ethan-1-one; 4-(4-Methoxyphenyl)-1-methyl-6-(1-(methylsulfonyl)piperidin-4-yl)-1H-imidazo[4,5-c]pyridine; 6-(1-(ethylsulfonyl)piperidin-4-yl)-4-(4-methoxyphenyl)-1-methyl-1H-imidazo[4,5-c]pyridine; 6-(1-(ethylsulfonyl)piperidin-4-yl)-1-isopropyl-4-(4-methoxyphenyl)-1H-imidazo[4,5-c]pyridine; 4-(4-methoxyphenyl)-1-methyl-6-(1-((trifluoromethyl)sulfonyl)piperidin-4-yl)-1H-imidazo[4,5-c]pyridine; and N-((4-(4-fluorophenyl)-1,8-naphthyridin-2-yl)methyl)acetamide.
[0016] In some embodiments, the compound of formula (II-AB): TIFF2024543912000005.tif27170, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, is provided, wherein: L' is TIFF2024543912000006.tif17170, wherein * indicates the point of attachment to Z and ** indicates TIFF2024543912000007.tif27170 indicates the junction point; X 1 is C or N, and X 1 is R 1and together with the atom to which they are attached, a 5- to 6-membered heteroaryl, a 5- to 6-membered heterocyclyl, a phenyl, or C fused to ring A 5-6 Forming a cycloalkyl; X 1 and R 1 5- to 6-membered heteroaryl, 5- to 6-membered heterocyclyl, phenyl, and C 5-6 Cycloalkyl may each independently be one or more R t optionally substituted with R t independently, in each occurrence, halo, C 1-15 Alkyl, HaloC 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e selected from the group consisting of: In the formula, R d and R e are each independently H or C 1-6 alkyl, and R d or R e C 1-6 The alkyl is optionally substituted with one or more substituents selected from halo, oxo, —OH and —CN; X 2 is N or CR s where R s H, halo, C 1-15 Alkyl, Hydroxyl C 1-6 Alkynyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3- to 15-membered heterocyclyl, -OH, -CN, C 1-15 Alkoxy, -NRd COR e , -CONR d R e , -SO2R d , -S(O)NHR d , -SO2NR d R e , -NR d SO2R e , and -NR d R e Selected from; In the formula, R s C 1-15 Alkyl and C 1-15 The alkoxy may each independently be one or more R t1 wherein R t1 is independently in each occurrence halo, oxo, —OH, —CN, 5- to 6-membered heteroaryl, or —NR d R e where R d and R e are each independently H or C 1-6 alkyl, where R d or R e C 1-6 The alkyl is optionally substituted with one or more substituents selected from halo, oxo, —OH, and —CN; and In the formula, R s C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 The cycloalkyl and 3- to 15-membered heterocyclyl each independently represent one or more R t2 wherein R t2 is independently in each occurrence halo, oxo, —OH, —CN, and C 1-6 alkyl; and In the formula, R d and R e are each independently H or C 1-6 alkyl, and R d or R e C 1-6 The alkyl is optionally substituted with one or more substituents selected from halo, oxo, —OH and —CN; X3 is N or CH; B is phenyl or 5- to 6-membered heteroaryl; the phenyl and 5- to 6-membered heteroaryl of B are each independently one or more R 2 and wherein R 2 independently, in each occurrence, halo;S(R y ) 5, wherein each R y is halo; or C optionally substituted with one or more halo 1-6 Is it alkoxy; R 3 is H or C 1-6 is alkyl; Z is -OH, -NR d R e , C 1-6 Alkoxy, -C(O)R a , or -S(O)R b and In the formula, R d and R e are each independently H or C 1-6 alkyl, and R d or R e C 1-6 The alkyl is optionally substituted with one or more substituents selected from halo, oxo, —OH and —CN; R a and R b are each independently: i) deuterium, C 1-6 Alkyl, Hydroxyl C 1-6 Alkyl, halo and haloC 1-6 C optionally substituted with one or more substituents selected from alkyl 2-6 alkenyl; or ii) C optionally substituted with one or more halo 1-6 is alkyl; L is one or more C 1-6 methylene optionally substituted with alkyl; and n and m are 1; or n and m are 2; However, 1) X 1 R 1 and together with the atom to which they are attached form phenyl, 2) X2 or X 3 is N, and 3) L' is TIFF2024543912000008.tif17170In formula (II-AB), B is phenyl, and R 2 Halo C 1-6 Provided that it is alkoxyl.
[0017] In some embodiments, the compound of formula (II-A) or (II-B): TIFF2024543912000009.tif59170, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein: X 1 is C or N, and X 1 is R 1 and together with the atom to which they are attached, a 5- to 6-membered heteroaryl, a 5- to 6-membered heterocyclyl, a phenyl, or C fused to ring A 5-6 Forming a cycloalkyl; X 1 and R 1 5- to 6-membered heteroaryl, 5- to 6-membered heterocyclyl, phenyl, and C 5-6 Cycloalkyl may each independently be one or more R t optionally substituted with R t independently, in each occurrence, halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e selected from the group consisting of: In the formula, R d and R eare each independently H or C 1-6 alkyl, and R d or R e C 1-6 The alkyl is optionally substituted with one or more substituents selected from halo, oxo, —OH and —CN; X 2 is N or CR s where R s H, halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e selected from the group consisting of: In the formula, R s C 1-15 Alkyl and C 1-15 The alkoxy may each independently be one or more R t1 wherein R t1 is independently in each occurrence halo, oxo, —OH, —CN, or —NR d R e where R d and R e are each independently H or C 1-6 is alkyl; and In the formula, R s C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 The cycloalkyl and 3- to 15-membered heterocyclyl each independently represent one or more R t2 wherein R t2 is independently in each occurrence halo, oxo, —OH, —CN, and C 1-6 alkyl; and R d and R e are each independently H or C 1-6 alkyl, and R d or R e C 1-6 The alkyl is optionally substituted with one or more substituents selected from halo, oxo, —OH and —CN; X 3 is N or CH; B is phenyl or 5- to 6-membered heteroaryl; the phenyl and 5- to 6-membered heteroaryl of B are each independently one or more R 2 and wherein R 2 independently, in each occurrence, halo;S(R y ) 5, wherein each R y is halo; or C optionally substituted with one or more halo 1-6 Is it alkoxy; R 3 is H or C 1-6 is alkyl; Z is -OH, -NR d R e , C 1-6 Alkoxy, -C(O)R a , or -S(O)R b and In the formula, R d and R e are each independently H or C 1-6 alkyl, and R d or R e C 1-6 The alkyl is optionally substituted with one or more substituents selected from halo, oxo, —OH and —CN; R a and R b are each independently: i) deuterium, C 1-6 Alkyl, halo and haloC 1-6 C optionally substituted with one or more substituents selected from alkyl 2-6 alkenyl; or ii) C optionally substituted with one or more halo 1-6 is alkyl; L is one or more C 1-6 methylene optionally substituted with alkyl; and n and m are each independently 1 or 2.
[0018] In some embodiments, a pharmaceutical composition is provided comprising a compound of Formula (II-A) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient.
[0019] In some embodiments, a pharmaceutical composition is provided comprising a compound of Formula (II-B) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient.
[0020] In some embodiments, a pharmaceutical composition is provided comprising a compound of Formula (II-AB) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient.
[0021] In some embodiments, a pharmaceutical composition is provided comprising a compound of formula (II-AB') or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient.
[0022] In some embodiments, a compound of Formula (II-A) or Formula (II-B) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof is provided for use in medical therapy.
[0023] In some embodiments, compounds of formula (II-AB) or stereoisomers, tautomers or pharmaceutically acceptable salts thereof are provided for use in medical therapy.
[0024] In some embodiments, a compound of formula (II-AB') or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof is provided for use in medical therapy.
[0025] In some embodiments, compounds of Formula (II-A) or Formula (II-B), or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, are provided for the treatment or prevention of cancer.
[0026] In some embodiments, compounds of formula (II-AB) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof are provided for the treatment or prevention of cancer.
[0027] In some embodiments, compounds of formula (II-AB') or stereoisomers, tautomers or pharmaceutically acceptable salts thereof are provided for the treatment or prevention of cancer.
[0028] In some embodiments, a compound of Formula (II-A) or Formula (II-B), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, is provided for the preparation of a medicament for the treatment or prevention of cancer.
[0029] In some embodiments, a compound of Formula (II-AB) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof is provided for the preparation of a medicament for the treatment or prevention of cancer.
[0030] In some embodiments, a compound of formula (II-AB') or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof is provided for the preparation of a medicament for the treatment or prevention of cancer.
[0031] In some embodiments, a method of treating cancer in a mammal is provided, comprising administering to the mammal a therapeutically effective amount of a compound of Formula (II-A) or Formula (II-B), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.
[0032] In some embodiments, a method of treating cancer in a mammal is provided, comprising administering to the mammal a therapeutically effective amount of a compound of Formula (II-AB) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.
[0033] In some embodiments, a method for treating cancer in a mammal is provided, comprising administering to the mammal a therapeutically effective amount of a compound of formula (II-AB') or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.
[0034] In some embodiments, a method of treating cancer in a mammal is provided, comprising administering to the mammal a therapeutically effective amount of a compound of Formula (II-A) or Formula (II-B), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, in combination with a second therapeutic agent.
[0035] In some embodiments, a method of treating cancer in a mammal is provided, comprising administering to the mammal a therapeutically effective amount of a compound of Formula (II-AB) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof in combination with a second therapeutic agent.
[0036] In some embodiments, a method of treating cancer in a mammal is provided, comprising administering to the mammal a therapeutically effective amount of a compound of formula (II-AB') or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof in combination with a second therapeutic agent.
[0037] In some embodiments, compounds of Formula (II-A) or Formula (II-B), or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, are provided for modulating TEAD activity.
[0038] In some aspects, compounds of formula (II-AB) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof are provided for modulating TEAD activity.
[0039] In some aspects, compounds of formula (II-AB') or stereoisomers, tautomers or pharmaceutically acceptable salts thereof are provided for modulating TEAD activity.
[0040] In some embodiments, compounds of Formula (II-A) or Formula (II-B), or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, are provided for the treatment or prevention of diseases or conditions mediated by TEAD activity.
[0041] In some embodiments, compounds of formula (II-AB) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof are provided for the treatment or prevention of diseases or conditions mediated by TEAD activity.
[0042] In some embodiments, compounds of formula (II-AB') or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof are provided for the treatment or prevention of diseases or conditions mediated by TEAD activity.
[0043] In some embodiments, a compound of Formula (II-A) or Formula (II-B), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, is provided for use in preparing a medicament for the treatment or prevention of a disease or condition mediated by TEAD activity.
[0044] In some embodiments, a compound of Formula (II-AB) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof is provided for use in preparing a medicament for the treatment or prevention of a disease or condition mediated by TEAD activity.
[0045] In some embodiments, a compound of formula (II-AB') or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof is provided for use in preparing a medicament for the treatment or prevention of a disease or condition mediated by TEAD activity.
[0046] In some aspects, a method of modulating TEAD activity is provided, comprising contacting a TEAD with a therapeutically effective amount of a compound of Formula (II-A) or Formula (II-B), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.
[0047] In some aspects, a method of modulating TEAD activity is provided, comprising contacting a TEAD with a therapeutically effective amount of a compound of formula (II-AB), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.
[0048] In some aspects, a method of modulating TEAD activity is provided, comprising contacting a TEAD with a therapeutically effective amount of a compound of formula (II-AB'), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.
[0049] In some embodiments, a method of treating a disease or condition mediated by TEAD activity in a mammal is provided, comprising administering to the mammal a therapeutically effective amount of a compound of Formula (II-A) or Formula (II-B), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.
[0050] In some embodiments, a method of treating a disease or condition mediated by TEAD activity in a mammal is provided, comprising administering to the mammal a therapeutically effective amount of a compound of formula (II-AB) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.
[0051] In some embodiments, a method for treating a disease or condition mediated by TEAD activity in a mammal is provided, comprising administering to the mammal a therapeutically effective amount of a compound of formula (II-AB') or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.
[0052] In one aspect, the present disclosure relates to a combination comprising: (i) one or more YAP / TAZ-TEAD inhibitors, or pharmaceutically acceptable salts thereof; and (ii) one or more KRAS inhibitors, or pharmaceutically acceptable salts thereof. In some aspects, one or more YAP / TAZ-TEAD inhibitors and one or more KRAS inhibitors are co-administered to an individual. In some aspects, the combination is administered to an individual in the same composition. In some aspects, the combination is administered to an individual in different compositions. Thus, it is understood that one or more YAP / TAZ-TEAD inhibitors and one or more KRAS inhibitors can be administered to an individual simultaneously or sequentially. In some aspects, provided herein are compositions comprising one or more YAP / TAZ-TEAD inhibitors and one or more KRAS inhibitors. In another aspect, the present disclosure relates to a method of modulating or inhibiting KRAS activity in a cell, comprising administering to the cell an effective amount of such a combination. In another aspect, the present disclosure relates to a method of treating cancer in a subject in need thereof, comprising administering to the subject an effective amount of such a combination. In another aspect, the present disclosure relates to a method of reducing a subject's resistance to a treatment comprising a KRAS inhibitor, comprising administering to the subject a therapeutically effective amount of a TEAD inhibitor.
[0053] In one aspect, the present disclosure relates to a process for preparing one or more TEAD inhibitors described herein. [Brief explanation of the drawings]
[0054] The following embodiments are representative of some aspects of the present disclosure.
[0055] [Figure 1] Figure 1 shows the % inhibition of H2030 cells (KRAS G12C) after administration of a combination comprising Compound T1 (YAP / TAZ-TEAD inhibitor) and Compound K1 (KRAS inhibitor).
[0056] [Figure 2]Figure 1 shows the % inhibition of H2030 cells (KRAS G12C) after administration of a combination comprising Compound T2 (YAP / TAZ-TEAD inhibitor) and Compound K1 (KRAS inhibitor).
[0057] [Figure 3] 1 shows the % inhibition of H2030 cells (KRAS G12C) after administration of a combination comprising Compound T3 (YAP / TAZ-TEAD inhibitor) and Compound K1 (KRAS inhibitor).
[0058] [Figure 4] 1 shows the % inhibition of H2030 cells (KRAS G12C) after administration of a combination comprising Compound T1 (YAP / TAZ-TEAD inhibitor) and Compound K2 (KRAS inhibitor).
[0059] [Figure 5] 1 shows the % inhibition of H2030 cells (KRAS G12C) after administration of a combination comprising Compound T2 (YAP / TAZ-TEAD inhibitor) and Compound K2 (KRAS inhibitor).
[0060] [Figure 6] 1 shows the % inhibition of H2030 cells (KRAS G12C) after administration of a combination comprising Compound T3 (YAP / TAZ-TEAD inhibitor) and Compound K2 (KRAS inhibitor).
[0061] [Figure 7] 1 shows the % inhibition of H2030 cells (KRAS G12C) after administration of a combination comprising Compound T1 (YAP / TAZ-TEAD inhibitor) and Compound K3 (KRAS inhibitor).
[0062] [Figure 8] 1 shows the % inhibition of H2030 cells (KRAS G12C) after administration of a combination comprising Compound T2 (YAP / TAZ-TEAD inhibitor) and Compound K3 (KRAS inhibitor).
[0063] [Figure 9]1 shows the % inhibition of H2030 cells (KRAS G12C) after administration of a combination comprising Compound T3 (YAP / TAZ-TEAD inhibitor) and Compound K3 (KRAS inhibitor).
[0064] [Figure 10] Figure 1 shows the % inhibition of H358 parental cells (KRAS G12C) after administration of a combination comprising Compound T1 (YAP / TAZ-TEAD inhibitor) and Compound K1 (KRAS inhibitor).
[0065] [Figure 11] Figure 1 shows the % inhibition of H358 parental cells (KRAS G12C) after administration of a combination comprising Compound T2 (YAP / TAZ-TEAD inhibitor) and Compound K1 (KRAS inhibitor).
[0066] [Figure 12] Figure 1 shows the % inhibition of H358 parental cells (KRAS G12C) after administration of a combination comprising Compound T3 (YAP / TAZ-TEAD inhibitor) and Compound K1 (KRAS inhibitor).
[0067] [Figure 13] Figure 1 shows the % inhibition of H358 parental cells (KRAS G12C) after administration of a combination comprising Compound T1 (YAP / TAZ-TEAD inhibitor) and Compound K2 (KRAS inhibitor).
[0068] [Figure 14] Figure 1 shows the % inhibition of H358 parental cells (KRAS G12C) after administration of a combination comprising Compound T2 (YAP / TAZ-TEAD inhibitor) and Compound K2 (KRAS inhibitor).
[0069] [Figure 15] Figure 1 shows the % inhibition of H358 parental cells (KRAS G12C) after administration of a combination comprising Compound T3 (YAP / TAZ-TEAD inhibitor) and Compound K2 (KRAS inhibitor).
[0070] [Figure 16]1 shows the % inhibition of H358 parental cells (KRAS G12C) after administration of a combination comprising Compound T1 (YAP / TAZ-TEAD inhibitor) and Compound K3 (KRAS inhibitor).
[0071] [Figure 17] Figure 1 shows the % inhibition of H358 parental cells (KRAS G12C) after administration of a combination comprising Compound T2 (YAP / TAZ-TEAD inhibitor) and Compound K3 (KRAS inhibitor).
[0072] [Figure 18] 1 shows the % inhibition of H358 parental cells (KRAS G12C) after administration of a combination comprising Compound T3 (YAP / TAZ-TEAD inhibitor) and Compound K3 (KRAS inhibitor).
[0073] [Figure 19] Figure 1 shows the % inhibition of H358 resistant cells (KRAS G12C) after administration of a combination comprising Compound T1 (YAP / TAZ-TEAD inhibitor) and Compound K1 (KRAS inhibitor).
[0074] [Figure 20] Figure 1 shows the % inhibition of H358 resistant cells (KRAS G12C) after administration of a combination comprising Compound T2 (YAP / TAZ-TEAD inhibitor) and Compound K1 (KRAS inhibitor).
[0075] [Figure 21] Figure 1 shows the % inhibition of H358 resistant cells (KRAS G12C) after administration of a combination comprising Compound T3 (YAP / TAZ-TEAD inhibitor) and Compound K1 (KRAS inhibitor).
[0076] [Figure 22] Figure 1 shows the % inhibition of H358 resistant cells (KRAS G12C) after administration of a combination comprising Compound T1 (YAP / TAZ-TEAD inhibitor) and Compound K2 (KRAS inhibitor).
[0077] [Figure 23]1 shows the % inhibition of H358 resistant cells (KRAS G12C) after administration of a combination comprising Compound T2 (YAP / TAZ-TEAD inhibitor) and Compound K2 (KRAS inhibitor).
[0078] [Figure 24] 1 shows the % inhibition of H358 resistant cells (KRAS G12C) after administration of a combination comprising Compound T3 (YAP / TAZ-TEAD inhibitor) and Compound K2 (KRAS inhibitor).
[0079] [Figure 25] Figure 1 shows the % inhibition of H358 resistant cells (KRAS G12C) after administration of a combination comprising Compound T1 (YAP / TAZ-TEAD inhibitor) and Compound K3 (KRAS inhibitor).
[0080] [Figure 26] 1 shows the % inhibition of H358 resistant cells (KRAS G12C) after administration of a combination comprising Compound T2 (YAP / TAZ-TEAD inhibitor) and Compound K3 (KRAS inhibitor).
[0081] [Figure 27] 1 shows the % inhibition of H358 resistant cells (KRAS G12C) after administration of a combination comprising Compound T3 (YAP / TAZ-TEAD inhibitor) and Compound K3 (KRAS inhibitor).
[0082] [Figure 28] Figure 1 shows the % inhibition of H2030 cells (KRAS G12C) after administration of a combination comprising Compound T4 (YAP / TAZ-TEAD inhibitor) and Compound K1 (KRAS inhibitor).
[0083] [Figure 29] 1 shows the % inhibition of H2030 cells (KRAS G12C) after administration of a combination comprising Compound T4 (YAP / TAZ-TEAD inhibitor) and Compound K2 (KRAS inhibitor).
[0084] [Figure 30]1 shows the % inhibition of H2030 cells (KRAS G12C) after administration of a combination comprising Compound T4 (YAP / TAZ-TEAD inhibitor) and Compound K3 (KRAS inhibitor).
[0085] [Figure 31] Figure 1 shows the % inhibition of H358 parental cells (KRAS G12C) after administration of a combination comprising Compound T4 (YAP / TAZ-TEAD inhibitor) and Compound K1 (KRAS inhibitor).
[0086] [Figure 32] 1 shows the % inhibition of H358 parental cells (KRAS G12C) after administration of a combination comprising Compound T4 (YAP / TAZ-TEAD inhibitor) and Compound K2 (KRAS inhibitor).
[0087] [Figure 33] 1 shows the % inhibition of H358 parental cells (KRAS G12C) after administration of a combination comprising Compound T4 (YAP / TAZ-TEAD inhibitor) and Compound K3 (KRAS inhibitor).
[0088] [Figure 34] Figure 1 shows the % inhibition of H358 resistant cells (KRAS G12C) after administration of a combination comprising Compound T4 (YAP / TAZ-TEAD inhibitor) and Compound K1 (KRAS inhibitor).
[0089] [Figure 35] 1 shows the % inhibition of H358 resistant cells (KRAS G12C) after administration of a combination comprising Compound T4 (YAP / TAZ-TEAD inhibitor) and Compound K2 (KRAS inhibitor).
[0090] [Figure 36] 1 shows the % inhibition of H358 resistant cells (KRAS G12C) after administration of a combination comprising Compound T4 (YAP / TAZ-TEAD inhibitor) and Compound K3 (KRAS inhibitor).
[0091] [Figure 37]1 shows the % inhibition of H2030 cells (KRAS G12C) after administration of a combination comprising Compound T1 (YAP / TAZ-TEAD inhibitor) and Compound K4 (KRAS inhibitor).
[0092] [Figure 38] 1 shows the % inhibition of H2030 cells (KRAS G12C) after administration of a combination comprising Compound T2 (YAP / TAZ-TEAD inhibitor) and Compound K4 (KRAS inhibitor).
[0093] [Figure 39] 1 shows the % inhibition of H2030 cells (KRAS G12C) after administration of a combination comprising Compound T3 (YAP / TAZ-TEAD inhibitor) and Compound K4 (KRAS inhibitor).
[0094] [Figure 40] 1 shows the % inhibition of H2030 cells (KRAS G12C) after administration of a combination comprising Compound T4 (YAP / TAZ-TEAD inhibitor) and Compound K4 (KRAS inhibitor).
[0095] [Figure 41] 1 shows the % inhibition of H358 parental cells (KRAS G12C) after administration of a combination comprising Compound T1 (YAP / TAZ-TEAD inhibitor) and Compound K4 (KRAS inhibitor).
[0096] [Figure 42] 1 shows the % inhibition of H358 parental cells (KRAS G12C) after administration of a combination comprising Compound T2 (YAP / TAZ-TEAD inhibitor) and Compound K4 (KRAS inhibitor).
[0097] [Figure 43] 1 shows the % inhibition of H358 parental cells (KRAS G12C) after administration of a combination comprising Compound T3 (YAP / TAZ-TEAD inhibitor) and Compound K4 (KRAS inhibitor).
[0098] [Figure 44]Figure 1 shows the % inhibition of H358 parental cells (KRAS G12C) after administration of a combination comprising Compound T4 (YAP / TAZ-TEAD inhibitor) and Compound K4 (KRAS inhibitor).
[0099] [Figure 45] 1 shows the % inhibition of H358 resistant cells (KRAS G12C) after administration of a combination comprising Compound T1 (YAP / TAZ-TEAD inhibitor) and Compound K4 (KRAS inhibitor).
[0100] [Figure 46] 1 shows the % inhibition of H358 resistant cells (KRAS G12C) after administration of a combination comprising Compound T2 (YAP / TAZ-TEAD inhibitor) and Compound K4 (KRAS inhibitor).
[0101] [Figure 47] 1 shows the % inhibition of H358 resistant cells (KRAS G12C) after administration of a combination comprising Compound T3 (YAP / TAZ-TEAD inhibitor) and Compound K4 (KRAS inhibitor).
[0102] [Figure 48] 1 shows the % inhibition of H358 resistant cells (KRAS G12C) after administration of a combination comprising Compound T4 (YAP / TAZ-TEAD inhibitor) and Compound K4 (KRAS inhibitor). DETAILED DESCRIPTION OF THE INVENTION
[0103] definition Unless otherwise indicated, the following specific terms used in the specification and claims are defined as follows:
[0104] The term "moiety" refers to an atom or chemically bonded atom or group that is attached to another atom or molecule by one or more chemical bonds, thereby forming part of the molecule.
[0105] The term "substituted" means that at least one of the moiety's hydrogen atoms has been replaced with another substituent or moiety.
[0106] The term "alkyl" refers to an aliphatic straight- or branched-chain saturated hydrocarbon moiety having 1 to 20 carbon atoms, e.g., 1 to 12 carbon atoms or 1 to 6 carbon atoms. An alkyl group may be optionally substituted.
[0107] In some embodiments, the alkyl is unsubstituted.
[0108] In some embodiments, a "hydroxylalkyl" is an alkyl substituted with one or more --OH.
[0109] In some embodiments, the "alkoxy" is --O-alkyl.
[0110] The term "cycloalkyl" refers to monocyclic or bicyclic (including bridged bicyclic) rings and saturated or partially unsaturated carbocyclic moieties having 3 to 10 carbon atoms in the ring. In certain embodiments, cycloalkyl can contain 3 to 8 carbon atoms (i.e., (C3-C8)cycloalkyl). In other certain embodiments, cycloalkyl contains 3 to 6 carbon atoms (i.e., (C3-C6)cycloalkyl). Examples of cycloalkyl moieties include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and their partially unsaturated (cycloalkenyl) derivatives (e.g., cyclopentenyl, cyclohexenyl, and cycloheptenyl). Cycloalkyl moieties can also be attached in a spirocyclic fashion, such as spirocyclopropyl: TIFF2024543912000010.tif13170
[0111] The term "haloalkyl" refers to an alkyl group in which one or more of the alkyl group's hydrogen atoms have been replaced by the same or different halogen atoms, such as fluorine atoms. Examples of haloalkyl include monofluoro-, difluoro-, or trifluoro-methyl, -ethyl, or -propyl, such as 3,3,3-trifluoropropyl, 2-fluoroethyl, 2,2,2-trifluoroethyl, fluoroethyl, or trifluoromethyl. Haloalkyl groups may be optionally substituted.
[0112] In some embodiments, the haloalkyl is unsubstituted.
[0113] The term "alkenyl" refers to a straight or branched chain alkyl or substituted alkyl group, as defined elsewhere herein, having at least one carbon-carbon double bond. Alkenyl groups can be optionally substituted.
[0114] In some embodiments, the alkenyl is unsubstituted.
[0115] The term "alkynyl" refers to a straight or branched chain alkyl or substituted alkyl group, as defined elsewhere herein, having at least one carbon-carbon triple bond. Alkynyl groups may be optionally substituted.
[0116] In some embodiments, the alkynyl is unsubstituted. In some embodiments, the hydroxylalkynyl is an alkynyl substituted with one or more -OH.
[0117] The terms "heterocyclyl" and "heterocycle" refer to 4-, 5-, 6-, and 7-membered monocyclic heterocyclic moieties, or 7-, 8-, 9-, and 10-membered bicyclic (including bridged bicyclic) heterocyclic moieties, which are saturated or partially unsaturated and have one or more (e.g., 1, 2, 3, or 4) heteroatoms selected from oxygen, nitrogen, and sulfur in the ring, with the remaining ring atoms being carbon. When used in reference to a ring atom of a heterocycle, nitrogen or sulfur may also be in oxidized form, and the nitrogen may be substituted. A heterocycle can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure, and any of the ring atoms can be optionally substituted. Examples of such saturated or partially unsaturated heterocycles include, but are not limited to, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, pyrrolidinyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazolyl, thiazepinyl, morpholinyl, and quinuclidinyl. The term heterocycle also includes groups in which a heterocycle is fused to one or more aryl, heteroaryl, or cycloalkyl rings, such as benzothiazolyl, benzofuranyl, furopyridinyl, indolinyl, 3H-indolyl, chromanyl, 2-azabicyclo[2.2.1]heptanyl, octahydroindolyl, or tetrahydroquinolinyl. Heterocyclyl groups may be optionally substituted.
[0118] In some embodiments, the heterocyclyl is unsubstituted.
[0119] The term "aryl" refers to a cyclic aromatic hydrocarbon moiety having a monocyclic, bicyclic, or tricyclic aromatic ring of 5 to 20 carbon ring atoms. Examples of aryl moieties include, but are not limited to, phenyl, naphthyl, benzyl, and the like. The term "aryl" also includes partially hydrogenated derivatives of cyclic aromatic hydrocarbon moieties, provided that at least one ring of the cyclic aromatic hydrocarbon moiety is aromatic, each of which may be optionally substituted. In some embodiments, a monocyclic aryl ring may have 5 or 6 carbon ring atoms. Aryl groups may be optionally substituted.
[0120] In some embodiments, the aryl is unsubstituted.
[0121] The term "heteroaryl" refers to an aromatic heterocyclic monocyclic or bicyclic ring system of 1 to 20 ring atoms containing 1, 2, 3, or 4 heteroatoms selected from N, O, and S, with the remaining ring atoms being carbon. Examples of heteroaryl include pyrrolyl, furanyl, thienyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyrimidinyl, triazinyl, isoxazolyl, benzofuranyl, isothiazolyl, benzothienyl, indolyl, isoindolyl, isobenzofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzoxadiazolyl, benzothiadiazolyl, benzotriazolyl, purinyl, quinolinyl, isoquinolinyl, quinazolinyl, or quinoxalinyl. Heteroaryl groups may be optionally substituted.
[0122] In some embodiments, the heteroaryl is unsubstituted.
[0123] The terms "halo" and "halogen" refer to fluoro, chloro, bromo, and iodo. In some embodiments, halogen is fluoro or chloro.
[0124] The term "oxo" refers to a =O moiety.
[0125] The term "cyano" refers to a -C≡N moiety.
[0126] The terms "spirocycle" and "spirocyclyl" refer to a carbocyclic bicyclic ring system containing 5 to 13 carbon atoms, with both rings connected through a single atom. The rings may be different in size and nature, or may be identical in size and nature. Examples include spiropentane, spirohexane, spiroheptane, spirooctane, spirodecane, or spirodecane. One or more of the carbon atoms in the spirocycle can be replaced with a heteroatom (e.g., O, N, S, or P). Spirocycle groups may be optionally substituted.
[0127] In some embodiments, the spiro ring is unsubstituted.
[0128] The term "pharmaceutically acceptable salt" refers to a salt that retains the biological effectiveness and properties of the free base or free acid, without being biologically or otherwise undesirable. Salts are formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, and phosphoric acid, preferably hydrochloric acid, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, salicylic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, and N-acetylcysteine. In addition, salts can be prepared by adding an inorganic or organic base to the free acid. Salts derived from inorganic bases include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, and magnesium salts, and the like. Salts derived from organic bases include, but are not limited to, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins such as isopropylamine resin, trimethylamine resin, diethylamine resin, triethylamine resin, tripropylamine resin, ethanolamine resin, lysine resin, arginine resin, N-ethylpiperidine resin, piperidine resin, and polyamine resin.
[0129] The term "prodrug" refers to a compound that readily undergoes chemical changes under physiological conditions to provide a compound of the present disclosure. Additionally, prodrugs can be converted to the compounds of the present disclosure by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to the compounds of the present disclosure when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent.
[0130] In some prodrug embodiments, the prodrug comprises a compound in which an amino acid residue, or a polypeptide chain of two or more (e.g., 2, 3, or 4) amino acid residues, is covalently bonded via an amide or ester bond to a free amino, hydroxy, or carboxylic acid group of a compound of the present disclosure. Amino acid residues include, but are not limited to, the 20 naturally occurring amino acids, commonly represented by their three-letter symbols, and also include phosphoserine, phosphothreonine, phosphotyrosine, 4-hydroxyproline, hydroxylysine, demosin, isodemosin, gamma-carboxyglutamate, hippuric acid, octahydroindole-2-carboxylic acid, statin, 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, penicillamine, ornithine, 3-methylhistidine, norvaline, beta-alanine, gamma-aminobutyric acid, citrulline, homocysteine, homoserine, methyl-alanine, para-benzoylphenylalanine, phenylglycine, propargylglycine, sarcosine, methionine sulfone, and tert-butylglycine.
[0131] In some other prodrug embodiments, free carboxyl groups of the compounds of the present disclosure can be derivatized as amides or alkyl esters. In yet other prodrug embodiments, prodrugs containing free hydroxy groups can be derivatized as prodrugs by converting the hydroxy group to groups such as, but not limited to, phosphate esters, hemisuccinates, dimethylaminoacetates, or phosphoryloxymethyloxycarbonyl groups, as outlined in Fleisher, D. et al. (1996) Improved oral drug delivery: solubility limitations overcome by the use of prodrugs (Advanced Drug Delivery Reviews, 19:115). Carbamate prodrugs of hydroxy and amino groups are also included, as are carbonate prodrugs, sulfonate esters, and sulfate esters of hydroxy groups. Derivatization of hydroxy groups as (acyloxy)methyl and (acyloxy)ethyl ethers is also encompassed, where the acyl group can be an alkyl ester optionally substituted with groups including, but not limited to, ether, amine, and carboxylic acid functionalities, or where the acyl group is an amino acid ester as described above. This type of prodrug is described in J. Med. Chem., (1996), 39:10. More specific examples include those in which the hydrogen atom of the alcohol group is substituted with (C 1-6 ) alkanoyloxymethyl, 1-((C 1~6 )alkanoyloxy)ethyl, 1-methyl-1-((C 1~6 )alkanoyloxy)ethyl, (C 1-6 )alkoxycarbonyloxymethyl, N-(C 1~6 ) alkoxycarbonylaminomethyl, succinoyl, (C 1~6 ) alkanoyl, alpha-amino (C 1~4 ) alkanoyl, arylacyl and alpha-aminoacyl, or alpha-aminoacyl-alpha-aminoacyl (each alpha-aminoacyl group is a natural L-amino acid, P(O)(OH)2, -P(O)(O(C 1~6) alkyl) 2 or glycosyl (independently selected from radicals generated by removing the hydroxyl group of the hemiacetal form of a carbohydrate).
[0132] For further examples of prodrug derivatives, see, for example, a) Design of Prodrugs, edited by H. Bundgaard, (Elsevier, 1985) and Methods in Enzymology, Vol. 42, pp. 309-396, edited by K. Widder, et al. (Academic Press, 1985); b) A Textbook of Drug Design and Development, edited by Krogsgaard-Larsen and H. Bundgaard, Chapter 5 "Design and Application of Prodrugs," by H. Bundgaard, pp. 113-191 (1991); c) H. Bundgaard, Advanced Drug Delivery Reviews, 8:1-38 (1992); d) H. Bundgaard, et al., Journal of Pharmaceutical Sciences, 77:285 (1988); and e) N. Kakeya, et al. al., Chem. Pharm. Bull., 32:692 (1984), each of which is specifically incorporated herein by reference.
[0133] Additionally, the present disclosure provides metabolic products of the disclosed compounds. As used herein, "metabolite" refers to a product produced through metabolism in the body of a particular compound or salt thereof. Such products may result, for example, from oxidation, reduction, hydrolysis, amidation, deamidation, esterification, deesterification, enzymatic cleavage, etc., of the administered compound.
[0134] The metabolites are typically radiolabeled (e.g., 14 C or 3H) isotopes are prepared and identified by parenteral administration of the isotope at a detectable dose (e.g., greater than about 0.5 mg / kg) to animals such as rats, mice, guinea pigs, monkeys, or humans, allowing sufficient time for metabolism to occur (typically about 30 seconds to 30 hours), and isolating the conversion products from urine, blood, or other physiological samples. Such products are easily isolated because they are labeled (others are isolated by the use of antibodies capable of binding to epitopes surviving in the metabolite). The structures of the metabolites are determined by conventional methods, such as MS, LC / MS, or NMR analysis. Metabolite analysis is generally performed in the same manner as conventional drug metabolism studies well known to those skilled in the art. Metabolites are useful in diagnostic assays for therapeutic dosing of the disclosed compounds, unless otherwise found in vivo.
[0135] Certain compounds of the present disclosure can exist in unsolvated forms and solvated forms, including hydrated forms. Generally, the solvated forms are equivalent to the unsolvated forms and are intended to be included within the scope of the present disclosure. Certain compounds of the present disclosure can exist in multiple crystalline or amorphous forms. Generally, all physical forms are equivalent for the uses contemplated by the present disclosure and are intended to be within the scope of the present disclosure.
[0136] Compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are called "isomers." Isomers that differ in the arrangement of their atoms in space are called "stereoisomers." Diastereomers are stereoisomers with opposite configurations at one or more chiral centers that are not mirror isomers. Stereoisomers with one or more asymmetric centers that are non-superimposable mirror images of each other are called "enantiomers." When a compound has an asymmetric center, for example, when one carbon atom is bonded to four different groups, a pair of enantiomers is possible. Enantiomers can be characterized by the absolute configuration of their asymmetric center(s) and are described by the Cahn-Ingold-Prelog R- and S-sequencing rules or by the way the molecule rotates the plane of polarized light and are designated as dextrorotatory or levorotatory (i.e., (+) or (-) isomers, respectively). Chiral compounds can exist as either individual enantiomers or as mixtures thereof. A mixture containing equal proportions of enantiomers is called a "racemic mixture." In certain embodiments, the compound is at least about 90% enriched by weight with a single diastereomer or enantiomer. In other embodiments, the compound is at least about 95%, 98%, or 99% enriched by weight with a single diastereomer or enantiomer.
[0137] Certain compounds of the present disclosure possess asymmetric carbon atoms (optical centers) or double bonds; the racemates, diastereomers, geometric isomers, positional isomers and individual isomers (e.g., separate enantiomers) are all intended to be encompassed within the scope of the present disclosure.
[0138] The compounds of the present disclosure may also exist in various tautomeric forms, and all such forms are included within the scope of the present disclosure. The term "tautomer" or "tautomeric form" refers to structural isomers with different energies that are interconvertible via a low energy barrier. For example, proton tautomers (also known as prototropic tautomers) include interconversions via migration of a proton, such as keto-enol and imine-enamine isomerizations. Valence tautomers include interconversions via reorganization of some of the bonding electrons.
[0139] Unless otherwise indicated, the term "a compound of the formula" or "a compound of formula" or "compounds of the formula" or "compounds of formula" refers to any compound selected from the genus of compounds as defined by the formula. In some embodiments or aspects, the term also includes pharmaceutically acceptable salts or esters of any such compound, stereoisomers or tautomers of such compounds. The term "therapeutically effective amount" of a compound means an amount of compound effective to prevent, alleviate or ameliorate symptoms of disease or to prolong the survival of the subject being treated. Determining a therapeutically effective amount is within the skill of the art. The therapeutically effective amount or therapeutically effective dose of a compound according to the present disclosure can vary within wide limits and can be determined in a manner known in the art. Such dosage will be tailored to the individual requirements of each particular case, including the particular compound being administered, the route of administration, the condition being treated, and the patient being treated. Generally, for oral or parenteral administration to an adult weighing approximately 70 kg, a daily dose of about 0.1 mg to about 5,000 mg, 1 mg to about 1,000 mg, or 1 mg to 100 mg may be appropriate, although the lower and upper limits may be exceeded when indicated. The daily dose can be administered as a single dose or in divided doses, or, for parenteral administration, as continuous infusion.
[0140] In some embodiments, the term "therapeutically effective amount" of a compound refers to an amount of compound effective to alleviate or ameliorate symptoms of a disease or to prolong the survival of a treated subject. Determining a therapeutically effective amount is within the skill of those in the art. The therapeutically effective amount or therapeutically effective dose of a compound according to the present disclosure can vary within wide limits and can be determined in a manner known in the art. Such dosages will be tailored to the individual requirements of each particular case, including the particular compound administered, the route of administration, the condition being treated, and the patient being treated. Generally, for oral or parenteral administration to an adult weighing approximately 70 kg, a daily dose of about 0.1 mg to about 5,000 mg, 1 mg to about 1,000 mg, or 1 mg to 100 mg may be appropriate, although the lower and upper limits may be exceeded when indicated. The daily dose can be administered as a single dose, in divided doses, or, for parenteral administration, as a continuous infusion.
[0141] In embodiments herein, a therapeutically effective amount of a compound can be an amount of compound that is effective to alleviate or ameliorate the condition or disease, or a symptom thereof, or prolong the survival of the subject being treated.
[0142] The term "pharmaceutically acceptable carrier" is intended to include any and all materials compatible with pharmaceutical administration, including solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and other materials and compounds compatible with pharmaceutical administration. Except insofar as any conventional media or agent is incompatible with the compounds of the present disclosure, its use in the compositions of the present disclosure is contemplated. Supplementary active compounds can also be incorporated into the compositions.
[0143] compound In some embodiments, the compound of formula (II-AB'): TIFF2024543912000011.tif27170, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein: L' is *-N(R 3)-L-** or TIFF2024543912000012.tif22170In the formula, * indicates the point of attachment to Z, and ** indicates TIFF2024543912000013.tif27170X 1 is C or N, and X 1 is R 1 and together with the atom to which they are attached, a 5- to 6-membered heteroaryl, a 5- to 6-membered heterocyclyl, a phenyl, or C fused to ring A 5-6 Forming a cycloalkyl; X 1 and R 1 5- to 6-membered heteroaryl, 5- to 6-membered heterocyclyl, phenyl, and C 5-6 Cycloalkyl may each independently be one or more R t optionally substituted with R t independently, in each occurrence, halo, C 1-15 Alkyl, HaloC 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e selected from the group consisting of: In the formula, R d and R e are each independently H or C 1-6 alkyl, and R d or R e C 1-6 The alkyl is optionally substituted with one or more substituents selected from halo, oxo, —OH and —CN; X 2 is N or CR s where Rs H, halo, C 1-15 Alkyl, Hydroxyl C 1-6 Alkynyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3- to 15-membered heterocyclyl, -OH, -CN, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -S(O)NHR d , -SO2NR d R e , -NR d SO2R e , and -NR d R e Selected from; In the formula, R s C 1-15 Alkyl and C 1-15 The alkoxy may each independently be one or more R t1 wherein R t1 is independently in each occurrence halo, oxo, —OH, —CN, 5- to 6-membered heteroaryl, or —NR d R e where R d and R e are each independently H or C 1-6 alkyl, where R d or R e C 1-6 The alkyl is optionally substituted with one or more substituents selected from halo, oxo, —OH, and —CN; and In the formula, R s C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 The cycloalkyl and 3- to 15-membered heterocyclyl each independently represent one or more R t2 wherein R t2 is independently in each occurrence halo, oxo, —OH, —CN, and C 1-6 alkyl; and In the formula, R d and Re are each independently H or C 1-6 alkyl, and R d or R e C 1-6 The alkyl is optionally substituted with one or more substituents selected from halo, oxo, —OH and —CN; X 3 is N or CH; B is i) phenyl or 5- to 6-membered heteroaryl; the phenyl and 5- to 6-membered heteroaryl of B are each independently one or more R 2 is replaced by In the formula, R 2 independently, in each occurrence, halo;S(R y ) 5, wherein each R y is halo; or C optionally substituted with one or more halo 1-6 Is it alkoxy; ii) Halo C 1-3 alkyl-substituted -O-phenyl (provided that B is haloC 1-3 When L' is -O-phenyl substituted with alkyl, L' is -N(R 3 )-L-**, Z is -C(O)CHCH2, and X 1 is C and X 2 is CR s and X 3 is CH); or iii) C 1-3 Is it an alkyl-substituted bicyclopentane (provided B is C)? 1-3 If it is an alkyl-substituted bicyclopentane, L' is *-N(R 3 )-L-**, provided that Z is —C(O)CHCH2; or iv) ethynyl or haloC 1-3 alkyl-substituted phenyl (provided that B is ethynyl or haloC 1-3 When L' is phenyl substituted with alkyl, L' is -N(R 3 )-L-**, Z is -C(O)CHCH2, and R s is C substituted with one or more -OH1-3 provided that it is alkyl); or v) Halo C 1-3 Alkyl or haloC 1-3 alkoxy-substituted piperidine, provided that B is haloC 1-3 Alkyl or haloC 1-3 When L' is an alkoxy-substituted piperidine, L' is -N(R 3 )-L-** and Z is -C(O)CHCH2); R 3 is H or C 1-6 is alkyl; Z is -OH, -NR d R e , C 1-6 Alkoxy, -C(O)R a , or -S(O)R b and In the formula, R d and R e are each independently H or C 1-6 alkyl, and R d or R e C 1-6 The alkyl is optionally substituted with one or more substituents selected from halo, oxo, —OH and —CN; R a and R b are each independently: i) deuterium, C 1-6 Alkyl, Hydroxyl C 1-6 Alkyl, halo and haloC 1-6 C optionally substituted with one or more substituents selected from alkyl 2-6 alkenyl; ii) C optionally substituted with one or more halo 1-6 alkyl; or iii) cyclobutenyl or bicyclobutanyl; L is methylene or ethylene, and the methylene of L is one C 1-6 optionally substituted with alkyl; Y is CH or C(CN), and n and m are each independently 1 or 2; However, subject to the following conditions: i)i-1)X1 R 1 and together with the atom to which they are attached form a phenyl, i-2) X 2 or X 3 is N, B in formula (II-AB') is phenyl, and R 2 Halo C 1-6 being alkoxyl; and ii) when n=1 and m=2, or when n=2 and m=1, B is phenyl substituted with halomethyloxyl; and iii) The compound of formula (II-AB') is not any of the following: N-((8-(4-fluorophenyl)imidazo[1,2-a]pyrazin-6-yl)methyl)acrylamide; N-((8-(4-(trifluoromethoxy)phenyl)imidazo[1,2-a]pyrazin-6-yl)methyl)acrylamide; N-((7-fluoro-4-(4-(trifluoromethoxy)phenyl)quinazolin-2-yl)methyl)acrylamide; N-((8-(4-(difluoromethoxy)phenyl)imidazo[1,2-a]pyrazin-6-yl)methyl)acrylamide; 1-(4-(4-(4-methoxyphenyl)-1-methyl-1H-imidazo[4,5-c]pyridin-6-yl)piperidin-1-yl)ethan-1-one; 4-(4-Methoxyphenyl)-1-methyl-6-(1-(methylsulfonyl)piperidin-4-yl)-1H-imidazo[4,5-c]pyridine; 6-(1-(ethylsulfonyl)piperidin-4-yl)-4-(4-methoxyphenyl)-1-methyl-1H-imidazo[4,5-c]pyridine; 6-(1-(ethylsulfonyl)piperidin-4-yl)-1-isopropyl-4-(4-methoxyphenyl)-1H-imidazo[4,5-c]pyridine; 4-(4-methoxyphenyl)-1-methyl-6-(1-((trifluoromethyl)sulfonyl)piperidin-4-yl)-1H-imidazo[4,5-c]pyridine; and N-((4-(4-fluorophenyl)-1,8-naphthyridin-2-yl)methyl)acetamide.
[0144] Any embodiment, aspect, or variation described herein with respect to one formula may, where applicable, be applied to any other formula listed herein. For example, any embodiment, aspect, or variation described herein with respect to any one or more of formulas (II-AB), (II-A), and (II-B), applies to formula (II-AB') as if each and every embodiment, aspect, and variation were specifically and individually recited with respect to formula (II-AB'). It is understood that such embodiments apply to structural features of the compounds and methods of making and using such compounds. For example, it is understood that methods of using any one or more of formulas (II-AB), (II-A), and (II-B), where applicable, apply to methods of using compounds of formula (II-AB'), as if each and every embodiment, aspect, and variation were specifically and individually recited with respect to formula (II-AB').
[0145] In some embodiments, in conjunction with the above or below embodiments, L′ in formula (II-AB′) is *-N(R 3 )-L-**. In some embodiments, in conjunction with the above or below embodiments, L' in formula (II-AB') is TIFF2024543912000014.tif20170
[0146] In some embodiments, the compound of formula (II-AB): TIFF2024543912000015.tif27170, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein: L' is TIFF2024543912000016.tif17170, wherein * indicates the point of attachment to Z and ** indicates TIFF2024543912000017.tif27170X 1 is C or N, and X1 is R 1 and together with the atom to which they are attached, a 5- to 6-membered heteroaryl, a 5- to 6-membered heterocyclyl, a phenyl, or C fused to ring A 5-6 Forming a cycloalkyl; X 1 and R 1 5- to 6-membered heteroaryl, 5- to 6-membered heterocyclyl, phenyl, and C 5-6 Cycloalkyl may each independently be one or more R t and optionally substituted with R t independently, in each occurrence, halo, C 1-15 Alkyl, HaloC 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e selected from the group consisting of: In the formula, R d and R e are each independently H or C 1-6 alkyl, and R d or R e C 1-6 The alkyl is optionally substituted with one or more substituents selected from halo, oxo, —OH and —CN; X 2 is N or CR s where R s H, halo, C 1-15 Alkyl, Hydroxyl C 1-6 Alkynyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20Cycloalkyl, 3- to 15-membered heterocyclyl, -OH, -CN, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -S(O)NHR d , -SO2NR d R e , -NR d SO2R e , and -NR d R e Selected from; In the formula, R s C 1-15 Alkyl and C 1-15 The alkoxy may each independently be one or more R t1 wherein R t1 is independently in each occurrence halo, oxo, —OH, —CN, 5- to 6-membered heteroaryl, or —NR d R e where R d and R e are each independently H or C 1-6 alkyl, where R d or R e C 1-6 The alkyl is optionally substituted with one or more substituents selected from halo, oxo, —OH, and —CN; and In the formula, R s C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 The cycloalkyl and 3- to 15-membered heterocyclyl each independently represent one or more R t2 wherein R t2 is independently in each occurrence halo, oxo, —OH, —CN, and C 1-6 alkyl; and In the formula, R d and R e are each independently H or C 1-6 alkyl, and R d or R e C 1-6The alkyl is optionally substituted with one or more substituents selected from halo, oxo, —OH and —CN; X 3 is N or CH; B is phenyl or 5- to 6-membered heteroaryl; the phenyl and 5- to 6-membered heteroaryl of B are each independently one or more R 2 and wherein R 2 independently, in each occurrence, halo;S(R y ) 5, wherein each R y is halo; or C optionally substituted with one or more halo 1-6 Is it alkoxy; R 3 is H or C 1-6 is alkyl; Z is -OH, -NR d R e , C 1-6 Alkoxy, -C(O)R a , -S(O)2R b and In the formula, R d and R e are each independently H or C 1-6 alkyl, and R d or R e C 1-6 The alkyl is optionally substituted with one or more substituents selected from halo, oxo, —OH and —CN; R a and R b are each independently: i) deuterium, C 1-6 Alkyl, Hydroxyl C 1-6 Alkyl, halo and haloC 1-6 C optionally substituted with one or more substituents selected from alkyl 2-6 alkenyl; or ii) C optionally substituted with one or more halo 1-6 is alkyl; L is one or more C 1-6 methylene optionally substituted with alkyl; and n and m are 1; or n and m are 2; However, 1) X 1 R 1 and together with the atom to which they are attached form a phenyl, and 2) X 2 or X 3 If is N, then In formula (II-AB), B is phenyl and R 2 Halo C 1-6 Provided that it is alkoxyl.
[0147] In some embodiments, the compound has the following formula (II-A) or formula (II-B), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: TIFF2024543912000018.tif59170, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein: X 1 is C or N, and X 1 is R 1 and together with the atom to which they are attached, a 5- to 6-membered heteroaryl, a 5- to 6-membered heterocyclyl, a phenyl, or C fused to ring A 5-6 Forming a cycloalkyl; X 1 and R 1 5-6-membered heteroaryl, 5-6-membered heterocyclyl, phenyl, and C 5-6 Cycloalkyl may each independently be one or more R t and optionally substituted with R t independently, in each occurrence, C 1-3 Alkyl, -OH, oxo, C 1-3 Alkoxy and -NR d R e selected from; and In the formula, R d and R e are each independently H or C 1-6 alkyl, and R d or R e C 1-6 The alkyl is optionally substituted with one or more substituents selected from halo, oxo, —OH and —CN; X 2is N or CR s where R s H, halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e selected from the group consisting of: In the formula, R s C 1-15 Alkyl and C 1-15 The alkoxy may each independently be one or more R t1 wherein R t1 is independently in each occurrence halo, oxo, —OH, —CN, or —NR d R e where R d and R e are each independently H or C 1-6 is alkyl; and In the formula, R s C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 The cycloalkyl and 3- to 15-membered heterocyclyl each independently represent one or more R t2 wherein R t2 is independently in each occurrence halo, oxo, —OH, —CN, and C 1-6 alkyl; and In the formula, R d and R e are each independently H or C 1-6 alkyl, and R d or R e C 1-6The alkyl is optionally substituted with one or more substituents selected from halo, oxo, —OH and —CN; X 3 is N or CH; B is phenyl or 5- to 6-membered heteroaryl; the phenyl and 5- to 6-membered heteroaryl of B each independently represent 1 to 5 R 2 is replaced by; R 2 independently, in each occurrence: i) halo; ii) S(R y ) 5, wherein each R y is halo; or iii) C optionally substituted with one or more halo. 1-6 Is it alkoxy; R 3 is H or C 1-6 is alkyl; Z is -OH, -NR d R e , C 1-6 Alkoxy, -C(O)R a , -S(O)2R a and In the formula, R d and R e are each independently H or C 1-6 alkyl, and R d or R e C 1-6 The alkyl is optionally substituted with one or more substituents selected from halo, oxo, —OH and —CN; R a is a hydrogen atom containing one or more deuterium atoms, 1-6 Alkyl, Halo, HaloC 1-6 C optionally substituted with alkyl 2-6 alkenyl; or ii) C optionally substituted with one or more halo 1-6 is alkyl; L is one or more C 1-6 methylene optionally substituted with alkyl; and n and m are each independently 1 or 2.
[0148] In some embodiments, a compound of formula (II-A) or (II-B): TIFF2024543912000019.tif59170, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein: X 1 is C or N, and X 1 is R 1 and together with the atom to which they are attached, a 5- to 6-membered heteroaryl, a 5- to 6-membered heterocyclyl, a phenyl, or C fused to ring A 5-6 Forming a cycloalkyl; X 1 and R 1 5- to 6-membered heteroaryl, 5- to 6-membered heterocyclyl, phenyl, and C 5-6 Cycloalkyl may each independently be one or more R t and optionally substituted with R t independently, in each occurrence, halo, C 1-15 Alkyl, HaloC 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e selected from the group consisting of: In the formula, R d and R e are each independently H or C 1-6 alkyl, and R d or R e C 1-6 The alkyl is optionally substituted with one or more substituents selected from halo, oxo, —OH and —CN; X 2 is N or CR s where R sH, halo, C 1-15 Alkyl, Hydroxyl C 1-6 Alkynyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3- to 15-membered heterocyclyl, -OH, -CN, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -S(O)NHR d , -SO2NR d R e , -NR d SO2R e , and -NR d R e Selected from; In the formula, R s C 1-15 Alkyl and C 1-15 The alkoxy may each independently be one or more R t1 wherein R t1 is independently in each occurrence halo, oxo, —OH, —CN, 5- to 6-membered heteroaryl, or —NR d R e where R d and R e are each independently H or C 1-6 alkyl, where R d or R e C 1-6 The alkyl is optionally substituted with one or more substituents selected from halo, oxo, —OH, and —CN; and In the formula, R s C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 The cycloalkyl and 3- to 15-membered heterocyclyl each independently represent one or more R t2 wherein R t2 is independently in each occurrence halo, oxo, —OH, —CN, and C 1-6 alkyl; and In the formula, R d and R eare each independently H or C 1-6 alkyl, and R d or R e C 1-6 The alkyl is optionally substituted with one or more substituents selected from halo, oxo, —OH and —CN; X 3 is N or CH; B is phenyl or 5- to 6-membered heteroaryl; the phenyl and 5- to 6-membered heteroaryl of B are each independently one or more R 2 and wherein R 2 independently, in each occurrence, halo;S(R y ) 5, wherein each R y is halo; or C optionally substituted with one or more halo 1-6 Is it alkoxy; R 3 is H or C 1-6 is alkyl; Z is -OH, -NR d R e , C 1-6 Alkoxy, -C(O)R a , or -S(O)R b and In the formula, R d and R e are each independently H or C 1-6 alkyl, and R d or R e C 1-6 The alkyl is optionally substituted with one or more substituents selected from halo, oxo, —OH and —CN; R a and R b are each independently: i) deuterium, C 1-6 Alkyl, Hydroxyl C 1-6 Alkyl, halo and haloC 1-6 C optionally substituted with one or more substituents selected from alkyl 2-6 alkenyl; or ii) C optionally substituted with one or more halo 1-6 is alkyl; L is one or more C1-6 methylene optionally substituted with alkyl; and n and m are 1; or n and m are 2; However, 1) X 1 R 1 and together with the atom to which they are attached form a phenyl, and 2) X 2 or X 3 If is N, then In formula (II-B), B is phenyl and R 2 Halo C 1-6 Provided that it is alkoxyl.
[0149] In some embodiments, provided herein are compounds of Formula (II-AB), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein L′ is *—N(R 3 )-L-**, where * represents the point of attachment to Z, and ** represents TIFF2024543912000020.tif27170
[0150] In some embodiments, provided herein are compounds of formula (II-AB), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein: TIFF2024543912000021.tif17170In the formula, * represents the point of attachment to Z, TIFF2024543912000022.tif27170
[0151] In some embodiments, provided herein are compounds of formula (II-AB), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is R 1 and together with the atom to which they are attached, a 5- to 6-membered heteroaryl, a 5- to 6-membered heterocyclyl, a phenyl, or C fused to ring A 5-6 Forms a cycloalkyl, X 1 and R 1 5- to 6-membered heteroaryl, 5- to 6-membered heterocyclyl, phenyl, and C 5-6Cycloalkyl may each independently be one or more R t and optionally substituted with R t independently, in each occurrence, halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , or -NR d R e wherein R d and R e are each independently H or C 1-6 In some embodiments, R d and R e are each independently H or C 1-6 In some embodiments, R d is H or C 1-6 In some embodiments, R d is H. In some embodiments, R d is C 1-6 In some embodiments, R e is H or C 1-6 In some embodiments, R e is H or C 1-6 In some embodiments, R e is H. In some embodiments, R e is C 1-6 It is alkyl.
[0152] In some embodiments, provided herein are compounds of formula (II-AB), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is R1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t independently, in each occurrence, halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e In some embodiments, X is selected from the group consisting of 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t independently, in each occurrence, halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e In some embodiments, X is selected from the group consisting of 1 is R 1and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t is halo. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t is C 1-15 In some embodiments, X is alkyl. 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t is C 6-20 In some embodiments, X is aryl. 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t is a 5- to 15-membered heteroaryl. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t is C 3-20 In some embodiments, X is cycloalkyl. 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t is 3-15 membered heterocyclyl. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more Rt is substituted with R t is —OH. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t is -CN. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t is oxo. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t is C 1-15 In some embodiments, X is alkoxy. 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t Ha-NR d COR e In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t -CONR d R e In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t Ha-SO2R dIn some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t Ha-SO2NR d R e In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t Ha-NR d SO2R e In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t Ha-NR d R e In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t Ha-NR d R e and R d and R e are each independently H or C 1-6 In some embodiments, X is alkyl. 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t Ha-NR d R e and R d is H or C 1-6 In some embodiments, X is alkyl. 1is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t Ha-NR d R e and R d is H. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t Ha-NR d R e and R d teeth 1-6 In some embodiments, X is alkyl. 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t Ha-NR d R e and R e is H or C 1-6 In some embodiments, X is alkyl. 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t Ha-NR d R e and R e is H or C 1-6 In some embodiments, X is alkyl. 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t Ha-NR d R e and R eis H. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t Ha-NR d R e and R e is C 1-6 It is alkyl.
[0153] In some embodiments, provided herein are compounds of formula (II-AB), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, the 5- to 6-membered heterocyclyl being one or more R t is substituted with R t independently, in each occurrence, halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e In some embodiments, X is selected from the group consisting of 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t independently, in each occurrence, halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e In some embodiments, X is selected from the group consisting of 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t is halo. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t is C 1-15 In some embodiments, X is alkyl. 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t is C 6-20 In some embodiments, X is aryl. 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t is 5-15 membered heterocyclyl. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with Rt is C 3-20 In some embodiments, X is cycloalkyl. 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t is 3-15 membered heterocyclyl. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t is —OH. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t is -CN. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t is oxo. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t is C 1-15 In some embodiments, X is alkoxy. 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t Ha-NR d COR e In some embodiments, X 1 is R 1and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t -CONR d R e In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t Ha-SO2R d In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t Ha-SO2NR d R e In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t Ha-NR d SO2R e In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t Ha-NR d R e In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t Ha-NR d R e and R dand R e are each independently H or C 1-6 In some embodiments, X is alkyl. 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t Ha-NR d R e and R d is H or C 1-6 In some embodiments, X is alkyl. 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t Ha-NR d R e and R d is H. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t Ha-NR d R e and R d is C 1-6 In some embodiments, X is alkyl. 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t Ha-NR d R e and R e is H or C 1-6 In some embodiments, R e is H or C 1-6 In some embodiments, X is alkyl. 1 is R 1and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t Ha-NR d R e and R e is H. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t Ha-NR d R e and R e is C 1-6 It is alkyl.
[0154] In some embodiments, provided herein are compounds of formula (II-AB), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being substituted with one or more R t is substituted with R t independently, in each occurrence, halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e In some embodiments, X is selected from the group consisting of 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more Rt is substituted with R t independently, in each occurrence, halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e In some embodiments, X is selected from the group consisting of 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t is halo. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t is C 1-15 In some embodiments, X is alkyl. 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t is C 6-20 In some embodiments, X is aryl. 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t is a 5- to 15-membered heteroaryl. In some embodiments, X 1 is R 1and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is replaced by R t is C 3-20 In some embodiments, X is cycloalkyl. 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t is 3-15 membered heterocyclyl. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t is —OH. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t is -CN. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t is oxo. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t is C 1-15 In some embodiments, X is alkoxy. 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t Ha-NR d COR e In some embodiments, X 1 is R 1and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t -CONR d R e In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t Ha-SO2R d In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t is -SO2NR d R e In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t Ha-NR d SO2R e In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t Ha-NR d R e In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t Ha-NR d R e and R d and R e are each independently H or C 1-6 In some embodiments, X is alkyl. 1 is R 1and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t Ha-NR d R e and R d is H or C 1-6 In some embodiments, X is alkyl. 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t Ha-NR d R e and R d is H. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t Ha-NR d R e and R d is C 1-6 In some embodiments, X is alkyl. 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t Ha-NR d R e and R e is H or C 1-6 In some embodiments, X is alkyl. 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t Ha-NR d R e and R e is H or C 1-6 In some embodiments, X is alkyl. 1 is R 1and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t Ha-NR d R e and R e is H. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t Ha-NR d R e and R e is C 1-6 It is alkyl.
[0155] In some embodiments, provided herein are compounds of formula (II-AB), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t independently, in each occurrence, halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e In some embodiments, X is selected from the group consisting of 1 is R 1 and together with the atoms to which they are attached, C 5-6Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t independently, in each occurrence, halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e In some embodiments, X is selected from the group consisting of 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t is halo. In some embodiments, X 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t is C 1-15 In some embodiments, X is alkyl. 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t is C 6-20 In some embodiments, X is aryl. 1 is R 1and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t is a 5-15 membered heteroaryl. In some embodiments, X 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t is C 3-20 In some embodiments, X is cycloalkyl. 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t is 3-15 membered heterocyclyl. 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t is —OH. In some embodiments, X 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t is -CN. In some embodiments, X 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t is oxo. In some embodiments, X1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t is C 1-15 In some embodiments, X is alkoxy. 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t is -NR d COR e In some embodiments, X 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t -CONR d R e In some embodiments, X 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t Ha-SO2R d In some embodiments, X 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t Ha-SO2NR d R e In some embodiments, X 1 is R 1 and together with the atoms to which they are attached, C5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t Ha-NR d SO2R e In some embodiments, X 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t Ha-NR d R e In some embodiments, X 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t Ha-NR d R e and R d and R e are each independently H or C 1-6 In some embodiments, X is alkyl. 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t Ha-NR d R e and R d is H or C 1-6 In some embodiments, X is alkyl. 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t Ha-NR d R eand R d is H. In some embodiments, X 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t Ha-NR d R e and R d is C 1-6 In some embodiments, X is alkyl. 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t Ha-NR d R e and R e is H or C 1-6 In some embodiments, X is alkyl. 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t Ha-NR d R e and R e is H or C 1-6 In some embodiments, X is alkyl. 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t Ha-NR d R e and R e is H. In some embodiments, X 1 is R 1 and together with the atoms to which they are attached, C5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t Ha-NR d R e and R e is C 1-6 It is alkyl.
[0156] In some embodiments, X 2 is N or CR s and R s H, halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , or -NR d R e Provided herein are compounds of formula (II-AB), wherein X is a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. 2 is N. In some embodiments, X 2 is CR s In some embodiments, X 2 is CR s where R s H, halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d Re , -NR d SO2R e , or -NR d R e In some embodiments, X 2 is CR s and R s is H. In some embodiments, X 2 is CR s and R s is halo. In some embodiments, X 2 is CR s and R s is C 1-15 In some embodiments, X is alkyl. 2 is CR s and R s is C 6-20 In some embodiments, X is aryl. 2 is CR s and R s is a 5- to 15-membered heteroaryl. In some embodiments, X 2 is CR s and R s is C 3-20 In some embodiments, X is cycloalkyl. 2 is CR s and R s is 3-15 membered heterocyclyl. In some embodiments, X 2 is CR s and R s is —OH. In some embodiments, X 2 is CR s and R s is -CN. In some embodiments, X 2 is CR s and R s is C 1-15 In another embodiment, X is alkoxy. 2 is CR s and R s Ha-NR d COR e In another embodiment, X 2 is CR s and R s -CONRd R e In another embodiment, X 2 is CR s and R s Ha-SO2R d In another embodiment, X 2 is CR s and R s Ha-SO2NR d R e In another embodiment, X 2 is CR s and R s Ha-NR d SO2R e In some embodiments, X 2 is CR s and R s Ha-NR d R e In some embodiments, X 2 is CR s and R s Ha-NR d R e , R d and R e are each independently H or C 1-6 In some embodiments, X is alkyl. 2 is CR s and R s Ha-NR d R e and R d is H or C 1-6 In some embodiments, X is alkyl. 2 is CR s and R s Ha-NR d R e and R d is H. In some embodiments, X 2 is CR s and R s Ha-NR d R e and R d is C 1-6 In some embodiments, X is alkyl. 2 is CR s and R s Ha-NRd R e and R e is H or C 1-6 In some embodiments, X is alkyl. 2 is CR s and R s Ha-NR d R e and R e is H or C 1-6 In some embodiments, X is alkyl. 2 is CR s and R s Ha-NR d R e and R e is H. In some embodiments, X 2 is CR s and R s Ha-NR d R e and R e is C 1-6 It is alkyl.
[0157] In some embodiments, provided herein are compounds of formula (II-AB), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 2 is CR s and R s is C 1-15 Alkyl or C 1-15 is alkoxy, and R s C 1-15 Alkyl and C 1-15 The alkoxy may each independently be one or more R t1 and optionally substituted with R t1 is independently in each occurrence, halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR dR e , -NR d SO2R e , and -NR d R e In some embodiments, X is selected from the group consisting of 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 alkyl, and R t1 is independently in each occurrence, halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e In some embodiments, X is selected from the group consisting of 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 alkyl, and R t1 is halo. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 alkyl, and R t1 is oxo. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 alkyl, and R t1 is —OH. In some embodiments, X 2 is CR sand R s is one or more R t1 C optionally substituted with 1-15 alkyl, and R t1 is -CN. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 alkyl, and R t1 Ha-NR d R e is.
[0158] In some embodiments, provided herein are compounds of formula (II-AB), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 is independently in each occurrence halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e In some embodiments, X is selected from the group consisting of 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 is halo. In some embodiments, X 2 is CR s and Rs is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 is oxo. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 is —OH. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 is -CN. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 Ha-NR d R e is.
[0159] In some embodiments, provided herein is a compound of formula (II-AB), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 Ha-NR d R e and R d and R e are each independently H or C 1-6 alkyl, and R d or R e C 1-6 The alkyl is optionally substituted with one or more halo, oxo, -OH, or -CN. In some embodiments, X 2 is CR s and R sis one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 Ha-NR d R e and R d is H. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 Ha-NR d R e and R d is C 1-6 In some embodiments, X is alkyl. 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 Ha-NR d R e and R e is H. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 Ha-NR d R e and R e is C 1-6 In some embodiments, X is alkyl. 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 Ha-NR d R e and R d or R e is independently C 1-6 alkyl, and R d or R e C 1-6The alkyl is optionally substituted with one or more halo, oxo, -OH, or -CN. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 Ha-NR d R e and R d is C 1-6 alkyl, and R d C 1-6 The alkyl is optionally substituted with one or more halo, oxo, -OH, or -CN. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 Ha-NR d R e and R d is C 1-6 alkyl, and R d C 1-6 The alkyl is optionally substituted with one or more halo. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 Ha-NR d R e and R d is C 1-6 alkyl, and R d C 1-6 The alkyl is optionally substituted with one or more oxo. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 Ha-NR d R e and R dis C 1-6 alkyl, and R d C 1-6 The alkyl is optionally substituted with one or more -OH. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 Ha-NR d R e and R d is C 1-6 alkyl, and R d C 1-6 The alkyl is optionally substituted with one or more -CN. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 Ha-NR d R e and R e is C 1-6 alkyl, and R e C 1-6 The alkyl is optionally substituted with one or more halo, oxo, -OH, or -CN. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 Ha-NR d R e and R e is C 1-6 is alkyl, e C 1-6 The alkyl is optionally substituted with one or more halo. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 Ha-NRd R e and R e is C 1-6 is alkyl, e C 1-6 The alkyl is optionally substituted with one or more oxo. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 Ha-NR d R e and R e is C 1-6 is alkyl, e C 1-6 The alkyl is optionally substituted with one or more -OH. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 Ha-NR d R e and R e is C 1-6 is alkyl, e C 1-6 The alkyl is optionally substituted with one or more -CN.
[0160] In some embodiments, provided herein are compounds of formula (II-AB), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 2 is CR s and R s is C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 cycloalkyl, or 3- to 15-membered heterocyclyl; R s C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl and 3- to 15-membered heterocyclyl each independently represent one or more R t2 and optionally substituted with Rt2 is independently in each occurrence, halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e In some embodiments, X is selected from the group consisting of 2 is CR s where R s is C 6-20 aryl, and R s C 6-20 Aryl can be one or more R t2 optionally substituted with R t2 is, independently in each occurrence, halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e In some embodiments, X is selected from the group consisting of 2 is CR s and R s is C 6-20 aryl, and R s C 6-20 Aryl is R t2 optionally substituted with R t2is halo. In some embodiments, X 2 is CR s and R s is C 6-20 aryl, and R s C 6-20 Aryl is R t2 optionally substituted with R t2 is oxo. In some embodiments, X 2 is CR s and R s is C 6-20 aryl, and R s C 6-20 Aryl is R t2 optionally substituted with R t2 is —OH. In some embodiments, X 2 is CR s and R s is C 6-20 aryl, and R s C 6-20 Aryl is R t2 optionally substituted with R t2 is -CN. In some embodiments, X 2 is CR s and R s is C 6-20 aryl, and R s C 6-20 Aryl is R t2 optionally substituted with R t2 is C 1-6 It is alkyl.
[0161] In some embodiments, provided herein are compounds of formula (II-AB), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 2 is CR s and R s is a 5- to 15-membered heteroaryl, and R s The 5- to 15-membered heteroaryl may be one or more R t2 optionally substituted with R t2 is independently in each occurrence halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e In some embodiments, X is selected from the group consisting of 2 is CR s and R s is a 5- to 15-membered heteroaryl, and R s The 5-15 membered heteroaryl is R t2 optionally substituted with R t2 is halo. In some embodiments, X 2 is CR s and R s is a 5- to 15-membered heteroaryl, and R s The 5-15 membered heteroaryl is R t2 optionally substituted with R t2 is oxo. In some embodiments, X 2 is CR s and R s is a 5- to 15-membered heteroaryl, and R s The 5-15 membered heteroaryl is R t2 optionally substituted with R t2 is —OH. In some embodiments, X 2 is CR s and R s is a 5- to 15-membered heteroaryl, and R s The 5-15 membered heteroaryl is R t2 optionally substituted with R t2 is -CN. In some embodiments, X 2 is CR s and R s is a 5- to 15-membered heteroaryl, and R s The 5-15 membered heteroaryl is R t2and optionally substituted with R t2 is C 1-6 It is alkyl.
[0162] In some embodiments, provided herein are compounds of formula (II-AB), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 2 is CR s and R s is C 6-20 is cycloalkyl, and R s C 6-20 Cycloalkyl can be one or more R t2 and optionally substituted with R t2 is independently in each occurrence halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e In some embodiments, X is selected from the group consisting of 2 is CR s and R s is C 6-20 is cycloalkyl, and R s C 6-20 Cycloalkyl is R t2 and optionally substituted with R t2 is halo. In some embodiments, X 2 is CR s and R s is C 6-20 is cycloalkyl, and R s C 6-20 Cycloalkyl is R t2 and optionally substituted with R t2is oxo. In some embodiments, X 2 is CR s and R s is C 6-20 is cycloalkyl, and R s C 6-20 Cycloalkyl is R t2 and optionally substituted with R t2 is —OH. In some embodiments, X 2 is CR s and R s is C 6-20 is cycloalkyl, and R s C 6-20 Cycloalkyl is R t2 and optionally substituted with R t2 is -CN. In some embodiments, X 2 is CR s and R s is C 6-20 is cycloalkyl, and R s C 6-20 Cycloalkyl is R t2 and optionally substituted with R t2 is C 1-6 It is alkyl.
[0163] In some embodiments, provided herein are compounds of formula (II-AB), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 2 is CR s and R s is a 5- to 15-membered heterocyclyl, and R s The 5- to 15-membered heterocyclyl may be one or more R t2 and optionally substituted with R t2 is independently in each occurrence halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2Rd , -SO2NR d R e , -NR d SO2R e , and -NR d R e In some embodiments, X is selected from the group consisting of 2 is CR s and R s is a 5- to 15-membered heterocyclyl, and R s 5-15 membered heterocyclyl is R t2 optionally substituted with R t2 is halo. In some embodiments, X 2 is CR s and R s is a 5- to 15-membered heterocyclyl, and R s 5-15 membered heterocyclyl is R t2 optionally substituted with R t2 is oxo. In some embodiments, X 2 is CR s and R s is a 5- to 15-membered heterocyclyl, and R s 5-15 membered heterocyclyl is R t2 optionally substituted with R t2 is —OH. In some embodiments, X 2 is CR s and R s is a 5- to 15-membered heterocyclyl, and R s 5-15 membered heterocyclyl is R t2 optionally substituted with R t2 is -CN. In some embodiments, X 2 is CR s and R s is a 5- to 15-membered heterocyclyl, and R s 5-15 membered heterocyclyl is R t2 optionally substituted with R t2 is C 1-6 It is alkyl.
[0164] In some embodiments, X 3Provided herein are compounds of formula (II-AB), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X is N or CH. In some embodiments, X 3 is N. In some embodiments, X 3 is CH.
[0165] In some embodiments, provided herein is a compound of Formula (II-AB), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein B is phenyl or 5-6 membered heteroaryl; and wherein the phenyl and 5-6 membered heteroaryl of B each independently represent 1-5 R 2 In some embodiments, B is substituted with 1 to 5 R 2 In some embodiments, B is phenyl independently substituted with 1 to 5 R 2 is a 5- to 6-membered heteroaryl independently substituted with
[0166] In some embodiments, provided herein are compounds of formula (II-AB), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R 2 independently, in each occurrence: i) halo; ii) S(R y )5 (in the formula, each R y is halo); or iii) C optionally substituted with one or more halo. 1-6 In some embodiments, R 2 is halo. In some embodiments, R 2 is S(R y )5, each R y is halo. In some embodiments, R 2 is C optionally substituted with one or more halo 1-6 In some embodiments, R 2 is the unsubstituted C 1-6 It is an alkoxy.
[0167] In some embodiments, R 3 is H or C 1-6Provided herein are compounds of Formula (II-AB), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R is alkyl. 3 is H. In some embodiments, R 3 is C 1-6 It is alkyl.
[0168] In some embodiments, Z is —OH, —NR d R e , C 1-6 Alkoxy, -C(O)R a , -S(O)2R a Provided herein are compounds of formula (II-AB), wherein: d R e and R d and R e are each independently H or C 1-6 In some embodiments, Z is NR d R e and R d is H. In some embodiments, Z is NR d R e and R d is C 1-6 In some embodiments, Z is NR d R e and R e is H. In some embodiments, Z is NR d R e and R e is C 1-6 In some embodiments, Z is —C(O)R a In some embodiments, Z is —C(O)R a where R a is a hydrogen atom containing one or more deuterium atoms, 1-6 Alkyl, Halo, HaloC 1-6 C optionally substituted with alkyl 2-6 alkenyl; or ii) C optionally substituted with one or more halo 1-6In some embodiments, Z is —C(O)R a where R a is one or more deuterium atoms, C 1-6 Alkyl, Halo, HaloC 1-6 C optionally substituted with alkyl 2-6 In some embodiments, Z is -C(O)R a where R a is C optionally substituted with one or more halo 1-6 In some embodiments, Z is —C(O)R a where R a is a C optionally substituted with one or more deuterium atoms 2-6 In some embodiments, Z is -C(O)R a where R a is C 1-6 In some embodiments, Z is —C(O)R a where R a is Haro C 1-6 It is alkyl.
[0169] In some embodiments, provided herein are compounds of Formula (II-AB), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein Z is —C(O)R a and R a is one or more deuterium atoms, C 1-6 Alkyl, Halo, HaloC 1-6 C optionally substituted with alkyl 2-6 alkenyl; B is one or more R 2 is phenyl substituted with R 2 is C optionally substituted with one or more halo 1-6 In some embodiments, Z is -C(O)R a and R a is a C optionally substituted with one or more deuterium atoms 2-6 alkenyl; B is one or more R 2 is phenyl substituted with R 2 is C optionally substituted with one or more halo1-6 In some embodiments, Z is -C(O)R a and R a is C optionally substituted with one or more halo 2-6 alkenyl; B is one or more R 2 is phenyl substituted with R 2 is C optionally substituted with one or more halo 1-6 In some embodiments, Z is -C(O)R a and R a is one or more C 1-6 C optionally substituted with alkyl 2-6 alkenyl; B is one or more R 2 is phenyl substituted with R 2 is C optionally substituted with one or more halo 1-6 In some embodiments, Z is -C(O)R a and R a is one or more halo C 1-6 C optionally substituted with alkyl 2-6 alkenyl; B is one or more R 2 is phenyl substituted with R 2 is C optionally substituted with one or more halo 1-6 It is an alkoxy.
[0170] In some embodiments, provided herein are compounds of formula (II-AB), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is C or N, and X 1 is R 1 and together with the atoms to which they are attached form a 5- to 6-membered heteroaryl, a 5- to 6-membered heterocyclyl, a phenyl, or a C5 cycloalkyl fused to ring A; X 2 is N or CR s where R s is a C optionally substituted with -OH, 5-membered heteroaryl, and -CN 1-15 alkyl; X 3is N or CH; B is phenyl or 5-membered heteroaryl, and the phenyl and 5- to 6-membered heteroaryl of B are each independently one or more R 2 is substituted with R 2 independently, in each occurrence, S(R y ) 5, wherein each R y is independently halo or C optionally substituted with one or more halo 1-6 alkoxy; L is C 1-6 methylene optionally substituted with alkyl; R 3 is H or C 1-6 alkyl; Z is -C(O)R a , -S(O)2R b where R a is C optionally substituted with deuterium 2-6 Alkenyl or halo substituted C 1-6 alkyl, and R b is a halo-substituted C 1-6 In some embodiments, R s is methyl or ethyl. In some embodiments, each R y is fluoro. In some embodiments, R 2 is trifluoromethoxy. In some embodiments, R a is ethenyl. In some embodiments, R a is chloromethyl. In some embodiments, R b is chloromethyl.
[0171] In some embodiments, X 1 Provided herein are compounds of formula (II-A), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X is C or N. In some embodiments, X 1 is C. In some embodiments, X 1 is N. In some embodiments, X 1 is R 1 and together with the atom to which they are attached, a 5- to 6-membered heteroaryl, a 5- to 6-membered heterocyclyl, a phenyl, or C fused to ring A5-6 In some embodiments, X forms a cycloalkyl. 1 is C and R 1 and together with the atom to which they are attached, a 5- to 6-membered heteroaryl, a 5- to 6-membered heterocyclyl, a phenyl, or C fused to ring A 5-6 In some embodiments, X forms a cycloalkyl. 1 is C and R 1 and together with the atoms to which they are attached form a 5-6 membered heteroaryl fused to ring A. In some embodiments, X 1 is C and R 1 and together with the atoms to which they are attached form a 5-6 membered heteroaryl fused to ring A. In some embodiments, X 1 is C and R 1 and together with the atom to which they are attached form a phenyl fused to ring A. In some embodiments, X 1 is C and R 1 and C fused to ring A together with the atoms to which they are attached. 5-6 In some embodiments, X forms a cycloalkyl. 1 is N and R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl or 5- to 6-membered heterocyclyl fused to ring A. In some embodiments, X 1 is N and R 1 and together with the atoms to which they are attached form a 5-6 membered heteroaryl fused to ring A. In some embodiments, X 1 is N and R 1 and together with the atoms to which they are attached form a 5- to 6-membered heterocyclyl fused to ring A.
[0172] In some embodiments, provided herein are compounds of formula (II-A), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is R 1and together with the atom to which they are attached, a 5- to 6-membered heteroaryl, a 5- to 6-membered heterocyclyl, a phenyl, or C fused to ring A 5-6 5-6 membered heteroaryl, 5-6 membered heterocyclyl, phenyl, or C fused to ring A to form a cycloalkyl 5-6 Cycloalkyl is TIFF2024543912000023.tif105170.
[0173] In some embodiments, in conjunction with the above or below embodiments, a 5- to 6-membered heteroaryl, 5- to 6-membered heterocyclyl, phenyl, or C fused to ring A 5-6 Cycloalkyl can be one or more R t is not replaced by
[0174] It is understood that the embodiments described herein with respect to any one of formulas (II-AB), (II-A), or (II-B) apply to formula (II-AB') as if each and every embodiment were specifically and individually recited with respect to formula (II-AB').
[0175] In some embodiments, provided herein are compounds of Formula (II-AB), (II-A), and (II-B), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is R 1 and together with the atom to which they are attached, a 5- to 6-membered heteroaryl, a 5- to 6-membered heterocyclyl, a phenyl, or C fused to ring A 5-6 5-6 membered heteroaryl, 5-6 membered heterocyclyl, phenyl, or C fused to ring A to form a cycloalkyl 5-6 Cycloalkyl is TIFF2024543912000024.tif138170; each of which is selected from the group consisting of one or more R t In some embodiments, each R t independently, in each occurrence, halo, C 1-15Alkyl, HaloC 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e wherein R d and R e are each independently H or C 1-6 alkyl, and R d or R e C 1-6 The alkyl is optionally substituted with one or more substituents selected from halo, oxo, —OH, and —CN. In some embodiments, R t is selected from the group consisting of methyl and -CHF2.
[0176] In some embodiments, in conjunction with the above or below embodiments, a 5- to 6-membered heteroaryl, 5- to 6-membered heterocyclyl, phenyl, or C fused to ring A 5-6 Cycloalkyl can be one or more R t is not replaced by
[0177] In some embodiments, provided herein are compounds of Formula (II-AB), (II-A), or (II-B), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is R 1 and together with the atom to which they are attached, a 5- to 6-membered heteroaryl, a 5- to 6-membered heterocyclyl, a phenyl, or C fused to ring A 5-6 5-6 membered heteroaryl, 5-6 membered heterocyclyl, phenyl, or C fused to ring A to form a cycloalkyl 5-6Cycloalkyl is TIFF2024543912000025.tif142170. In some embodiments, each R t independently, in each occurrence, halo, C 1-15 Alkyl, HaloC 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e wherein R d and R e are each independently H or C 1-6 alkyl, and R d or R e C 1-6 The alkyl is optionally substituted with one or more substituents selected from halo, oxo, —OH, and —CN. In some embodiments, R t is selected from the group consisting of methyl and -CHF2.
[0178] In some embodiments, in conjunction with the above or below embodiments, a 5- to 6-membered heteroaryl, 5- to 6-membered heterocyclyl, phenyl, or C fused to ring A 5-6 Cycloalkyl can be one or more R t is not replaced by
[0179] In some embodiments, provided herein are compounds of Formula (II-AB), (II-A), and (II-B), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is R 1and together with the atom to which they are attached, a 5- to 6-membered heteroaryl, a 5- to 6-membered heterocyclyl, a phenyl, or C fused to ring A 5-6 5-6 membered heteroaryl, 5-6 membered heterocyclyl, phenyl, or C fused to ring A to form a cycloalkyl 5-6 Cycloalkyl is TIFF2024543912000026.tif160170; each of which is selected from the group consisting of one or more R t In some embodiments, each R t independently, in each occurrence, halo, C 1-15 Alkyl, HaloC 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e wherein R d and R e are each independently H or C 1-6 alkyl, and R d or R e C 1-6 The alkyl is optionally substituted with one or more substituents selected from halo, oxo, —OH, and —CN. In some embodiments, R t is selected from the group consisting of methyl and -CHF2.
[0180] In some embodiments, in conjunction with the above or below embodiments, a 5- to 6-membered heteroaryl, 5- to 6-membered heterocyclyl, phenyl, or C fused to ring A 5-6 Cycloalkyl can be one or more R tis not replaced by
[0181] In some embodiments, provided herein are compounds of Formula (II-AB), (II-A), or (II-B), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is R 1 and together with the atom to which they are attached, a 5- to 6-membered heteroaryl, a 5- to 6-membered heterocyclyl, a phenyl, or C fused to ring A 5-6 5-6 membered heteroaryl, 5-6 membered heterocyclyl, phenyl, or C fused to ring A to form a cycloalkyl 5-6 Cycloalkyl is TIFF2024543912000027.tif149170. In some embodiments, each R t independently, in each occurrence, halo, C 1-15 Alkyl, HaloC 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e wherein R d and R e are each independently H or C 1-6 alkyl, and R d or R e C 1-6 The alkyl is optionally substituted with one or more substituents selected from halo, oxo, —OH, and —CN. In some embodiments, R t is selected from the group consisting of methyl and -CHF2.
[0182] In some embodiments, in conjunction with the above or below embodiments, a 5- to 6-membered heteroaryl, 5- to 6-membered heterocyclyl, phenyl, or C fused to ring A 5-6 Cycloalkyl can be one or more R t is not replaced by
[0183] In some embodiments, provided herein are compounds of formula (II-A), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is R 1 and together with the atom to which they are attached, a 5- to 6-membered heteroaryl, a 5- to 6-membered heterocyclyl, a phenyl, or C fused to ring A 5-6 Forms a cycloalkyl, X 1 and R 1 5- to 6-membered heteroaryl, 5- to 6-membered heterocyclyl, phenyl, and C 5-6 Cycloalkyl may each independently be one or more R t and optionally substituted with R t independently, in each occurrence, halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , or -NR d R e wherein R d and R e are each independently H or C 1-6 In some embodiments, R d and R e are each independently H or C 1-6 In some embodiments, Rd is H or C 1-6 In some embodiments, R d is H. In some embodiments, R d is C 1-6 In some embodiments, R e is H or C 1-6 In some embodiments, R e is H or C 1-6 In some embodiments, R e is H. In some embodiments, R e is C 1-6 It is alkyl.
[0184] In some embodiments, provided herein are compounds of formula (II-A), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t independently, in each occurrence, halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e In some embodiments, X is selected from the group consisting of 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with Rt independently, in each occurrence, halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e In some embodiments, X is selected from the group consisting of 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t is halo. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t is C 1-15 In some embodiments, X is alkyl. 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t is C 6-20 In some embodiments, X is aryl. 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t is a 5- to 15-membered heteroaryl. In some embodiments, X 1 is R1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t is C 3-20 In some embodiments, X is cycloalkyl. 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t is 3-15 membered heterocyclyl. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t is —OH. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t is -CN. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t is oxo. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t is C 1-15 In some embodiments, X is alkoxy. 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R tis substituted with R t Ha-NR d COR e In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t -CONR d R e In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t Ha-SO2R d In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t Ha-SO2NR d R e In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t Ha-NR d SO2R e In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t Ha-NR d R e In some embodiments, X 1 is R 1and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t Ha-NR d R e and R d and R e are each independently H or C 1-6 In some embodiments, X is alkyl. 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t Ha-NR d R e and R d is H or C 1-6 In some embodiments, X is alkyl. 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t Ha-NR d R e and R d is H. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t Ha-NR d R e and R d teeth 1-6 In some embodiments, X is alkyl. 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t Ha-NR d R e and R e is H or C1-6 In some embodiments, X is alkyl. 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t Ha-NR d R e and R e is H or C 1-6 In some embodiments, X is alkyl. 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t Ha-NR d R e and R e is H. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t Ha-NR d R e and R e is C 1-6 It is alkyl.
[0185] In some embodiments, in conjunction with the above or below embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which 5- to 6-membered heteroaryl may be one or more R t is not replaced by
[0186] In some embodiments, provided herein are compounds of formula (II-A), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is R 1and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, the 5- to 6-membered heterocyclyl being one or more R t is substituted with R t independently, in each occurrence, halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e In some embodiments, X is selected from the group consisting of 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t independently, in each occurrence, halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e In some embodiments, X is selected from the group consisting of 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more Rt is substituted with R t is halo. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t is C 1-15 In some embodiments, X is alkyl. 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t is C 6-20 In some embodiments, X is aryl. 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t is 5-15 membered heterocyclyl. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t is C 3-20 In some embodiments, X is cycloalkyl. 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t is 3-15 membered heterocyclyl. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t is —OH. In some embodiments, X 1is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t is -CN. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t is oxo. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t is C 1-15 In some embodiments, X is alkoxy. 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t Ha-NR d COR e In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t -CONR d R e In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t Ha-SO2R d In some embodiments, X 1 is R 1and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t Ha-SO2NR d R e In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t Ha-NR d SO2R e In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t Ha-NR d R e In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t Ha-NR d R e and R d and R e are each independently H or C 1-6 In some embodiments, X is alkyl. 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t Ha-NR d R e and R d is H or C 1-6 In some embodiments, X is alkyl. 1 is R 1and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t Ha-NR d R e and R d is H. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t Ha-NR d R e and R d is C 1-6 In some embodiments, X is alkyl. 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t Ha-NR d R e and R e is H or C 1-6 In some embodiments, R e is H or C 1-6 In some embodiments, X is alkyl. 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t Ha-NR d R e and R e is H. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t Ha-NR d R e and R eis C 1-6 It is alkyl.
[0187] In some embodiments, in conjunction with the above or below embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, the 5- to 6-membered heterocyclyl being one or more R t is not replaced by
[0188] In some embodiments, provided herein are compounds of formula (II-A), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being substituted with one or more R t is substituted with R t independently, in each occurrence, halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e In some embodiments, X is selected from the group consisting of 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t independently, in each occurrence, halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e In some embodiments, X is selected from the group consisting of 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t is halo. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t is C 1-15 In some embodiments, X is alkyl. 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t is C 6-20 In some embodiments, X is aryl. 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t is a 5- to 15-membered heteroaryl. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is replaced by R t is C 3-20 In some embodiments, X is cycloalkyl. 1 is R 1and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t is 3-15 membered heterocyclyl. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t is —OH. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t is -CN. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t is oxo. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t is C 1-15 In some embodiments, X is alkoxy. 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t Ha-NR d COR e In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t -CONR d R e In some embodiments, X 1 is R 1and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t Ha-SO2R d In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t is -SO2NR d R e In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t Ha-NR d SO2R e In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t Ha-NR d R e In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t Ha-NR d R e and R d and R e are each independently H or C 1-6 In some embodiments, X is alkyl. 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t Ha-NR d R e and R d is H or C 1-6In some embodiments, X is alkyl. 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t Ha-NR d R e and R d is H. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t Ha-NR d R e and R d is C 1-6 In some embodiments, X is alkyl. 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t Ha-NR d R e and R e is H or C 1-6 In some embodiments, X is alkyl. 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t Ha-NR d R e and R e is H or C 1-6 In some embodiments, X is alkyl. 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t Ha-NR d R e and R e is H. In some embodiments, X 1 is R 1and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t Ha-NR d R e and R e is C 1-6 It is alkyl.
[0189] In some embodiments, in conjunction with the above or below embodiments, X 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being substituted with one or more R t is not replaced by
[0190] In some embodiments, provided herein are compounds of formula (II-A), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t independently, in each occurrence, halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e In some embodiments, X is selected from the group consisting of 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C5-6 Cycloalkyl can be one or more R t is substituted with R t independently, in each occurrence, halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e In some embodiments, X is selected from the group consisting of 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t is halo. In some embodiments, X 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t is C 1-15 In some embodiments, X is alkyl. 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t is C 6-20 In some embodiments, X is aryl. 1 is R 1 and together with the atoms to which they are attached, C 5-6Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t is a 5-15 membered heteroaryl. In some embodiments, X 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t is C 3-20 In some embodiments, X is cycloalkyl. 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t is 3-15 membered heterocyclyl. 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t is —OH. In some embodiments, X 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t is -CN. In some embodiments, X 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t is oxo. In some embodiments, X 1 is R 1and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t is C 1-15 In some embodiments, X is alkoxy. 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t is -NR d COR e In some embodiments, X 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t -CONR d R e In some embodiments, X 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t Ha-SO2R d In some embodiments, X 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t is -SO2NR d R e In some embodiments, X 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C5-6 Cycloalkyl can be one or more R t is substituted with R t Ha-NR d SO2R e In some embodiments, X 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t Ha-NR d R e In some embodiments, X 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t Ha-NR d R e and R d and R e are each independently H or C 1-6 In some embodiments, X is alkyl. 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t Ha-NR d R e and R d is H or C 1-6 In some embodiments, X is alkyl. 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t Ha-NR d R e and R dis H. In some embodiments, X 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t Ha-NR d R e and R d is C 1-6 In some embodiments, X is alkyl. 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t Ha-NR d R e and R e is H or C 1-6 In some embodiments, X is alkyl. 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t Ha-NR d R e and R e is H or C 1-6 In some embodiments, X is alkyl. 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t Ha-NR d R e and R e is H. In some embodiments, X 1 is R 1 and together with the atoms to which they are attached, C 5-6Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t Ha-NR d R e and R e is C 1-6 It is alkyl.
[0191] In some embodiments, in conjunction with the above or below embodiments, X 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is not replaced by
[0192] In some embodiments, X 2 is N or CR s and R s H, halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , or -NR d R e Provided herein are compounds of formula (II-A), wherein X is a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In some embodiments, X is a 2 is N. In some embodiments, X 2 is CR s In some embodiments, X 2 is CR s where R s H, halo, C 1-15 Alkyl, C 6-20Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , or -NR d R e In some embodiments, X 2 is CR s and R s is H. In some embodiments, X 2 is CR s and R s is halo. In some embodiments, X 2 is CR s and R s is C 1-15 In some embodiments, X is alkyl. 2 is CR s and R s is C 6-20 In some embodiments, X is aryl. 2 is CR s and R s is a 5- to 15-membered heteroaryl. In some embodiments, X 2 is CR s and R s is C 3-20 In some embodiments, X is cycloalkyl. 2 is CR s and R s is 3-15 membered heterocyclyl. In some embodiments, X 2 is CR s and R s is —OH. In some embodiments, X 2 is CR s and R s is -CN. In some embodiments, X 2 is CR s and Rs is C 1-15 In another embodiment, X is alkoxy. 2 is CR s and R s Ha-NR d COR e In another embodiment, X 2 is CR s and R s -CONR d R e In another embodiment, X 2 is CR s and R s Ha-SO2R d In another embodiment, X 2 is CR s and R s Ha-SO2NR d R e In another embodiment, X 2 is CR s and R s Ha-NR d SO2R e In some embodiments, X 2 is CR s and R s Ha-NR d R e In some embodiments, X 2 is CR s and R s Ha-NR d R e , R d and R e are each independently H or C 1-6 In some embodiments, X is alkyl. 2 is CR s and R s Ha-NR d R e and R d is H or C 1-6 In some embodiments, X is alkyl. 2 is CR s and R s Ha-NR d R e and R dis H. In some embodiments, X 2 is CR s and R s Ha-NR d R e and R d is C 1-6 In some embodiments, X is alkyl. 2 is CR s and R s Ha-NR d R e and R e is H or C 1-6 In some embodiments, X is alkyl. 2 is CR s and R s Ha-NR d R e and R e is H or C 1-6 In some embodiments, X is alkyl. 2 is CR s and R s Ha-NR d R e and R e is H. In some embodiments, X 2 is CR s and R s Ha-NR d R e and R e is C 1-6 It is alkyl.
[0193] In some embodiments, provided herein are compounds of formula (II-A), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 2 is CR s and R s is C 1-15 Alkyl or C 1-15 is alkoxy, and R s C 1-15 Alkyl and C 1-15 The alkoxy may each independently be one or more R t1 and optionally substituted with R t1 is independently in each occurrence, halo, C 1-15Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e In some embodiments, X is selected from the group consisting of 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 alkyl, and R t1 is independently in each occurrence, halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e In some embodiments, X is selected from the group consisting of 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 alkyl, and R t1 is halo. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15alkyl, and R t1 is oxo. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 alkyl, and R t1 is —OH. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 alkyl, and R t1 is -CN. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 alkyl, and R t1 Ha-NR d R e is.
[0194] In some embodiments, provided herein are compounds of formula (II-A), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 is independently in each occurrence halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d Re In some embodiments, X is selected from the group consisting of 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 is halo. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 is oxo. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 is —OH. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 is -CN. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 Ha-NR d R e is.
[0195] In some embodiments, provided herein is a compound of formula (II-A), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 Ha-NR d R e and Rd and R e are each independently H or C 1-6 alkyl, and R d or R e C 1-6 The alkyl is optionally substituted with one or more halo, oxo, -OH, or -CN. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 Ha-NR d R e and R d is H. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 Ha-NR d R e and R d is C 1-6 In some embodiments, X is alkyl. 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 Ha-NR d R e and R e is H. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 Ha-NR d R e and R e is C 1-6 In some embodiments, X is alkyl. 2 is CR s and R s is one or more R t1C optionally substituted with 1-15 is alkoxy, and R t1 Ha-NR d R e and R d or R e is independently C 1-6 alkyl, and R d or R e C 1-6 The alkyl is optionally substituted with one or more halo, oxo, -OH, or -CN. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 Ha-NR d R e and R d is C 1-6 alkyl, and R d C 1-6 The alkyl is optionally substituted with one or more halo, oxo, -OH, or -CN. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 Ha-NR d R e and R d is C 1-6 alkyl, and R d C 1-6 The alkyl is optionally substituted with one or more halo. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 Ha-NR d R e and R d is C 1-6 alkyl, and R d C 1-6The alkyl is optionally substituted with one or more oxo. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 Ha-NR d R e and R d is C 1-6 alkyl, and R d C 1-6 The alkyl is optionally substituted with one or more -OH. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 Ha-NR d R e and R d is C 1-6 alkyl, and R d C 1-6 The alkyl is optionally substituted with one or more -CN. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 Ha-NR d R e and R e is C 1-6 alkyl, and R e C 1-6 The alkyl is optionally substituted with one or more halo, oxo, -OH, or -CN. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 Ha-NR d R e and R e is C1-6 is alkyl, e C 1-6 The alkyl is optionally substituted with one or more halo. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 Ha-NR d R e and R e is C 1-6 is alkyl, e C 1-6 The alkyl is optionally substituted with one or more oxo. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 Ha-NR d R e and R e is C 1-6 is alkyl, e C 1-6 The alkyl is optionally substituted with one or more -OH. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 Ha-NR d R e and R e is C 1-6 is alkyl, e C 1-6 The alkyl is optionally substituted with one or more -CN.
[0196] In some embodiments, provided herein are compounds of formula (II-A), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 2 is CR s and R s is C6-20 Aryl, 5-15 membered heteroaryl, C 3-20 cycloalkyl, or 3- to 15-membered heterocyclyl; R s C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl and 3- to 15-membered heterocyclyl each independently represent one or more R t2 optionally substituted with R t2 is independently in each occurrence, halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e In some embodiments, X is selected from the group consisting of 2 is CR s where R s is C 6-20 aryl, and R s C 6-20 Aryl can be one or more R t2 optionally substituted with R t2 is, independently in each occurrence, halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e, and -NR d R e In some embodiments, X is selected from the group consisting of 2 is CR s and R s is C 6-20 aryl, and R s C 6-20 Aryl is R t2 and optionally substituted with R t2 is halo. In some embodiments, X 2 is CR s and R s is C 6-20 aryl, and R s C 6-20 Aryl is R t2 and optionally substituted with R t2 is oxo. In some embodiments, X 2 is CR s and R s is C 6-20 aryl, and R s C 6-20 Aryl is R t2 and optionally substituted with R t2 is —OH. In some embodiments, X 2 is CR s and R s is C 6-20 aryl, and R s C 6-20 Aryl is R t2 and optionally substituted with R t2 is -CN. In some embodiments, X 2 is CR s and R s is C 6-20 aryl, and R s C 6-20 Aryl is R t2 and optionally substituted with R t2 is C 1-6 It is alkyl.
[0197] In some embodiments, provided herein are compounds of formula (II-A), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X2 is CR s and R s is a 5- to 15-membered heteroaryl, and R s The 5- to 15-membered heteroaryl may be one or more R t2 optionally substituted with R t2 is independently in each occurrence halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e In some embodiments, X is selected from the group consisting of 2 is CR s and R s is a 5- to 15-membered heteroaryl, and R s The 5-15 membered heteroaryl is R t2 optionally substituted with R t2 is halo. In some embodiments, X 2 is CR s and R s is a 5- to 15-membered heteroaryl, and R s The 5-15 membered heteroaryl is R t2 optionally substituted with R t2 is oxo. In some embodiments, X 2 is CR s and R s is a 5- to 15-membered heteroaryl, and R s The 5-15 membered heteroaryl is R t2 optionally substituted with R t2 is —OH. In some embodiments, X 2 is CR s and R sis a 5- to 15-membered heteroaryl, and R s 5-15 membered heteroaryl is R t2 and optionally substituted with R t2 is -CN. In some embodiments, X 2 is CR s and R s is a 5- to 15-membered heteroaryl, and R s 5-15 membered heteroaryl is R t2 and optionally substituted with R t2 is C 1-6 It is alkyl.
[0198] In some embodiments, provided herein are compounds of formula (II-A), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 2 is CR s and R s is C 6-20 is cycloalkyl, and R s C 6-20 Cycloalkyl can be one or more R t2 and optionally substituted with R t2 is independently in each occurrence halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e In some embodiments, X is selected from the group consisting of 2 is CR s and R s is C 6-20 is cycloalkyl, and R s C 6-20 Cycloalkyl is R t2and optionally substituted with R t2 is halo. In some embodiments, X 2 is CR s and R s is C 6-20 is cycloalkyl, and R s C 6-20 Cycloalkyl is R t2 and optionally substituted with R t2 is oxo. In some embodiments, X 2 is CR s and R s is C 6-20 is cycloalkyl, and R s C 6-20 Cycloalkyl is R t2 and optionally substituted with R t2 is —OH. In some embodiments, X 2 is CR s and R s is C 6-20 is cycloalkyl, and R s C 6-20 Cycloalkyl is R t2 and optionally substituted with R t2 is -CN. In some embodiments, X 2 is CR s and R s is C 6-20 is cycloalkyl, and R s C 6-20 Cycloalkyl is R t2 and optionally substituted with R t2 is C 1-6 It is alkyl.
[0199] In some embodiments, provided herein are compounds of formula (II-A), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 2 is CR s and R s is a 5- to 15-membered heterocyclyl, and R s The 5- to 15-membered heterocyclyl may be one or more R t2 and optionally substituted with R t2 is independently in each occurrence halo, C1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e In some embodiments, X is selected from the group consisting of 2 is CR s and R s is a 5- to 15-membered heterocyclyl, and R s 5-15 membered heterocyclyl is R t2 optionally substituted with R t2 is halo. In some embodiments, X 2 is CR s and R s is a 5- to 15-membered heterocyclyl, and R s 5-15 membered heterocyclyl is R t2 optionally substituted with R t2 is oxo. In some embodiments, X 2 is CR s and R s is a 5- to 15-membered heterocyclyl, and R s 5-15 membered heterocyclyl is R t2 optionally substituted with R t2 is —OH. In some embodiments, X 2 is CR s and R s is a 5- to 15-membered heterocyclyl, and R s 5-15 membered heterocyclyl is R t2 optionally substituted with R t2 is -CN. In some embodiments, X 2 is CR s and R sis a 5- to 15-membered heterocyclyl, and R s 5-15 membered heterocyclyl is R t2 and optionally substituted with R t2 is C 1-6 It is alkyl.
[0200] In some embodiments, X 3 Provided herein are compounds of formula (II-A), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X is N or CH. In some embodiments, X 3 is N. In some embodiments, X 3 is CH.
[0201] In some embodiments, provided herein is a compound of Formula (II-A), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein B is phenyl or 5-6 membered heteroaryl; and wherein the phenyl and 5-6 membered heteroaryl of B each independently represent 1-5 R 2 In some embodiments, B is substituted with 1 to 5 R 2 In some embodiments, B is phenyl independently substituted with 1 to 5 R 2 is a 5- to 6-membered heteroaryl independently substituted with
[0202] In some embodiments, in conjunction with the above or below embodiments, B is one R 2 is a 5- to 6-membered heteroaryl independently substituted with
[0203] In some embodiments, provided herein are compounds of formula (II-A), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R 2 independently, in each occurrence: i) halo; ii) S(R y )5 (in the formula, each R y is halo); or iii) C optionally substituted with one or more halo. 1-6 In some embodiments, R 2 is halo. In some embodiments, R2 is S(R y )5, each R y is halo. In some embodiments, R 2 is C optionally substituted with one or more halo 1-6 In some embodiments, R 2 is the unsubstituted C 1-6 It is an alkoxy.
[0204] In some embodiments, R 3 is H or C 1-6 Provided herein are compounds of formula (II-A) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R is alkyl. In some embodiments, R 3 is H. In some embodiments, R 3 is C 1-6 It is alkyl.
[0205] In some embodiments, Z is —OH, —NR d R e , C 1-6 Alkoxy, -C(O)R a , -S(O)2R a Provided herein are compounds of formula (II-A), wherein: d R e and R d and R e are each independently H or C 1-6 In some embodiments, Z is NR d R e and R d is H. In some embodiments, Z is NR d R e and R d is C 1-6 In some embodiments, Z is NR d R e and R e is H. In some embodiments, Z is NR d Re and R e is C 1-6 In some embodiments, Z is —C(O)R a In some embodiments, Z is —C(O)R a where R a is a hydrogen atom containing one or more deuterium atoms, 1-6 Alkyl, Halo, HaloC 1-6 C optionally substituted with alkyl 2-6 alkenyl; or ii) C optionally substituted with one or more halo 1-6 In some embodiments, Z is —C(O)R a where R a is one or more deuterium atoms, C 1-6 Alkyl, Halo, HaloC 1-6 C optionally substituted with alkyl 2-6 In some embodiments, Z is -C(O)R a where R a is C optionally substituted with one or more halo 1-6 In some embodiments, Z is —C(O)R a where R a is a C optionally substituted with one or more deuterium atoms 2-6 In some embodiments, Z is -C(O)R a where R a is C 1-6 In some embodiments, Z is —C(O)R a where R a is Haro C 1-6 It is alkyl.
[0206] In some embodiments, provided herein are compounds of Formula (II-A), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein Z is —C(O)R a and R a is one or more deuterium atoms, C 1-6 Alkyl, Halo, HaloC 1-6 C optionally substituted with alkyl 2-6alkenyl; B is one or more R 2 is phenyl substituted with R 2 is C optionally substituted with one or more halo 1-6 In some embodiments, Z is -C(O)R a and R a is a C optionally substituted with one or more deuterium atoms 2-6 alkenyl; B is one or more R 2 is phenyl substituted with R 2 is C optionally substituted with one or more halo 1-6 In some embodiments, Z is -C(O)R a and R a is C optionally substituted with one or more halo 2-6 alkenyl; B is one or more R 2 is phenyl substituted with R 2 is C optionally substituted with one or more halo 1-6 In some embodiments, Z is -C(O)R a and R a is one or more C 1-6 C optionally substituted with alkyl 2-6 alkenyl; B is one or more R 2 is phenyl substituted with R 2 is C optionally substituted with one or more halo 1-6 In some embodiments, Z is -C(O)R a and R a is one or more halo C 1-6 C optionally substituted with alkyl 2-6 alkenyl; B is one or more R 2 is phenyl substituted with R 2 is C optionally substituted with one or more halo 1-6 It is an alkoxy.
[0207] In some embodiments, provided herein are compounds of formula (II-A), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is C or N, and X 1 is R 1 and together with the atoms to which they are attached form a 5- to 6-membered heteroaryl, a 5- to 6-membered heterocyclyl, a phenyl, or a C5 cycloalkyl fused to ring A; X 2 is N or CR s where R s is a C optionally substituted with -OH, 5-membered heteroaryl, and -CN 1-15 alkyl; X 3 is N or CH; B is phenyl or 5-membered heteroaryl, and the phenyl and 5- to 6-membered heteroaryl of B are each independently one or more R 2 is substituted with R 2 independently, in each occurrence, S(R y ) 5, wherein each R y is independently halo or C optionally substituted with one or more halo 1-6 alkoxy; L is C 1-6 methylene optionally substituted with alkyl; R 3 is H or C 1-6 alkyl; Z is -C(O)R a , -S(O)2R b where R a is C optionally substituted with deuterium 2-6 Alkenyl or halo substituted C 1-6 alkyl, and R b is a halo-substituted C 1-6 In some embodiments, R s is methyl or ethyl. In some embodiments, each R y is fluoro. In some embodiments, R 2 is trifluoromethoxy. In some embodiments, R a is ethenyl. In some embodiments, R a is chloromethyl. In some embodiments, Rb is chloromethyl.
[0208] In some embodiments, X 2 is CR s Provided herein are compounds of formula (II-AB), (II-A) or (II-B), wherein X is a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. In some embodiments, X is a 2 is CR s and R s is hydroxyl C 1-6 It is alkynyl.
[0209] In some embodiments, X 2 is CR s Provided herein are compounds of formula (II-AB), (II-A) or (II-B), wherein X is a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. In some embodiments, X is a 2 is CR s and R s -S(O)NHR d and R d is C optionally substituted with one or more substituents selected from the group consisting of H and halo, oxo, -OH and -CN; 1-6 In some embodiments, X is selected from the group consisting of alkyl. 2 is CR s and R s -S(O)NHR d and R d is H. In some embodiments, X 2 is CR s and R s -S(O)NHR d and R d is unsubstituted C 1-6 In some embodiments, X is alkyl. 2 is CR s and R s -S(O)NHR d and R d C substituted with one or more halo 1-6 In some embodiments, X is alkyl. 2 is CRs and R s -S(O)NHR d and R d is C substituted with one or more oxo groups 1-6 In some embodiments, X is alkyl. 2 is CR s and R s -S(O)NHR d and R d is C substituted with one or more -OH 1-6 In some embodiments, X is alkyl. 2 is CR s and R s -S(O)NHR d and R d is C substituted with one or more -CN 1-6 It is alkyl.
[0210] In some embodiments, X 2 is CR s Provided herein are compounds of formula (II-AB), (II-A) or (II-B), or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein X 2 is CR s and R s are -CN, -CH3, TIFF2024543912000028.tif42170. In some embodiments, X 2 is CR s and R s is -CN. In some embodiments, X 2 is CR s and R s is —CH3. In some embodiments, X 2 is CR s and TIFF2024543912000029.tif8170 In some embodiments, X 2 is CR s and TIFF2024543912000030.tif17170 In some embodiments, X 2is CR s and TIFF2024543912000031.tif8170 In some embodiments, X 2 is CR s and TIFF2024543912000032.tif13170 In some embodiments, X 2 is CR s and TIFF2024543912000033.tif13170 In some embodiments, X 2 is CR s and TIFF2024543912000034.tif13170 In some embodiments, X 2 is CR s and TIFF2024543912000035.tif11170 In some embodiments, X 2 is CR s and TIFF2024543912000036.tif19170 In some embodiments, X 2 is CR s and TIFF2024543912000037.tif12170 In some embodiments, X 2 is CR s and TIFF2024543912000038.tif19170 In some embodiments, X 2 is CR s and TIFF2024543912000039.tif13170 In some embodiments, X 2 is CR s and TIFF2024543912000040.tif13170
[0211] In some embodiments, X 1 Provided herein are compounds of formula (II-B), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X is C or N. In some embodiments, X1 is C. In some embodiments, X 1 is N. In some embodiments, X 1 is R 1 and together with the atom to which they are attached, a 5- to 6-membered heteroaryl, a 5- to 6-membered heterocyclyl, a phenyl, or C fused to ring A 5-6 In some embodiments, X forms a cycloalkyl. 1 is C and R 1 and together with the atom to which they are attached, a 5- to 6-membered heteroaryl, a 5- to 6-membered heterocyclyl, a phenyl, or C fused to ring A 5-6 In some embodiments, X forms a cycloalkyl. 1 is C and R 1 and together with the atoms to which they are attached form a 5-6 membered heteroaryl fused to ring A. In some embodiments, X 1 is C and R 1 and together with the atoms to which they are attached form a 5-6 membered heteroaryl fused to ring A. In some embodiments, X 1 is C and R 1 and together with the atom to which they are attached form a phenyl fused to ring A. In some embodiments, X 1 is C and R 1 and C fused to ring A together with the atoms to which they are attached. 5-6 In some embodiments, X forms a cycloalkyl. 1 is N and R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl or 5- to 6-membered heterocyclyl fused to ring A. In some embodiments, X 1 is N and R 1 and together with the atoms to which they are attached form a 5-6 membered heteroaryl fused to ring A. In some embodiments, X 1 is N and R 1 and together with the atoms to which they are attached form a 5- to 6-membered heterocyclyl fused to ring A.
[0212] In some embodiments, provided herein are compounds of formula (II-B), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is R 1 and together with the atom to which they are attached, a 5- to 6-membered heteroaryl, a 5- to 6-membered heterocyclyl, a phenyl, or C fused to ring A 5-6 5-6 membered heteroaryl, 5-6 membered heterocyclyl, phenyl, or C fused to ring A to form a cycloalkyl 5-6 Cycloalkyl is TIFF2024543912000041.tif77170.
[0213] In some embodiments, provided herein are compounds of formula (II-B), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is R 1 and together with the atom to which they are attached, a 5- to 6-membered heteroaryl, a 5- to 6-membered heterocyclyl, a phenyl, or C fused to ring A 5-6 Forms a cycloalkyl, X 1 and R 1 5- to 6-membered heteroaryl, 5- to 6-membered heterocyclyl, phenyl, and C 5-6 Cycloalkyl may each independently be one or more R t and optionally substituted with R t independently, in each occurrence, halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NRd R e wherein R d and R e are each independently H or C 1-6 In some embodiments, R d and R e are each independently H or C 1-6 In some embodiments, R d is H or C 1-6 In some embodiments, R d is H. In some embodiments, R d is C 1-6 In some embodiments, R e is H or C 1-6 In some embodiments, R e is H or C 1-6 In some embodiments, R e is H. In some embodiments, R e is C 1-6 It is alkyl.
[0214] In some embodiments, provided herein are compounds of formula (II-B), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t independently, in each occurrence, halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NRd SO2R e , and -NR d R e In some embodiments, X is selected from the group consisting of 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t independently, in each occurrence, halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e In some embodiments, X is selected from the group consisting of 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t is halo. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t is C 1-15 In some embodiments, X is alkyl. 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t is C 6-20In some embodiments, X is aryl. 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t is a 5- to 15-membered heteroaryl. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t is C 3-20 In some embodiments, X is cycloalkyl. 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t is 3-15 membered heterocyclyl. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t is —OH. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t is -CN. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t is oxo. In some embodiments, X 1 is R 1and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t is C 1-15 In some embodiments, X is alkoxy. 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t Ha-NR d COR e In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t -CONR d R e In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t Ha-SO2R d In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t Ha-SO2NR d R e In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t Ha-NR d SO2R e In some embodiments, X 1is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t Ha-NR d R e In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t Ha-NR d R e and R d and R e are each independently H or C 1-6 In some embodiments, X is alkyl. 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t Ha-NR d R e and R d is H or C 1-6 In some embodiments, X is alkyl. 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t Ha-NR d R e and R d is H. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t Ha-NR d R e and R d teeth 1-6In some embodiments, X is alkyl. 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t Ha-NR d R e and R e is H or C 1-6 In some embodiments, X is alkyl. 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t Ha-NR d R e and R e is H or C 1-6 In some embodiments, X is alkyl. 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t Ha-NR d R e and R e is H. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heteroaryl, which may be one or more R t is substituted with R t Ha-NR d R e and R e is C 1-6 It is alkyl.
[0215] In some embodiments, provided herein are compounds of formula (II-B), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is R 1and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, the 5- to 6-membered heterocyclyl being one or more R t is substituted with R t independently, in each occurrence, halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e In some embodiments, X is selected from the group consisting of 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t independently, in each occurrence, halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e In some embodiments, X is selected from the group consisting of 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more Rt is substituted with R t is halo. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t is C 1-15 In some embodiments, X is alkyl. 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t is C 6-20 In some embodiments, X is aryl. 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t is 5-15 membered heterocyclyl. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t is C 3-20 In some embodiments, X is cycloalkyl. 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t is 3-15 membered heterocyclyl. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t is —OH. In some embodiments, X 1is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t is -CN. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t is oxo. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t is C 1-15 In some embodiments, X is alkoxy. 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t Ha-NR d COR e In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t -CONR d R e In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t Ha-SO2R d In some embodiments, X 1 is R 1and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t Ha-SO2NR d R e In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t Ha-NR d SO2R e In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t Ha-NR d R e In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t Ha-NR d R e and R d and R e are each independently H or C 1-6 In some embodiments, X is alkyl. 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t Ha-NR d R e and R d is H or C 1-6 In some embodiments, X is alkyl. 1 is R 1and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t Ha-NR d R e and R d is H. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t Ha-NR d R e and R d is C 1-6 In some embodiments, X is alkyl. 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t Ha-NR d R e and R e is H or C 1-6 In some embodiments, R e is H or C 1-6 In some embodiments, X is alkyl. 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t Ha-NR d R e and R e is H. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a 5- to 6-membered heterocyclyl, which may be one or more R t is substituted with R t Ha-NR d R e and R eis C 1-6 It is alkyl.
[0216] In some embodiments, provided herein are compounds of formula (II-B), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being substituted with one or more R t is substituted with R t independently, in each occurrence, halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e In some embodiments, X is selected from the group consisting of 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t independently, in each occurrence, halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NRd R e In some embodiments, X is selected from the group consisting of 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t is halo. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t is C 1-15 In some embodiments, X is alkyl. 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t is C 6-20 In some embodiments, X is aryl. 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t is a 5- to 15-membered heteroaryl. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is replaced by R t is C 3-20 In some embodiments, X is cycloalkyl. 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t is 3-15 membered heterocyclyl. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R tis —OH. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t is -CN. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t is oxo. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t is C 1-15 In some embodiments, X is alkoxy. 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t Ha-NR d COR e In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t -CONR d R e In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t Ha-SO2R d In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R tis -SO2NR d R e In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t Ha-NR d SO2R e In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t Ha-NR d R e In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t Ha-NR d R e and R d and R e are each independently H or C 1-6 In some embodiments, X is alkyl. 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t Ha-NR d R e and R d is H or C 1-6 In some embodiments, X is alkyl. 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t Ha-NR d R e and R d is H. In some embodiments, X 1 is R 1and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t Ha-NR d R e and R d is C 1-6 In some embodiments, X is alkyl. 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t Ha-NR d R e and R e is H or C 1-6 In some embodiments, X is alkyl. 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t Ha-NR d R e and R e is H or C 1-6 In some embodiments, X is alkyl. 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t Ha-NR d R e and R e is H. In some embodiments, X 1 is R 1 and together with the atom to which they are attached form a phenyl, the phenyl being selected from one or more R t is substituted with R t Ha-NR d R e and R e is C 1-6 It is alkyl.
[0217] In some embodiments, provided herein are compounds of formula (II-B), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t independently, in each occurrence, halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e In some embodiments, X is selected from the group consisting of 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t independently, in each occurrence, halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e, and -NR d R e In some embodiments, X is selected from the group consisting of 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t is halo. In some embodiments, X 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t is C 1-15 In some embodiments, X is alkyl. 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t is C 6-20 In some embodiments, X is aryl. 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t is a 5-15 membered heteroaryl. In some embodiments, X 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t is C 3-20 In some embodiments, X is cycloalkyl. 1 is R 1 and together with the atoms to which they are attached, C5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t is 3-15 membered heterocyclyl. 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t is —OH. In some embodiments, X 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t is -CN. In some embodiments, X 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t is oxo. In some embodiments, X 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t is C 1-15 In some embodiments, X is alkoxy. 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t is -NR d COR e In some embodiments, X1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t -CONR d R e In some embodiments, X 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t Ha-SO2R d In some embodiments, X 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t is -SO2NR d R e In some embodiments, X 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t Ha-NR d SO2R e In some embodiments, X 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t Ha-NR d R e In some embodiments, X 1 is R 1and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t Ha-NR d R e and R d and R e are each independently H or C 1-6 In some embodiments, X is alkyl. 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t Ha-NR d R e and R d is H or C 1-6 In some embodiments, X is alkyl. 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t Ha-NR d R e and R d is H. In some embodiments, X 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t Ha-NR d R e and R d is C 1-6 In some embodiments, X is alkyl. 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6Cycloalkyl can be one or more R t is substituted with R t Ha-NR d R e and R e is H or C 1-6 In some embodiments, X is alkyl. 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t Ha-NR d R e and R e is H or C 1-6 In some embodiments, X is alkyl. 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t Ha-NR d R e and R e is H. In some embodiments, X 1 is R 1 and together with the atoms to which they are attached, C 5-6 Forms a cycloalkyl, C 5-6 Cycloalkyl can be one or more R t is substituted with R t Ha-NR d R e and R e is C 1-6 It is alkyl.
[0218] In some embodiments, X 2 is N or CR s and R s H, halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , or -NR d R e Provided herein are compounds of formula (II-B), wherein X is a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. In some embodiments, X is a 2 is N. In some embodiments, X 2 is CR s In some embodiments, X 2 is CR s where R s H, halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3- to 15-membered heterocyclyl, -OH, -CN, C 1-15 Alkoxy or -NR d R e In some embodiments, X 2 is CR s and R s is H. In some embodiments, X 2 is CR s and R s is halo. In some embodiments, X 2 is CR s and R s is C 1-15 In some embodiments, X is alkyl. 2 is CR s and R s is C 6-20 In some embodiments, X is aryl. 2 is CR s and R s is a 5- to 15-membered heteroaryl. In some embodiments, X 2 is CRs and R s is C 3-20 In some embodiments, X is cycloalkyl. 2 is CR s and R s is 3-15 membered heterocyclyl. In some embodiments, X 2 is CR s and R s is —OH. In some embodiments, X 2 is CR s and R s is -CN. In some embodiments, X 2 is CR s and R s is C 1-15 In another embodiment, X is alkoxy. 2 is CR s and R s Ha-NR d COR e In another embodiment, X 2 is CR s and R s -CONR d R e In another embodiment, X 2 is CR s and R s Ha-SO2R d In another embodiment, X 2 is CR s and R s Ha-SO2NR d R e In another embodiment, X 2 is CR s and R s Ha-NR d SO2R e In some embodiments, X 2 is CR s and R s Ha-NR d R e In some embodiments, X 2 is CR s and R s Ha-NR d R e , Rd and R e are each independently H or C 1-6 In some embodiments, X is alkyl. 2 is CR s and R s Ha-NR d R e and R d is H or C 1-6 In some embodiments, X is alkyl. 2 is CR s and R s Ha-NR d R e and R d is H. In some embodiments, X 2 is CR s and R s Ha-NR d R e and R d is C 1-6 In some embodiments, X is alkyl. 2 is CR s and R s Ha-NR d R e and R e is H or C 1-6 In some embodiments, X is alkyl. 2 is CR s and R s Ha-NR d R e and R e is H or C 1-6 In some embodiments, X is alkyl. 2 is CR s and R s Ha-NR d R e and R e is H. In some embodiments, X 2 is CR s and R s Ha-NR d R e and R e is C 1-6 It is alkyl.
[0219] In some embodiments, provided herein are compounds of formula (II-B), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 2 is CR s and R s is C 1-15 Alkyl or C 1-15 is alkoxy, and R s C 1-15 Alkyl and C 1-15 The alkoxy may each independently be one or more R t1 and optionally substituted with R t1 is independently in each occurrence, halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e In some embodiments, X is selected from the group consisting of 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 alkyl, and R t1 is independently in each occurrence halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR dSO2R e , and -NR d R e In some embodiments, X is selected from the group consisting of 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 alkyl, and R t1 is halo. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 alkyl, and R t1 is oxo. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 alkyl, and R t1 is —OH. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 alkyl, and R t1 is -CN. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 alkyl, and R t1 Ha-NR d R e is.
[0220] In some embodiments, provided herein are compounds of formula (II-B), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1is independently in each occurrence halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e In some embodiments, X is selected from the group consisting of 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 is halo. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 is oxo. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 is —OH. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 is -CN. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and Rt1 Ha-NR d R e is.
[0221] In some embodiments, provided herein are compounds of formula (II-B), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 Ha-NR d R e and R d and R e are each independently H or C 1-6 alkyl, and R d or R e C 1-6 The alkyl is optionally substituted with one or more halo, oxo, -OH, or -CN. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 Ha-NR d R e and R d is H. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 Ha-NR d R e and R d is C 1-6 In some embodiments, X is alkyl. 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 Ha-NR d R eand R e is H. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 Ha-NR d R e and R e is C 1-6 In some embodiments, X is alkyl. 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 Ha-NR d R e and R d or R e is independently C 1-6 alkyl, and R d or R e C 1-6 The alkyl is optionally substituted with one or more halo, oxo, -OH, or -CN. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 Ha-NR d R e and R d is C 1-6 alkyl, and R d C 1-6 The alkyl is optionally substituted with one or more halo, oxo, -OH, or -CN. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 Ha-NR d R e and R d is C 1-6alkyl, and R d C 1-6 The alkyl is optionally substituted with one or more halo. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 Ha-NR d R e and R d is C 1-6 alkyl, and R d C 1-6 The alkyl is optionally substituted with one or more oxo. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 Ha-NR d R e and R d is C 1-6 alkyl, and R d C 1-6 The alkyl is optionally substituted with one or more -OH. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 Ha-NR d R e and R d is C 1-6 alkyl, and R d C 1-6 The alkyl is optionally substituted with one or more -CN. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 Ha-NR d R e and Re is C 1-6 alkyl, and R e C 1-6 The alkyl is optionally substituted with one or more halo, oxo, -OH, or -CN. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 Ha-NR d R e and R e is C 1-6 is alkyl, e C 1-6 The alkyl is optionally substituted with one or more halo. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 Ha-NR d R e and R e is C 1-6 is alkyl, e C 1-6 The alkyl is optionally substituted with one or more oxo. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1 Ha-NR d R e and R e is C 1-6 is alkyl, e C 1-6 The alkyl is optionally substituted with one or more -OH. In some embodiments, X 2 is CR s and R s is one or more R t1 C optionally substituted with 1-15 is alkoxy, and R t1Ha-NR d R e and R e is C 1-6 is alkyl, e C 1-6 The alkyl is optionally substituted with one or more -CN.
[0222] In some embodiments, provided herein are compounds of formula (II-B), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 2 is CR s and R s is C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 cycloalkyl, or 3- to 15-membered heterocyclyl; R s C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl and 3- to 15-membered heterocyclyl each independently represent one or more R t2 optionally substituted with R t2 is independently in each occurrence, halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e In some embodiments, X is selected from the group consisting of 2 is CR s where R s is C 6-20 aryl, and R s C 6-20 Aryl can be one or more R t2 optionally substituted with R t2is, independently in each occurrence, halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e In some embodiments, X is selected from the group consisting of 2 is CR s and R s is C 6-20 aryl, and R s C 6-20 Aryl is R t2 and optionally substituted with R t2 is halo. In some embodiments, X 2 is CR s and R s is C 6-20 aryl, and R s C 6-20 Aryl is R t2 and optionally substituted with R t2 is oxo. In some embodiments, X 2 is CR s and R s is C 6-20 aryl, and R s C 6-20 Aryl is R t2 and optionally substituted with R t2 is —OH. In some embodiments, X 2 is CR s and R s is C 6-20 aryl, and R s C 6-20 Aryl is R t2 and optionally substituted with R t2is -CN. In some embodiments, X 2 is CR s and R s is C 6-20 aryl, and R s C 6-20 Aryl is R t2 optionally substituted with R t2 is C 1-6 It is alkyl.
[0223] In some embodiments, provided herein are compounds of formula (II-B), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 2 is CR s and R s is a 5- to 15-membered heteroaryl, and R s The 5- to 15-membered heteroaryl may be one or more R t2 optionally substituted with R t2 is independently in each occurrence halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e In some embodiments, X is selected from the group consisting of 2 is CR s and R s is a 5- to 15-membered heteroaryl, and R s The 5-15 membered heteroaryl is R t2 optionally substituted with R t2 is halo. In some embodiments, X 2 is CR s and R s is a 5- to 15-membered heteroaryl, and Rs 5-15 membered heteroaryl is R t2 and optionally substituted with R t2 is oxo. In some embodiments, X 2 is CR s and R s is a 5- to 15-membered heteroaryl, and R s 5-15 membered heteroaryl is R t2 and optionally substituted with R t2 is —OH. In some embodiments, X 2 is CR s and R s is a 5- to 15-membered heteroaryl, and R s 5-15 membered heteroaryl is R t2 and optionally substituted with R t2 is -CN. In some embodiments, X 2 is CR s and R s is a 5- to 15-membered heteroaryl, and R s 5-15 membered heteroaryl is R t2 and optionally substituted with R t2 is C 1-6 It is alkyl.
[0224] In some embodiments, provided herein are compounds of formula (II-B), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 2 is CR s and R s is C 6-20 is cycloalkyl, and R s C 6-20 Cycloalkyl can be one or more R t2 and optionally substituted with R t2 is independently in each occurrence halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR dR e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e In some embodiments, X is selected from the group consisting of 2 is CR s and R s is C 6-20 is cycloalkyl, and R s C 6-20 Cycloalkyl is R t2 and optionally substituted with R t2 is halo. In some embodiments, X 2 is CR s and R s is C 6-20 is cycloalkyl, and R s C 6-20 Cycloalkyl is R t2 and optionally substituted with R t2 is oxo. In some embodiments, X 2 is CR s and R s is C 6-20 is cycloalkyl, and R s C 6-20 Cycloalkyl is R t2 and optionally substituted with R t2 is —OH. In some embodiments, X 2 is CR s and R s is C 6-20 is cycloalkyl, and R s C 6-20 Cycloalkyl is R t2 and optionally substituted with R t2 is -CN. In some embodiments, X 2 is CR s and R s is C 6-20 is cycloalkyl, and R s C 6-20 Cycloalkyl is R t2 and optionally substituted with R t2 is C1-6 It is alkyl.
[0225] In some embodiments, provided herein are compounds of formula (II-B), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 2 is CR s and R s is a 5- to 15-membered heterocyclyl, and R s The 5- to 15-membered heterocyclyl may be one or more R t2 and optionally substituted with R t2 is independently in each occurrence halo, C 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3-15 membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d COR e , -CONR d R e , -SO2R d , -SO2NR d R e , -NR d SO2R e , and -NR d R e In some embodiments, X is selected from the group consisting of 2 is CR s and R s is a 5- to 15-membered heterocyclyl, and R s 5-15 membered heterocyclyl is R t2 and optionally substituted with R t2 is halo. In some embodiments, X 2 is CR s and R s is a 5- to 15-membered heterocyclyl, and R s 5-15 membered heterocyclyl is R t2 and optionally substituted with R t2 is oxo. In some embodiments, X 2 is CR s and R s is a 5- to 15-membered heterocyclyl, and R s5-15 membered heterocyclyl is R t2 and optionally substituted with R t2 is —OH. In some embodiments, X 2 is CR s and R s is a 5- to 15-membered heterocyclyl, and R s 5-15 membered heterocyclyl is R t2 and optionally substituted with R t2 is -CN. In some embodiments, X 2 is CR s and R s is a 5- to 15-membered heterocyclyl, and R s 5-15 membered heterocyclyl is R t2 and optionally substituted with R t2 is C 1-6 It is alkyl.
[0226] In some embodiments, X 3 Provided herein are compounds of formula (II-B), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X is N or CH. In some embodiments, X 3 is N. In some embodiments, X 3 is CH.
[0227] In some embodiments, provided herein is a compound of Formula (II-B), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein B is phenyl or 5-6 membered heteroaryl; and wherein the phenyl and 5-6 membered heteroaryl of B each independently represent 1-5 R 2 In some embodiments, B is substituted with 1 to 5 R 2 In some embodiments, B is phenyl independently substituted with 1 to 5 R 2 is a 5- to 6-membered heteroaryl independently substituted with
[0228] In some embodiments, in conjunction with the above or below embodiments, B is one R 2 is a 5- to 6-membered heteroaryl independently substituted with
[0229] In some embodiments, provided herein are compounds of formula (II-B), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein R 2 independently, in each occurrence: i) halo; ii) S(R y )5 (in the formula, each R y is halo); or iii) C optionally substituted with one or more halo. 1-6 In some embodiments, R 2 is halo. In some embodiments, R 2 is S(R y )5, each R y is halo. In some embodiments, R 2 is C optionally substituted with one or more halo 1-6 In some embodiments, R 2 is the unsubstituted C 1-6 It is an alkoxy.
[0230] In some embodiments, Z is —OH, —NR d R e , C 1-6 Alkoxy, -C(O)R a , -S(O)2R a Provided herein are compounds of formula (II-B), wherein: d R e and R d and R e are each independently H or C 1-6 In some embodiments, Z is NR d R e and R d is H. In some embodiments, Z is NR d R e and R d is C 1-6 In some embodiments, Z is NR d R eand R e is H. In some embodiments, Z is NR d R e and R e is C 1-6 In some embodiments, Z is —C(O)R a In some embodiments, Z is —C(O)R a where R a is a hydrogen atom containing one or more deuterium atoms, 1-6 Alkyl, Halo, HaloC 1-6 C optionally substituted with alkyl 2-6 alkenyl; or ii) C optionally substituted with one or more halo 1-6 In some embodiments, Z is —C(O)R a where R a is one or more deuterium atoms, C 1-6 Alkyl, Halo, HaloC 1-6 C optionally substituted with alkyl 2-6 In some embodiments, Z is -C(O)R a where R a is C optionally substituted with one or more halo 1-6 In some embodiments, Z is —C(O)R a where R a is a C optionally substituted with one or more deuterium atoms 2-6 In some embodiments, Z is -C(O)R a where R a is C 1-6 In some embodiments, Z is —C(O)R a where R a is Haro C 1-6 It is alkyl.
[0231] In some embodiments, provided herein are compounds of Formula (II-B), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein Z is —C(O)R a and R a is one or more deuterium atoms, C 1-6Alkyl, Halo, HaloC 1-6 C optionally substituted with alkyl 2-6 alkenyl; B is one or more R 2 is phenyl substituted with R 2 is C optionally substituted with one or more halo 1-6 In some embodiments, Z is -C(O)R a and R a is a C optionally substituted with one or more deuterium atoms 2-6 alkenyl; B is one or more R 2 is phenyl substituted with R 2 is C optionally substituted with one or more halo 1-6 In some embodiments, Z is -C(O)R a and R a is C optionally substituted with one or more halo 2-6 alkenyl; B is one or more R 2 is phenyl substituted with R 2 is C optionally substituted with one or more halo 1-6 In some embodiments, Z is -C(O)R a and R a is one or more C 1-6 C optionally substituted with alkyl 2-6 alkenyl; B is one or more R 2 is phenyl substituted with R 2 is C optionally substituted with one or more halo 1-6 In some embodiments, Z is -C(O)R a and R a is one or more halo C 1-6 C optionally substituted with alkyl 2-6 alkenyl; B is one or more R 2 is phenyl substituted with R 2 is C optionally substituted with one or more halo 1-6 It is an alkoxy.
[0232] In some embodiments, provided herein is a compound of Formula (II-B), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein n and m are each independently 1 or 2. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, n is 1 and m is 1. In some embodiments, n is 1 and m is 2. In some embodiments, n is 2 and m is 1. In some embodiments, n is 2 and m is 2.
[0233] In some embodiments, in conjunction with the above or below embodiments, provided herein is a compound of Formula (II-AB'), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein B is i) phenyl or 5-6 membered heteroaryl, wherein the phenyl and 5-6 membered heteroaryl of B are each independently selected from one or more R 2 is substituted with R 2 independently, in each occurrence, halo;S(R y )5 (in the formula, each R y is halo); C optionally substituted with one or more halo 1-6 alkoxy); or ii) haloC 1-3 alkyl-substituted -O-phenyl (provided that B is haloC 1-3 When L' is -O-phenyl substituted with alkyl, L' is -N(R 3 )-L-**, Z is -C(O)CHCH2, and X 1 is C and X 2 is CR s and X 3 is CH); or iii) C 1-3 Is it an alkyl-substituted bicyclopentane (provided B is C)? 1-3 If it is an alkyl-substituted bicyclopentane, L' is *-N(R 3 )-L-**, provided that Z is —C(O)CHCH2; or iv) ethynyl or haloC 1-3alkyl-substituted phenyl (provided that B is ethynyl or haloC 1-3 When L' is phenyl substituted with alkyl, L' is -N(R 3 )-L-**, Z is -C(O)CHCH2, and R s is C substituted with one or more -OH 1-3 alkyl; or v) haloC 1-3 Alkyl or haloC 1-3 alkoxy-substituted piperidine (provided that B is haloC 1-3 Alkyl or haloC 1-3 When L' is an alkoxy-substituted piperidine, L' is -N(R 3 )-L-**, with the proviso that Z is —C(O)CHCH2. In some embodiments, B is phenyl or 5-6 membered heteroaryl; the phenyl and 5-6 membered heteroaryl of B are each independently selected from one or more R 2 is substituted with R 2 independently, in each occurrence, halo;S(R y )5 (in the formula, each R y is halo); C optionally substituted with one or more halo 1-6 In some embodiments, B is haloC 1-3 alkyl-substituted -O-phenyl, provided that B is haloC 1-3 When L' is -O-phenyl substituted with alkyl, L' is -N(R 3 )-L-**, Z is -C(O)CHCH2, and X 1 is C and X 2 is CR s and X 3 is CH. In some embodiments, B is C 1-3 Alkyl-substituted bicyclopentane, provided that B is C 1-3 If it is an alkyl-substituted bicyclopentane, L' is *-N(R 3 )-L-** and Z is —C(O)CHCH2. In some embodiments, B is ethynyl or haloC 1-3alkyl-substituted phenyl, provided that B is ethynyl or haloC 1-3 When L' is phenyl substituted with alkyl, L' is -N(R 3 )-L-**, Z is -C(O)CHCH2, and R s is C substituted with one or more -OH 1-3 In some embodiments, B is haloC 1-3 Alkyl or haloC 1-3 Alkoxy-substituted piperidine, provided that B is haloC 1-3 Alkyl or haloC 1-3 When L' is an alkoxy-substituted piperidine, L' is -N(R 3 )-L-** and Z is —C(O)CHCH2.
[0234] In some embodiments, in conjunction with the above or below embodiments, provided herein are compounds of Formula (II-AB'), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein Z is -OH, -NR d R e , C 1-6 Alkoxy, -C(O)R a , or -S(O)R b and R d and R e are each independently H or C 1-6 alkyl, and R d or R e C 1-6 alkyl is optionally substituted with one or more substituents selected from halo, oxo, —OH, and —CN; R a and R b are each independently: i) deuterium, C 1-6 Alkyl, Hydroxyl C 1-6 Alkyl, halo and haloC 1-6 C optionally substituted with one or more substituents selected from alkyl 2-6 alkenyl; ii) C optionally substituted with one or more halo 1-6or iii) cyclobutenyl or bicyclobutanyl. In some embodiments, Z is -C(O)R a or -S(O)2R b where R a and R b are independently deuterium, C 1-6 Alkyl, Hydroxyl C 1-6 Alkyl, halo and haloC 1-6 C optionally substituted with one or more substituents selected from alkyl 2-6 In some embodiments, Z is -C(O)R a or -S(O)2R b where R a and R b each independently represents a C optionally substituted with one or more halo 1-6 In some embodiments, Z is —C(O)R a or -S(O)2R b where R a and R b are each independently cyclobutenyl or bicyclobutanyl.
[0235] In some embodiments, in conjunction with the above or below embodiments, provided herein are compounds of Formula (II-AB'), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein L is methylene or ethylene; 1-6 In some embodiments, L is optionally substituted with alkyl. 1-6 In some embodiments, L is ethylene.
[0236] In some embodiments, in conjunction with the above or below embodiments, provided herein is a compound of Formula (II-AB'), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein: TIFF2024543912000042.tif21170Y is CH or C(CN). In some embodiments, in conjunction with any of the above or below embodiments, provided herein are compounds of Formula (II-AB'), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein: TIFF2024543912000043.tif22170In some embodiments, provided herein, in conjunction with any of the above or below embodiments, is a compound of formula (II-AB'), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein n and m are each independently 1 or 2.
[0237] In some embodiments, in conjunction with the above or below embodiments, provided herein are compounds of Formula (II-AB'), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein X 1 R 1 and together with the atom to which they are attached form a phenyl, X 2 or X 3 is N, B is phenyl, and R 2 Halo C 1-6and the compound of formula (II-AB') is not any of the following: N-((8-(4-fluorophenyl)imidazo[1,2-a]pyrazin-6-yl)methyl)acrylamide; N-((8-(4-(trifluoromethoxy)phenyl)imidazo[1,2-a]pyrazin-6-yl)methyl)acrylamide; N-((7-fluoro-4-(4-(trifluoromethoxy)phenyl)quinazolin-2-yl)methyl)acrylamide; N-((8-(4-(difluoromethoxy)phenyl)imidazo[1,2-a]pyrazin-6-yl)methyl)acrylamide; 1-(4-(4-(4-methoxyphenyl)-1-methyl-1H-imidazo[4,5-c]pyrazin-6-yl)methyl)acrylamide 6-(1-(ethylsulfonyl)piperidin-4-yl)-4-(4-methoxyphenyl)-1-methyl-1H-imidazo[4,5-c]pyridine;6-(1-(ethylsulfonyl)piperidin-4-yl)-4-(4-methoxyphenyl)-1-methyl-1H-imidazo[4,5-c]pyridine;6-(1-(ethylsulfonyl)piperidin-4-yl)-4-(4-methoxyphenyl)-1-methyl-1H-imidazo[4,5-c]pyridine 4-(4-Methoxyphenyl)-1-methyl-6-(1-((trifluoromethyl)sulfonyl)piperidin-4-yl)-1H-imidazo[4,5-c]pyridine; 4-(4-Methoxyphenyl)-1-methyl-6-(1-((trifluoromethyl)sulfonyl)piperidin-4-yl)-1H-imidazo[4,5-c]pyridine; and N-((4-(4-fluorophenyl)-1,8-naphthyridin-2-yl)methyl)acetamide.
[0238] In some embodiments, in conjunction with the above or below embodiments, a reference to "one or more" may be 1 to 5, 1 to 4, 1 to 3, 1 to 2, 5, 4, 3, 2, or 1.
[0239] In some embodiments, in conjunction with the above or below embodiments, "one or more substituents" such as "C 1-6 Reference to "one or more substituents of an alkyl" can be 1 to 3 substituents, 1 to 2 substituents, 2 substituents, or 1 substituent.
[0240] In some embodiments, in conjunction with the above or below embodiments, B may be one or more R t If optionally substituted with R t is C optionally substituted with 1 to 3 halo 1-15 In some embodiments, in conjunction with the above or below embodiments, R t is C substituted with 1 to 3 halo 1-15 In some embodiments, in conjunction with the above or below embodiments, R t is OCF3.
[0241] In some embodiments, in conjunction with the above or below embodiments, X 1 is CR s If TIFF2024543912000044.tif13170 or a stereoisomer thereof. TIFF2024543912000045.tif8170
[0242] In some embodiments, in conjunction with the above or below embodiments, n and m are each 1.
[0243] In some embodiments, there is provided a compound of the following formula (II-A-1), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: In one embodiment, X in formula (II-A-1) 1 , X 2 , X 3 , R 1 , R 2 , R 3 , L, A, and Z are as defined in formula (II-AB'). In one embodiment, X in formula (II-A-1) 1 , X 2 , X 3 , R 1 , R 2 , R 3 , L, A, and Z are as defined in formula (II-AB). In one embodiment, X in formula (II-A-1)1 , X 2 , X 3 , R 1 , R 2 , R 3 , L, A, and Z are as defined in formula (II-A). X described for formula (II-AB'), (II-AB) or (II-A) 1 , X 2 , X 3 , R 1 , R 2 , R 3 It is understood that the embodiments of L, A, and Z, where applicable, may be applied to formula (II-A-1) in some embodiments.
[0244] In some embodiments, there is provided a compound of the following formula (II-A-2), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: TIFF2024543912000047.tif33170 In one embodiment, X in formula (II-A-2) 1 , X 2 , X 3 , R 1 , R 2 , R 3 , L, A, and Z are as defined in formula (II-AB'). In one embodiment, X in formula (II-A-2) 1 , X 2 , X 3 , R 1 , R 2 , R 3 , L, A, and Z are as defined in formula (II-AB). In one embodiment, X in formula (II-A-2) 1 , X 2 , X 3 , R 1 , R 2 , R 3 , L, A, and Z are as defined in formula (II-A). X described for formula (II-AB'), (II-AB) or (II-A) 1 , X 2 , X 3 , R 1 , R 2 , R 3It is understood that the embodiments of L, A, and Z, where applicable, may be applied to formula (II-A-2) in some embodiments.
[0245] In some embodiments, there is provided a compound of the following formula (II-A-3), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: TIFF2024543912000048.tif27170In one embodiment, X in formula (II-A-3) 1 , R 1 , R 3 , L, A, B, and Z are as defined in formula (II-AB'). In one embodiment, X in formula (II-A-3) 1 , R 1 , R 3 , L, A, B, and Z are as defined in formula (II-AB). In one embodiment, X in formula (II-A-3) 1 , R 1 , R 3 , L, A, B and Z are as defined in formula (II-A). X described for formula (II-AB'), (II-AB) or (II-A) 1 , R 1 , R 3 It is understood that the embodiments of L, A, B, and Z, where applicable, may be applied to formula (II-A-3) in some embodiments.
[0246] In some embodiments, there is provided a compound of the following formula (II-A-4), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: TIFF2024543912000049.tif27170In one embodiment, X in formula (II-A-4) 1 , R 1 , R 3 , L, A, B, and Z are as defined in formula (II-AB'). In one embodiment, X in formula (II-A-4) 1 , R 1 , R 3 , L, A, B, and Z are as defined in formula (II-AB). In one embodiment, X in formula (II-A-4) 1 , R 1 , R 3, L, A, B and Z are as defined in formula (II-A). X described for formula (II-AB'), (II-AB) or (II-A) 1 , R 1 , R 3 It is understood that the embodiments of L, A, B, and Z, where applicable, may be applied to formula (II-A-4) in some embodiments.
[0247] In some embodiments, there is provided a compound of the following formula (II-A-5), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: TIFF2024543912000050.tif27170In one embodiment, X in formula (II-A-5) 1 , R 1 , R 3 , L, A, B, and Z are as defined in formula (II-AB'). In one embodiment, X in formula (II-A-5) 1 , R 1 , R 3 , L, A, B, and Z are as defined in formula (II-AB). In one embodiment, X in formula (II-A-5) 1 , R 1 , R 3 , L, A, B and Z are as defined in formula (II-A). X described for formula (II-AB'), (II-AB) or (II-A) 1 , R 1 , R 3 It is understood that the embodiments of L, A, B, and Z, where applicable, may be applied to formula (II-A-5) in some embodiments.
[0248] In some embodiments, there is provided a compound of the following formula (II-A-6), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: TIFF2024543912000051.tif33170 In one embodiment, X in formula (II-A-6) 2 , X 3 , R 3 , L, A, B, and Z are as defined in formula (II-AB'). In one embodiment, X in formula (II-A-6) 2 , X3 , R 3 , L, A, B, and Z are as defined in formula (II-AB). In one embodiment, X in formula (II-A-6) 2 , X 3 , R 3 , L, A, B and Z are as defined in formula (II-A). X described for formula (II-AB'), (II-AB) or (II-A) 2 , X 3 , R 3 It is understood that the embodiments of L, A, B, and Z, where applicable, may be applied to formula (II-A-6) in some embodiments.
[0249] In some embodiments, there is provided a compound of the following formula (II-A-7), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: TIFF2024543912000052.tif33170 In one embodiment, X in formula (II-A-7) 3 , R 3 , L, A, B, and Z are as defined in formula (II-AB'). In one embodiment, X in formula (II-A-7) 3 , R 3 , L, A, B, and Z are as defined in formula (II-AB). In one embodiment, X in formula (II-A-7) 3 , R 3 , L, A, B and Z are as defined in formula (II-A). X described for formula (II-AB'), (II-AB) or (II-A) 3 , R 3 It is understood that the embodiments of L, A, B, and Z, where applicable, may be applied to formula (II-A-7) in some embodiments.
[0250] In some embodiments, there is provided a compound of the following formula (II-A-8), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: TIFF2024543912000053.tif33170 In one embodiment, R of formula (II-A-8) 3, L, A, B, and Z are as defined in formula (II-AB'). In one embodiment, R of formula (II-A-8) 3 , L, A, B, and Z are as defined in formula (II-AB). In one embodiment, R of formula (II-A-8) 3 , L, A, B, and Z are as defined in formula (II-A). R described for formula (II-AB'), (II-AB) or (II-A) 3 It is understood that the embodiments of L, A, B, and Z, where applicable, may be applied to formula (II-A-8) in some embodiments.
[0251] In some embodiments, there is provided a compound of the following formula (II-A-9), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: TIFF2024543912000054.tif33170 In one embodiment, R of formula (II-A-9) 3 , L, A, B, and Z are as defined in formula (II-AB'). In one embodiment, R of formula (II-A-9) 3 , L, A, B, and Z are as defined in formula (II-AB). In one embodiment, R of formula (II-A-9) 3 , L, A, B, and Z are as defined in formula (II-A). R described for formula (II-AB'), (II-AB) or (II-A) 3 It is understood that the embodiments of L, A, B, and Z, where applicable, may be applied to formula (II-A-9) in some embodiments.
[0252] In some embodiments, there is provided a compound of the following formula (II-A-10), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: TIFF2024543912000055.tif33170 In one embodiment, R of formula (II-A-10) 3 , L, A, B, and Z are as defined in formula (II-AB'). In one embodiment, R of formula (II-A-10) 3 , L, A, B, and Z are as defined in formula (II-AB). In one embodiment, R of formula (II-A-10)3 , L, A, B, and Z are as defined in formula (II-A). R described for formula (II-AB'), (II-AB) or (II-A) 3 It is understood that the embodiments of L, A, B, and Z, where applicable, may be applied to formula (II-A-10) in some embodiments.
[0253] In some embodiments, there is provided a compound of the following formula (II-A-11), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: In one embodiment, R of formula (II-A-11) 3 , L, A, B, and Z are as defined in formula (II-AB'). In one embodiment, R of formula (II-A-11) 3 , L, A, B, and Z are as defined in formula (II-AB). In one embodiment, R of formula (II-A-11) 3 , L, A, B, and Z are as defined in formula (II-A). R described for formula (II-AB'), (II-AB) or (II-A) 3 It is understood that the embodiments of L, A, B, and Z, where applicable, may be applied to formula (II-A-11) in some embodiments.
[0254] In some embodiments, there is provided a compound of the following formula (II-A-12), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: TIFF2024543912000057.tif33170 In one embodiment, X in formula (II-A-12) 2 , X 3 , R 3 , L, A, B, and Z are as defined in formula (II-AB'). In one embodiment, X in formula (II-A-12) 2 , X 3 , R 3 , L, A, B, and Z are as defined in formula (II-AB). In one embodiment, X in formula (II-A-12) 2 , X 3 , R 3, L, A, B and Z are as defined in formula (II-A). X described for formula (II-AB'), (II-AB) or (II-A) 2 , X 3 , R 3 It is understood that the embodiments of L, A, B, and Z, where applicable, may be applied to formula (II-A-12) in some embodiments.
[0255] In some embodiments, there is provided a compound of the following formula (II-A-13), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: TIFF2024543912000058.tif33170 In one embodiment, X in formula (II-A-13) 2 , R 3 , L, A, B, and Z are as defined in formula (II-AB'). In one embodiment, X in formula (II-A-13) 2 , R 3 , L, A, B, and Z are as defined in formula (II-AB). In one embodiment, X in formula (II-A-13) 2 , R 3 , L, A, B and Z are as defined in formula (II-A). X described for formula (II-AB'), (II-AB) or (II-A) 2 , R 3 It is understood that the embodiments of L, A, B, and Z, where applicable, can be applied to formula (II-A-13) in some embodiments.
[0256] In some embodiments, there is provided a compound of the following formula (II-A-14), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: TIFF2024543912000059.tif33170 In one embodiment, R of formula (II-A-14) 3 , L, A, B, and Z are as defined in formula (II-AB'). In one embodiment, R of formula (II-A-14) 3 , L, A, B, and Z are as defined in formula (II-AB). In one embodiment, R of formula (II-A-14) 3, L, A, B, and Z are as defined in formula (II-A). R described for formula (II-AB'), (II-AB) or (II-A) 3 It is understood that the embodiments of L, A, B, and Z, where applicable, can be applied to formula (II-A-14) in some embodiments.
[0257] In some embodiments, there is provided a compound of the following formula (II-A-15), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: TIFF2024543912000060.tif33170 In one embodiment, R of formula (II-A-15) 3 , L, A, B, and Z are as defined in formula (II-AB'). In one embodiment, R of formula (II-A-15) 3 , L, A, B, and Z are as defined in formula (II-AB). In one embodiment, R of formula (II-A-15) 3 , L, A, B, and Z are as defined in formula (II-A). R described for formula (II-AB'), (II-AB) or (II-A) 3 It is understood that the embodiments of L, A, B, and Z, where applicable, may be applied to formula (II-A-15) in some embodiments.
[0258] In some embodiments, there is provided a compound of the following formula (II-A-16), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: TIFF2024543912000061.tif32170 In one embodiment, R of formula (II-A-16) 1 , R 2 , X 1 , X 2 , X 3 and A are as defined in formula (II-AB'). In one embodiment, R of formula (II-A-16) 1 , R 2 , X 1 , X 2 , X 3 and A is as defined in formula (II-AB). In one embodiment, R of formula (II-A-16) 1 , R2 , X 1 , X 2 , X 3 and A are as defined in formula (II-A). R described for formula (II-AB'), (II-AB), or (II-A) 1 , R 2 , X 1 , X 2 , X 3 It is understood that the embodiments of A and B, where applicable, may in some embodiments be applied to formula (II-A-16).
[0259] In some embodiments, there is provided a compound of the following formula (II-A-17), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: TIFF2024543912000062.tif32170 In one embodiment, R of formula (II-A-17) 1 , R 2 , X 1 , X 2 , X 3 and A are as defined in formula (II-AB'). In one embodiment, R of formula (II-A-17) 1 , R 2 , X 1 , X 2 , X 3 and A is as defined in formula (II-AB). In one embodiment, R of formula (II-A-17) 1 , R 2 , X 1 , X 2 , X 3 and A are as defined in formula (II-A). R described for formula (II-AB'), (II-AB), or (II-A) 1 , R 2 , X 1 , X 2 , X 3 It is understood that the embodiments of A and B, where applicable, may in some embodiments be applied to formula (II-A-17).
[0260] In some embodiments, there is provided a compound of the following formula (II-A-18), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: TIFF2024543912000063.tif32170 In one embodiment, R of formula (II-A-18) 1 , R 3 , X 1 , X 2 , X 3 , L, A, and Z are as defined in formula (II-AB'). In one embodiment, R of formula (II-A-18) 1 , R 3 , X 1 , X 2 , X 3 , L, A, and Z are as defined in formula (II-AB). In one embodiment, R of formula (II-A-18) 1 , R 3 , X 1 , X 2 , X 3 , L, A, and Z are as defined in formula (II-A). R described for formula (II-AB'), (II-AB), or (II-A) 1 , R 3 , X 1 , X 2 , X 3 It is understood that the embodiments of L, A, and Z, where applicable, may be applied to formula (II-A-18) in some embodiments.
[0261] In some embodiments, there is provided a compound of the following formula (II-A-19), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: In one embodiment, R of formula (II-A-19) 1 , R 3 , X 1 , X 2 , X 3 , A, B, and L are as defined in formula (II-AB'). In one embodiment, R of formula (II-A-19) 1 , R 3 , X 1 , X 2 , X 3, A, B, and L are as defined in formula (II-AB). In one embodiment, R of formula (II-A-19) 1 , R 3 , X 1 , X 2 , X 3 , A, B, and L are as defined in formula (II-A). R described for formula (II-AB'), (II-AB), or (II-A) 1 , R 3 , X 1 , X 2 , X 3 It is understood that the embodiments of A, B, and L, where applicable, may be applied to formula (II-A-19) in some embodiments.
[0262] In some embodiments, there is provided a compound of the following formula (II-A-20), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: In one embodiment, R of formula (II-A-20) 1 , R 3 , X 1 , X 2 , X 3 , A, and L are as defined in formula (II-AB'). In one embodiment, R of formula (II-A-20) 1 , R 3 , X 1 , X 2 , X 3 , A, and L are as defined in formula (II-AB). In one embodiment, R 1 , R 3 , X 1 , X 2 , X 3 , A, and L are as defined in formula (II-A). R described for formula (II-AB'), (II-AB), or (II-A) 1 , R 3 , X 1 , X 2 , X 3 It is understood that the embodiments of A and L, where applicable, may be applied to formula (II-A-20) in some embodiments.
[0263] In some embodiments, there is provided a compound of the following formula (II-A-21), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: In one embodiment, R of formula (II-A-21) 1 , R 3 , X 1 , X 2 , X 3 , A, B, and Z are as defined in formula (II-AB'). In one embodiment, R of formula (II-A-21) 1 , R 3 , X 1 , X 2 , X 3 , A, B, and Z are as defined in formula (II-AB). In one embodiment, R of formula (II-A-21) 1 , R 3 , X 1 , X 2 , X 3 , A, B, and Z are as defined in formula (II-A). R described for formula (II-AB'), (II-AB), or (II-A) 1 , R 3 , X 1 , X 2 , X 3 It is understood that the embodiments of A, B, and Z, where applicable, can be applied to formula (II-A-21) in some embodiments.
[0264] In some embodiments, there is provided a compound of the following formula (II-A-22), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: In one embodiment, R of formula (II-A-22) t , R 3 , X 2 , X 3 , A, B, L, and Z are as defined in formula (II-AB'). In one embodiment, R of formula (II-A-22) t , R 3 , X 2 , X 3, A, B, L, and Z are as defined in formula (II-AB). In one embodiment, R of formula (II-A-22) t , R 3 , X 2 , X 3 , A, B, L, and Z are as defined in formula (II-A). R described for formula (II-AB'), (II-AB), or (II-A) t , R 3 , X 2 , X 3 It is understood that the embodiments of A, B, L, and Z, where applicable, can be applied to formula (II-A-22) in some embodiments.
[0265] In some embodiments, there is provided a compound of the following formula (II-A-23), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: TIFF2024543912000068.tif37170 In one embodiment, R of formula (II-A-23) 3 , X 2 , X 3 , A, B, L, and Z are as defined in formula (II-AB'). In one embodiment, R of formula (II-A-23) 3 , X 2 , X 3 , A, B, L, and Z are as defined in formula (II-AB). In one embodiment, R of formula (II-A-23) 3 , X 2 , X 3 , A, B, L, and Z are as defined in formula (II-A). R described for formula (II-AB'), (II-AB), or (II-A) 3 , X 2 , X 3 It is understood that the embodiments of A, B, L, and Z, where applicable, can be applied to formula (II-A-23) in some embodiments.
[0266] In some embodiments, there is provided a compound of the following formula (II-A-24), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: In one embodiment, R of formula (II-A-24) t , R 3 , X 2 , X 3 , A, B, L, and Z are as defined in formula (II-AB'). In one embodiment, R of formula (II-A-24) t , R 3 , X 2 , X 3 , A, B, L, and Z are as defined in formula (II-AB). In one embodiment, R of formula (II-A-24) t , R 3 , X 2 , X 3 , A, B, L, and Z are as defined in formula (II-A). R described for formula (II-AB'), (II-AB), or (II-A) t , R 3 , X 2 , X 3 It is understood that the embodiments of A, B, L, and Z, where applicable, may be applied to formula (II-A-24) in some embodiments.
[0267] In some embodiments, there is provided a compound of the following formula (II-A-25), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: TIFF2024543912000070.tif33170 In one embodiment, R of formula (II-A-25) t , R 3 , X 2 , X 3 , A, B, L, and Z are as defined in formula (II-AB'). In one embodiment, R of formula (II-A-25) t , R 3 , X 2 , X 3 , A, B, L, and Z are as defined in formula (II-AB). In one embodiment, R of formula (II-A-25) t , R 3 , X 2 , X 3, A, B, L, and Z are as defined in formula (II-A). R described for formula (II-AB'), (II-AB), or (II-A) t , R 3 , X 2 , X 3 It is understood that the embodiments of A, B, L, and Z, where applicable, can be applied to formula (II-A-25) in some embodiments.
[0268] In some embodiments, there is provided a compound of the following formula (II-A-26), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: TIFF2024543912000071.tif37170 In one embodiment, R of formula (II-A-26) 3 , X 2 , X 3 , A, B, L, and Z are as defined in formula (II-AB'). In one embodiment, R of formula (II-A-26) 3 , X 2 , X 3 , A, B, L, and Z are as defined in formula (II-AB). In one embodiment, R of formula (II-A-26) 3 , X 2 , X 3 , A, B, L, and Z are as defined in formula (II-A). R described for formula (II-AB'), (II-AB), or (II-A) 3 , X 2 , X 3 It is understood that the embodiments of A, B, L, and Z, where applicable, may be applied to formula (II-A-26) in some embodiments.
[0269] In some embodiments, there is provided a compound of the following formula (II-B-1), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: In one embodiment, R of formula (II-B-1) 1 , R 2 , X 1 , X 2 , X 3, n, m, A, and Z are as defined in formula (II-AB'). In one embodiment, R 1 , R 2 , X 1 , X 2 , X 3 , n, m, A, and Z are as defined in formula (II-AB). In one embodiment, R 1 , R 2 , X 1 , X 2 , X 3 , n, m, A, and Z are as defined in formula (II-B). R described for formula (II-AB'), (II-AB) or (II-B) 1 , R 2 , X 1 , X 2 , X 3 It is understood that the embodiments of n, m, A, and Z, where applicable, may be applied to formula (II-B-1) in some embodiments.
[0270] In some embodiments, there is provided a compound of the following formula (II-B-2), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: In one embodiment, R of formula (II-B-2) 1 , R 2 , X 1 , X 2 , X 3 , n, m, A, and Z are as defined in formula (II-AB'). In one embodiment, R 1 , R 2 , X 1 , X 2 , X 3 , n, m, A, and Z are as defined in formula (II-AB). In one embodiment, R 1 , R 2 , X 1 , X 2 , X 3 , n, m, A, and Z are as defined in formula (II-B). R described for formula (II-AB'), (II-AB) or (II-B) 1, R 2 , X 1 , X 2 , X 3 It is understood that the embodiments of n, m, A, and Z, where applicable, may be applied to formula (II-B-2) in some embodiments.
[0271] In some embodiments, there is provided a compound of the following formula (II-B-3), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: In one embodiment, R of formula (II-B-3) 1 , X 1 , n, m, A, B, and Z are as defined in formula (II-AB'). In one embodiment, R of formula (II-B-3) 1 , X 1 , n, m, A, B, and Z are as defined in formula (II-AB). In one embodiment, R 1 , X 1 , n, m, A, B, and Z are as defined in formula (II-B). R described for formula (II-AB'), (II-AB) or (II-B) 1 , X 1 , n, m, A, B, and Z, where applicable, may be applied to formula (II-B-3) in some embodiments.
[0272] In some embodiments, there is provided a compound of the following formula (II-B-4), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: In one embodiment, R of formula (II-B-4) 1 , X 1 , n, m, A, B, and Z are as defined in formula (II-AB'). In one embodiment, R of formula (II-B-4) 1 , X 1 , n, m, A, B, and Z are as defined in formula (II-AB). In one embodiment, R of formula (II-B-4) 1 , X 1, n, m, A, B, and Z are as defined in formula (II-B). R described for formula (II-AB'), (II-AB), or (II-B) 1 , X 1 , n, m, A, B, and Z, where applicable, may be applied to formula (II-B-4) in some embodiments.
[0273] In some embodiments, there is provided a compound of the following formula (II-B-5), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: In one embodiment, R of formula (II-B-5) 1 , X 1 , n, m, A, B, and Z are as defined in formula (II-AB'). In one embodiment, R of formula (II-B-5) 1 , X 1 , n, m, A, B, and Z are as defined in formula (II-AB). In one embodiment, R of formula (II-B-5) 1 , X 1 , n, m, A, B, and Z are as defined in formula (II-B). R described for formula (II-AB'), (II-AB), or (II-B) 1 , X 1 , n, m, A, B, and Z, where applicable, may be applied to formula (II-B-5) in some embodiments.
[0274] In some embodiments, there is provided a compound of the following formula (II-B-6), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: In one embodiment, X in formula (II-B-6) 2 , X 3 , n, m, A, B, and Z are as defined in formula (II-AB'). In one embodiment, X in formula (II-B-6) 2 , X 3 , n, m, A, B, and Z are as defined in formula (II-AB). In one embodiment, X in formula (II-B-6) 2 , X3 , n, m, A, B, and Z are as defined in formula (II-B). X described for formula (II-AB'), (II-AB) or (II-B) 2 , X 3 , n, m, A, B, and Z, where applicable, may be applied to formula (II-B-6) in some embodiments.
[0275] In some embodiments, there is provided a compound of the following formula (II-B-7), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: In one embodiment, X in formula (II-B-7) 3 , n, m, A, B, and Z are as defined in formula (II-AB'). In one embodiment, X in formula (II-B-7) 3 , n, m, A, B, and Z are as defined in formula (II-AB). In one embodiment, X in formula (II-B-7) 3 , n, m, A, B, and Z are as defined in formula (II-B). X described for formula (II-AB'), (II-AB) or (II-B) 3 , n, m, A, B, and Z, where applicable, may be applied to formula (II-B-7) in some embodiments.
[0276] In some embodiments, there is provided a compound of the following formula (II-B-8), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: TIFF2024543912000079.tif33170 In one aspect, n, m, A, B, and Z of Formula (II-B-8) are as defined in Formula (II-AB'). In one aspect, n, m, A, B, and Z of Formula (II-B-8) are as defined in Formula (II-AB). In one aspect, n, m, A, B, and Z of Formula (II-B-8) are as defined in Formula (II-B). It is understood that embodiments of n, m, A, B, and Z described for Formula (II-AB'), (II-AB), or (II-B) may be applied to Formula (II-B-8) in some embodiments, where applicable.
[0277] In some embodiments, there is provided a compound of the following formula (II-B-9), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: TIFF2024543912000080.tif33170 In one aspect, n, m, A, B, and Z of Formula (II-B-9) are as defined in Formula (II-AB'). In one aspect, n, m, A, B, and Z of Formula (II-B-9) are as defined in Formula (II-AB). In one aspect, n, m, A, B, and Z of Formula (II-B-9) are as defined in Formula (II-B). It is understood that embodiments of n, m, A, B, and Z described for Formula (II-AB'), (II-AB), or (II-B) may be applied to Formula (II-B-9) in some embodiments, where applicable.
[0278] In some embodiments, there is provided a compound of the following formula (II-B-10), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: TIFF2024543912000081.tif33170 In one aspect, n, m, A, B, and Z of Formula (II-B-10) are as defined in Formula (II-AB'). In one aspect, n, m, A, B, and Z of Formula (II-B-10) are as defined in Formula (II-AB). In one aspect, n, m, A, B, and Z of Formula (II-B-10) are as defined in Formula (II-B). It is understood that embodiments of n, m, A, B, and Z described for Formula (II-AB'), (II-AB), or (II-B) may be applied to Formula (II-B-10) in some embodiments, where applicable.
[0279] In some embodiments, there is provided a compound of the following formula (II-B-11), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: TIFF2024543912000082.tif33170 In one aspect, n, m, A, B, and Z of Formula (II-B-11) are as defined in Formula (II-AB'). In one aspect, n, m, A, B, and Z of Formula (II-B-11) are as defined in Formula (II-AB). In one aspect, n, m, A, B, and Z of Formula (II-B-11) are as defined in Formula (II-B). It is understood that embodiments of n, m, A, B, and Z described for Formula (II-AB'), (II-AB), or (II-B) may be applied to Formula (II-B-11) in some embodiments, where applicable.
[0280] In some embodiments, there is provided a compound of the following formula (II-B-12), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: TIFF2024543912000083.tif33170 In one embodiment, X in formula (II-B-12) 1 , X 2 , n, m, A, B, and Z are as defined in formula (II-AB'). In one embodiment, X in formula (II-B-12) 1 , X 2 , n, m, A, B, and Z are as defined in formula (II-AB). In one embodiment, X in formula (II-B-12)1 , X 2 , n, m, A, B, and Z are as defined in formula (II-B). X described for formula (II-AB'), (II-AB) or (II-B) 1 , X 2 It is understood that the embodiments of n, m, A, B, and Z, where applicable, may be applied to formula (II-B-12) in some embodiments.
[0281] In some embodiments, there is provided a compound of the following formula (II-B-13), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: TIFF2024543912000084.tif33170 In one embodiment, X in formula (II-B-13) 2 , n, m, A, B, and Z are as defined in formula (II-AB'). In one embodiment, X in formula (II-B-13) 2 , n, m, A, B, and Z are as defined in formula (II-AB). In one embodiment, X in formula (II-B-13) 2 , n, m, A, B, and Z are as defined in formula (II-B). X described for formula (II-AB'), (II-AB) or (II-B) 2 , n, m, A, B, and Z, where applicable, may be applied to formula (II-B-13) in some embodiments.
[0282] In some embodiments, there is provided a compound of the following formula (II-B-14), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: TIFF2024543912000085.tif33170 In one aspect, n, m, A, B, and Z of Formula (II-B-14) are as defined in Formula (II-AB'). In one aspect, n, m, A, B, and Z of Formula (II-B-14) are as defined in Formula (II-AB). In one aspect, n, m, A, B, and Z of Formula (II-B-14) are as defined in Formula (II-B). It is understood that embodiments of n, m, A, B, and Z described for Formula (II-AB'), (II-AB), or (II-B) may be applied to Formula (II-B-14) in some embodiments, where applicable.
[0283] In some embodiments, there is provided a compound of the following formula (II-B-15), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: TIFF2024543912000086.tif33170 In one embodiment, X of formula (II-B-15) 2 , n, m, A, B, and Z are as defined in formula (II-AB'). In one embodiment, X in formula (II-B-15) 2 , n, m, A, B, and Z are as defined in formula (II-AB). In one embodiment, X in formula (II-B-15) 2 , n, m, A, B, and Z are as defined in formula (II-B). X described for formula (II-AB'), (II-AB) or (II-B) 2 , n, m, A, B, and Z, where applicable, may be applied to formula (II-B-15) in some embodiments.
[0284] In some embodiments, there is provided a compound of the following formula (II-B-16), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: TIFF2024543912000087.tif32170 In one embodiment, R of formula (II-B-16) 1 , X 1 , X 2 , X 3 , n, m, A, and Z are as defined in formula (II-AB'). In one embodiment, R1 , X 1 , X 2 , X 3 , n, m, A, and Z are as defined in formula (II-AB). In one embodiment, R 1 , X 1 , X 2 , X 3 , n, m, A, and Z are as defined in formula (II-B). R described for formula (II-AB'), (II-AB), or (II-B) 1 , X 1 , X 2 , X 3 It is understood that the embodiments of n, m, A, and Z, where applicable, may be applied to formula (II-B-16) in some embodiments.
[0285] In some embodiments, there is provided a compound of the following formula (II-B-17), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: In one embodiment, R of formula (II-B-17) 1 , X 1 , X 2 , X 3 , n, m, A, and B are as defined in formula (II-AB'). In one embodiment, R of formula (II-B-17) 1 , X 1 , X 2 , X 3 , n, m, A, and B are as defined in formula (II-AB). In one embodiment, R of formula (II-B-17) 1 , X 1 , X 2 , X 3 , n, m, A, and B are as defined in formula (II-B). R described for formula (II-AB'), (II-AB) or (II-B) 1 , X 1 , X 2 , X 3 It is understood that the embodiments of n, m, A and B, where applicable, may be applied to formula (II-B-17) in some embodiments.
[0286] In some embodiments, there is provided a compound of the following formula (II-B-18), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: In one embodiment, R of formula (II-B-18) 1 , X 1 , X 2 , X 3 , n, m, and A are as defined in formula (II-AB'). In one embodiment, R 1 , X 1 , X 2 , X 3 , n, m, and A are as defined in formula (II-AB). In one embodiment, R 1 , X 1 , X 2 , X 3 , n, m, and A are as defined in formula (II-B). R described for formula (II-AB'), (II-AB) or (II-B) 1 , X 1 , X 2 , X 3 It is understood that the embodiments of n, m, and A, where applicable, may be applied to formula (II-B-18) in some embodiments.
[0287] In some embodiments, there is provided a compound of the following formula (II-B-19), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: TIFF2024543912000090.tif27170 In one embodiment, R of formula (II-B-19) 1 , X 1 , X 2 , X 3 , A, B, and Z are as defined in formula (II-AB'). In one embodiment, R of formula (II-B-19) 1 , X 1 , X 2 , X 3 , A, B, and Z are as defined in formula (II-AB). In one embodiment, R of formula (II-B-19) 1 , X 1 , X2 , X 3 , A, B, and Z are as defined in formula (II-B). R described for formula (II-AB'), (II-AB) or (II-B) 1 , X 1 , X 2 , X 3 It is understood that the embodiments of A, B, and Z, where applicable, can be applied to formula (II-B-19) in some embodiments.
[0288] In some embodiments, there is provided a compound of the following formula (II-B-20), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: In one embodiment, R of formula (II-B-20) t , X 2 , X 3 , n, m, A, B, and Z are as defined in formula (II-AB'). In one embodiment, R t , X 2 , X 3 , n, m, A, B, and Z are as defined in formula (II-AB). In one embodiment, R t , X 2 , X 3 , n, m, A, B, and Z are as defined in formula (II-B). R described for formula (II-AB'), (II-AB) or (II-B) t , X 2 , X 3 , n, m, A, B, and Z, where applicable, may be applied to formula (II-B-20) in some embodiments.
[0289] In some embodiments, there is provided a compound of the following formula (II-B-21), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: TIFF2024543912000092.tif37170 In one embodiment, X in formula (II-B-21) 2 , X 3, n, m, A, B, and Z are as defined in formula (II-AB'). In one embodiment, X in formula (II-B-21) 2 , X 3 , n, m, A, B, and Z are as defined in formula (II-AB). In one embodiment, X in formula (II-B-21) 2 , X 3 , n, m, A, B, and Z are as defined in formula (II-B). X described for formula (II-AB'), (II-AB) or (II-B) 2 , X 3 , n, m, A, B, and Z, where applicable, may be applied to formula (II-B-21) in some embodiments.
[0290] In some embodiments, there is provided a compound of the following formula (II-B-22), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: In one embodiment, R of formula (II-B-22) t , X 2 , X 3 , n, m, A, B, and Z are as defined in formula (II-AB'). In one embodiment, R of formula (II-B-22) t , X 2 , X 3 , n, m, A, B, and Z are as defined in formula (II-AB). In one embodiment, R t , X 2 , X 3 , n, m, A, B, and Z are as defined in formula (II-B). R described for formula (II-AB'), (II-AB) or (II-B) t , X 2 , X 3 , n, m, A, B, and Z, where applicable, may be applied to formula (II-B-22) in some embodiments.
[0291] In some embodiments, there is provided a compound of the following formula (II-B-23), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: In one embodiment, R of formula (II-B-23) t , X 2 , X 3 , n, m, A, B, and Z are as defined in formula (II-AB'). In one embodiment, R of formula (II-B-23) t , X 2 , X 3 , n, m, A, B, and Z are as defined in formula (II-AB). In one embodiment, R of formula (II-B-23) t , X 2 , X 3 , n, m, A, B, and Z are as defined in formula (II-B). R described for formula (II-AB'), (II-AB) or (II-B) t , X 2 , X 3 , n, m, A, B, and Z, where applicable, may be applied to formula (II-B-23) in some embodiments.
[0292] In some embodiments, there is provided a compound of the following formula (II-B-24), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: TIFF2024543912000095.tif37170 In one embodiment, X in formula (II-B-24) 2 , X 3 , n, m, A, B, and Z are as defined in formula (II-AB'). In one embodiment, X in formula (II-B-24) 2 , X 3 , n, m, A, B, and Z are as defined in formula (II-AB). In one embodiment, X in formula (II-B-24) 2 , X 3 , n, m, A, B, and Z are as defined in formula (II-B). X described for formula (II-AB'), (II-AB) or (II-B) 2 , X 3 , n, m, A, B, and Z, where applicable, may be applied to formula (II-B-24) in some embodiments.
[0293] In some embodiments, in conjunction with the above or below embodiments, B may be one or more R 2 When R is phenyl substituted with 2 In some embodiments, in conjunction with the above or below embodiments, L' in formula (II-AB') or (II-AB) can be *-N(R 3 )-L-**.
[0294] In some embodiments, in conjunction with the above or below embodiments, L' in formula (II-AB') or (II-AB) When TIFF2024543912000096.tif21170B is phenyl substituted with one or more alkoxy, the one or more alkoxy are substituted with one or more halo (eg, F, Cl, or Br).
[0295] In some embodiments, in conjunction with the above or below embodiments, X 1 R 1 and together with the atom to which they are attached, a 5- to 6-membered heteroaryl, a 5- to 6-membered heterocyclyl, a phenyl, or C fused to ring A 5-6 Forms a cycloalkyl, X 1 and R 1 5-6 membered heteroaryl, 5-6 membered heterocyclyl, phenyl, and C 5-6 Each cycloalkyl is independently one or more R t If replaced by R t cannot be oxo.
[0296] In some embodiments, in conjunction with the above or below embodiments, L′ in formula (II-AB′) or (II-AB) is *-N(R 3 )-L-**, then Z is -C(O)R a or -S(O)2R b where R a and R b is deuterium, C 1-6 Alkyl, Hydroxyl C 1-6 Alkyl, halo and haloC1-6 C optionally substituted with one or more substituents selected from alkyl 2-6 It is alkenyl.
[0297] In some embodiments, in conjunction with the above or below embodiments, L' in formula (II-AB') or (II-AB) TIFF2024543912000097.tif21170Z is -C(O)R a where R a is deuterium, C 1-6 Alkyl, Hydroxyl C 1-6 Alkyl, halo and haloC 1-6 C optionally substituted with one or more substituents selected from alkyl 2-6 It is alkenyl.
[0298] In some aspects, the compound of formula (II-AB'), (II-AB), (II-A) or (II-B), or any variation or embodiment thereof, is selected from the compounds listed in Table 1 below, including racemic mixtures and resolved isomers, as appropriate. [Table 1] TIFF2024543912000099.tif225170TIFF2024543912000100.tif254170TIFF20245439120001 01.tif235170TIFF2024543912000102.tif254170TIFF2024543912000103.tif233170TIFF202 4543912000104.tif228170TIFF2024543912000105.tif243170TIFF2024543912000106.tif23 7170TIFF2024543912000107.tif245170TIFF2024543912000108.tif240170TIFF20245439120 00109.tif233170TIFF2024543912000110.tif252170TIFF2024543912000111.tif247170TIF F2024543912000112.tif233170TIFF2024543912000113.tif230170TIFF2024543912000114.t if237170TIFF2024543912000115.tif242170TIFF2024543912000116.tif249170TIFF2024543 912000117.tif216170TIFF2024543912000118.tif212170TIFF2024543912000119.tif146170
[0299] Provided herein is a compound selected from the group consisting of: 2-Chloro-N-methyl-N-[[7-[4-(trifluoromethoxy)phenyl]thiazolo[5,4-d]pyrimidin-5-yl]methyl]acetamide N-[[4-cyano-7-[4-(trifluoromethoxy)phenyl]-2,3-dihydrobenzofuran-5-yl]methyl]prop-2-enamide N-[[7-(hydroxymethyl)-4-[6-(trifluoromethoxy)-3-pyridyl]-1,3-benzoxazol-6-yl]methyl]prop-2-enamide N-[[4-[4-(trifluoromethoxy)phenyl]-6,7-dihydro-5H-pyrano[2,3-d]pyrimidin-2-yl]methyl]prop-2-enamide N-[[5-hydroxymethyl-8-[4-(trifluoromethoxy)phenyl]imidazo[1,2-a]pyridin-6-yl]methyl]prop-2-enamide N-[[4-[4-(trifluoromethoxy)phenyl]-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-yl]methyl]prop-2-enamide N-[[4-[4-(trifluoromethoxy)phenyl]quinazolin-2-yl]methyl]prop-2-enamide N-[[7-[2-fluoro-4-(trifluoromethoxy)phenyl]-4-(hydroxymethyl)-2,3-dihydrobenzofuran-5-yl]methyl]prop-2-enamide N-[[7-[4-(trifluoromethoxy)phenyl]oxazolo[5,4-b]pyridin-5-yl]methyl]prop-2-enamide N-[[4-[4-(trifluoromethoxy)phenyl]furo[3,2-d]pyrimidin-2-yl]methyl]prop-2-enamide N-Methyl-N-[[7-[4-(trifluoromethoxy)phenyl]thiazolo[5,4-d]pyrimidin-5-yl]methyl]prop-2-enamide N-[[4-(hydroxymethyl)-7-[4-(trifluoromethoxy)phenyl]-2,3-dihydrobenzofuran-5-yl]methyl]prop-2-enamide N-[[4-[4-(trifluoromethoxy)phenyl]-6,7-dihydrofuro[3,2-d]pyrimidin-2-yl]methyl]prop-2-enamide 1-chloro-N-[[4-(hydroxymethyl)-7-[4-(trifluoromethoxy)phenyl]-2,3-dihydrobenzofuran-5-yl]methyl]methanesulfonamide 2-Chloro-N-[[7-[4-(trifluoromethoxy)phenyl]thiazolo[5,4-d]pyrimidin-5-yl]methyl]acetamide N-[[5-cyano-8-[4-(trifluoromethoxy)phenyl]-6-quinolyl]methyl]prop-2-enamide N-[(1R)-1-[4-(hydroxymethyl)-7-[4-(trifluoromethoxy)phenyl]-2,3-dihydrobenzofuran-5-yl]ethyl]prop-2-enamide N-[(1S)-1-[4-(hydroxymethyl)-7-[4-(trifluoromethoxy)phenyl]-2,3-dihydrobenzofuran-5-yl]ethyl]prop-2-enamide N-[[4-(hydroxymethyl)-7-[4-(trifluoromethoxy)phenyl]-2,3-dihydrobenzofuran-5-yl]methyl]ethenesulfonamide 2,3,3-Trideuterio-N-[[4-(hydroxymethyl)-7-[4-(trifluoromethoxy)phenyl]-2,3-dihydrobenzofuran-5-yl]methyl]prop-2-enamide N-[[7-[4-(trifluoromethoxy)phenyl]thiazolo[5,4-d]pyrimidin-5-yl]methyl]prop-2-enamide N-[[4-(hydroxymethyl)-7-(5-isopropoxythiazol-2-yl)-2,3-dihydrobenzofuran-5-yl]methyl]prop-2-enamide N-[[4-imidazol-1-yl-7-[4-(trifluoromethoxy)phenyl]-2,3-dihydrobenzofuran-5-yl]methyl]prop-2-enamide N-[[4-(hydroxymethyl)-7-[4-(pentafluoro-lambda-6-sulfanyl)phenyl]-2,3-dihydrobenzofuran-5-yl]methyl]prop-2-enamide 2-Chloro-N-[[4-(hydroxymethyl)-7-[4-(trifluoromethoxy)phenyl]-2,3-dihydrobenzofuran-5-yl]methyl]acetamide N-[[5-ethyl-8-[4-(trifluoromethoxy)phenyl]imidazo[1,2-a]pyridin-6-yl]methyl]prop-2-enamide N-[[4-cyano-3-methyl-7-[4-(trifluoromethoxy)phenyl]benzimidazol-5-yl]methyl]prop-2-enamide; N-[[5-[(1R)-1,2-dihydroxyethyl]-8-[4-(trifluoromethoxy)phenyl]quinoxalin-6-yl]methyl]prop-2-enamide; N-[[4-(hydroxymethyl)-3-methyl-7-[4-(trifluoromethoxy)phenyl]benzimidazol-5-yl]methyl]prop-2-enamide; N-[[3-methyl-4-[(1S)-1,2-dihydroxyethyl]-7-[4-(trifluoromethoxy)phenyl]benzimidazol-5-yl]methyl]prop-2-enamide; N-[[3-methyl-4-[(1R)-1,2-dihydroxyethyl]-7-[4-(trifluoromethoxy)phenyl]benzimidazol-5-yl]methyl]prop-2-enamide; N-[[3-methyl-4-[(1R)-1-hydroxyethyl]-7-[4-(trifluoromethoxy)phenyl]benzimidazol-5-yl]methyl]prop-2-enamide; N-[[3-methyl-4-[(1S)-1-hydroxyethyl]-7-[4-(trifluoromethoxy)phenyl]benzimidazol-5-yl]methyl]prop-2-enamide; N-[[3-methyl-4-(1H-pyrazol-4-ylmethyl)-7-[4-(trifluoromethoxy)phenyl]benzimidazol-5-yl]methyl]prop-2-enamide; N-[[2-methyl-7-[4-(trifluoromethoxy)phenyl]thiazolo[5,4-d]pyrimidin-5-yl]methyl]prop-2-enamide; N-[[5-hydroxymethyl-8-[4-(trifluoromethoxy)phenyl]imidazo[1,2-a]pyridin-6-yl]methyl]-N-methyl-prop-2-enamide; N-[[8-[4-(trifluoromethoxy)phenyl]imidazo[1,2-a]pyridin-6-yl]methyl]prop-2-enamide; N-Methyl-N-[[8-[4-(trifluoromethoxy)phenyl]imidazo[1,2-a]pyridin-6-yl]methyl]prop-2-enamide N-[[3-(difluoromethyl)-4-(hydroxymethyl)-7-[4-(trifluoromethoxy)phenyl]benzimidazol-5-yl]methyl]prop-2-enamide; (R)—N-((1-(difluoromethyl)-7-(1,2-dihydroxyethyl)-4-(4-(trifluoromethoxy)phenyl)-1H-benzo[d]imidazol-6-yl)methyl)acrylamide; (S)—N-((1-(difluoromethyl)-7-(1,2-dihydroxyethyl)-4-(4-(trifluoromethoxy)phenyl)-1H-benzo[d]imidazol-6-yl)methyl)acrylamide; N-[2-[4-cyano-3-methyl-7-[4-(trifluoromethoxy)phenyl]benzimidazol-5-yl]ethyl]prop-2-enamide; N-[[8-methyl-5-[4-(trifluoromethoxy)phenyl]-7-quinolyl]methyl]prop-2-enamide; N-[[8-(hydroxymethyl)-5-[4-(trifluoromethoxy)phenyl]-7-quinolyl]methyl]prop-2-enamide; (S)-N-((8-(1,2-dihydroxyethyl)-5-(4-(trifluoromethoxy)phenyl)quinolin-7-yl)methyl)acrylamide; (R)-N-((8-(1,2-dihydroxyethyl)-5-(4-(trifluoromethoxy)phenyl)quinolin-7-yl)methyl)acrylamide; (S)—N-((5-(1,2-dihydroxyethyl)-8-(4-(trifluoromethoxy)phenyl)quinolin-6-yl)methyl)acrylamide; (R)-N-((5-(1,2-dihydroxyethyl)-8-(4-(trifluoromethoxy)phenyl)quinolin-6-yl)methyl)acrylamide; N-[[5-(hydroxymethyl)-8-[4-(trifluoromethoxy)phenyl]-6-quinolyl]methyl]-N-methyl-prop-2-enamide; N-[[5-(hydroxymethyl)-8-[4-(trifluoromethoxy)phenyl]-6-quinolyl]methyl]prop-2-enamide; N-[[5-[(1S)-1,2-dihydroxyethyl]-8-[4-(trifluoromethoxy)phenyl]-6-quinolyl]methyl]-N-methyl-prop-2-enamide; N-[[5-[(1R)-1,2-dihydroxyethyl]-8-[4-(trifluoromethoxy)phenyl]-6-quinolyl]methyl]-N-methyl-prop-2-enamide; (S)—N-((4-(1,2-dihydroxyethyl)-7-(4-(trifluoromethoxy)phenyl)-2,3-dihydrobenzofuran-5-yl)methyl)acrylamide; (R)-N-((4-(1,2-dihydroxyethyl)-7-(4-(trifluoromethoxy)phenyl)-2,3-dihydrobenzofuran-5-yl)methyl)acrylamide; (S)—N-((4-(1,2-dihydroxyethyl)-7-(4-(trifluoromethoxy)phenyl)-2,3-dihydrobenzofuran-5-yl)methyl)-N-methylacrylamide; (R)-N-((4-(1,2-dihydroxyethyl)-7-(4-(trifluoromethoxy)phenyl)-2,3-dihydrobenzofuran-5-yl)methyl)-N-methylacrylamide; N-[[3-methyl-4-methylsulfonyl-7-[4-(trifluoromethoxy)phenyl]benzimidazol-5-yl]methyl]prop-2-enamide; N-[[4-(3-hydroxyprop-1-ynyl)-3-methyl-7-[4-(trifluoromethoxy)phenyl]benzimidazol-5-yl]methyl]prop-2-enamide; 2-Fluoro-1-[3-[4-(hydroxymethyl)-3-methyl-7-[4-(trifluoromethoxy)phenyl]benzimidazol-5-yl]azetidin-1-yl]prop-2-en-1-one; (S)—N-((1-methyl-7-(S-methylsulfonimidoyl)-4-(4-(trifluoromethoxy)phenyl)-1H-benzo[d]imidazol-6-yl)methyl)acrylamide; (R)—N-((1-methyl-7-(S-methylsulfonimidoyl)-4-(4-(trifluoromethoxy)phenyl)-1H-benzo[d]imidazol-6-yl)methyl)acrylamide; 1-[3-[9-methyl-6-[4-(trifluoromethoxy)phenyl]purin-2-yl]azetidin-1-yl]prop-2-en-1-one; 2-Fluoro-N-[[4-(hydroxymethyl)-3-methyl-7-[4-(trifluoromethoxy)phenyl]benzimidazol-5-yl]methyl]prop-2-enamide; (E)-4-hydroxy-N-[[4-(hydroxymethyl)-3-methyl-7-[4-(trifluoromethoxy)phenyl]benzimidazol-5-yl]methyl]-N-methyl-but-2-enamide; (R)-N-((7-(1,2-dihydroxyethyl)-1-methyl-4-(4-(trifluoromethoxy)phenyl)-1H-benzo[d]imidazol-6-yl)methyl)-2-fluoro-N-methylacrylamide; (S)—N-((7-(1,2-dihydroxyethyl)-1-methyl-4-(4-(trifluoromethoxy)phenyl)-1H-benzo[d]imidazol-6-yl)methyl)-2-fluoro-N-methylacrylamide; N-[[4-cyano-7-[4-(trifluoromethoxy)phenyl]-2,3-dihydrobenzofuran-5-yl]methyl]-2-fluoro-prop-2-enamide; N-[[1-methyl-7-[4-(trifluoromethoxy)phenyl]benzimidazol-5-yl]methyl]prop-2-enamide; N-[[9-methyl-6-[4-(trifluoromethoxy)phenyl]purin-2-yl]methyl]prop-2-enamide; N-[[7-[(1S)-1,2-dihydroxyethyl)-1-methyl-4-[4-(trifluoromethoxy)phenyl]imidazo[4,5-c]pyridin-6-yl]methyl]prop-2-enamide; N-[[7-[(1R)-1,2-dihydroxyethyl)-1-methyl-4-[4-(trifluoromethoxy)phenyl]imidazo[4,5-c]pyridin-6-yl]methyl]prop-2-enamide; N-[[3-methyl-4-(1H-pyrazol-4-yl)-7-[4-(trifluoromethoxy)phenyl]benzimidazol-5-yl]methyl]prop-2-enamide; N-((7-(hydroxymethyl)-1-methyl-4-(4-(trifluoromethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-6-yl)methyl)acrylamide; (S)—N-((7-(3,4-dihydroxybut-1-yn-1-yl)-1-methyl-4-(4-(trifluoromethoxy)phenyl)-1H-benzo[d]imidazol-6-yl)methyl)acrylamide; (R)—N-((7-(3,4-dihydroxybut-1-yn-1-yl)-1-methyl-4-(4-(trifluoromethoxy)phenyl)-1H-benzo[d]imidazol-6-yl)methyl)acrylamide; 3-methyl-5-[(prop-2-enoylamino)methyl]-7-[4-(trifluoromethoxy)phenyl]benzimidazole-4-carboxamide; N-[[4-(difluoromethyl)-3-methyl-7-[4-(trifluoromethoxy)phenyl]benzimidazol-5-yl]methyl]prop-2-enamide; N-((7-(1H-imidazol-1-yl)-1-methyl-4-(4-(trifluoromethoxy)phenyl)-1H-benzo[d]imidazol-6-yl)methyl)acrylamide; (S)-N-((5-(1,2-dihydroxyethyl)-8-(4-(trifluoromethoxy)phenyl)quinoxalin-6-yl)methyl)acrylamide; (R)-N-((5-(1,2-dihydroxyethyl)-8-(4-(trifluoromethoxy)phenyl)quinoxalin-6-yl)methyl)-2-fluoroacrylamide; (R)-N-((5-(1,2-dihydroxyethyl)-8-(4-(trifluoromethoxy)phenyl)quinoxalin-6-yl)methyl)cyclobut-1-ene-1-carboxamide; (R)-N-((5-(1-hydroxyethyl)-8-(4-(trifluoromethoxy)phenyl)quinoxalin-6-yl)methyl)acrylamide; (S)—N-((5-(1-hydroxyethyl)-8-(4-(trifluoromethoxy)phenyl)quinoxalin-6-yl)methyl)acrylamide; N-((5-(hydroxymethyl)-8-(4-(trifluoromethoxy)phenyl)quinoxalin-6-yl)methyl)acrylamide; N-((5-cyano-8-(4-(trifluoromethoxy)phenyl)quinoxalin-6-yl)methyl)acrylamide; (R)-Cyclobut-1-en-1-yl(3-(5-(1,2-dihydroxyethyl)-8-(4-(trifluoromethoxy)phenyl)quinoxalin-6-yl)azetidin-1-yl)methanone; (S)-Cyclobut-1-en-1-yl(3-(5-(1,2-dihydroxyethyl)-8-(4-(trifluoromethoxy)phenyl)quinoxalin-6-yl)azetidin-1-yl)methanone; N-((4-(hydroxymethyl)-7-(4-(trifluoromethoxy)phenyl)-2,3-dihydrobenzofuran-5-yl)methyl)-N-methylacrylamide; N-((4-((1S,2S)-1,2-dihydroxypropyl)-7-(4-(trifluoromethoxy)phenyl)-2,3-dihydrobenzofuran-5-yl)methyl)acrylamide; N-((4-((1R,2R)-1,2-dihydroxypropyl)-7-(4-(trifluoromethoxy)phenyl)-2,3-dihydrobenzofuran-5-yl)methyl)acrylamide; (R)-N-((4-(2-cyano-1-hydroxyethyl)-7-(4-(trifluoromethoxy)phenyl)-2,3-dihydrobenzofuran-5-yl)methyl)acrylamide; (S)—N-((4-(2-cyano-1-hydroxyethyl)-7-(4-(trifluoromethoxy)phenyl)-2,3-dihydrobenzofuran-5-yl)methyl)acrylamide; N-((7-(4-ethynylphenyl)-4-(hydroxymethyl)-2,3-dihydrobenzofuran-5-yl)methyl)acrylamide; N-((7-(4-ethynylphenyl)-4-(hydroxymethyl)-2,3-dihydrobenzofuran-5-yl)methyl)-N-methylacrylamide; N-((4-cyano-7-(4-(trifluoromethoxy)phenyl)-2,3-dihydrobenzofuran-5-yl)methyl)-N-methylacrylamide; N-[[7-[4-(pentafluoro-6-sulfanyl)phenyl]-4-[rac-(1R)-1,2-dihydroxyethyl]-2,3-dihydrobenzofuran-5-yl]methyl]prop-2-enamide; N-[[7-[4-(pentafluoro-6-sulfanyl)phenyl]-4-[rac-(1S)-1,2-dihydroxyethyl]-2,3-dihydrobenzofuran-5-yl]methyl]prop-2-enamide; N-ethyl-N-((7-(4-(trifluoromethoxy)phenyl)thiazolo[5,4-d]pyrimidin-5-yl)methyl)acrylamide; 1-(3-(7-(4-(trifluoromethoxy)phenyl)thiazolo[5,4-d]pyrimidin-5-yl)azetidin-1-yl)prop-2-en-1-one; (E)-4-hydroxy-1-(3-(7-(4-(trifluoromethoxy)phenyl)thiazolo[5,4-d]pyrimidin-5-yl)azetidin-1-yl)but-2-en-1-one; N-((7-(4-(trifluoromethoxy)phenyl)thiazolo[5,4-d]pyrimidin-5-yl)methyl)acrylamide-2,3,3-d3; N-((7-(3-isopropylbicyclo[1.1.1]pentan-1-yl)thiazolo[5,4-d]pyrimidin-5-yl)methyl)acrylamide; N-methyl-N-[[7-[4-(pentafluoro-6-sulfanyl)phenyl]thiazolo[5,4-d]pyrimidin-5-yl]methyl]prop-2-enamide; N-((7-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-4-(4-(trifluoromethoxy)phenyl)benzo[d]thiazol-6-yl)methyl)acrylamide; (S)-N-((7-(1,2-dihydroxyethyl)-4-(4-(trifluoromethoxy)phenyl)benzo[d]oxazol-6-yl)methyl)acrylamide; (R)-N-((7-(1,2-dihydroxyethyl)-4-(4-(trifluoromethoxy)phenyl)benzo[d]oxazol-6-yl)methyl)acrylamide; (S)-N-((7-(1,2-dihydroxyethyl)-4-(4-(trifluoromethoxy)phenyl)benzo[d]oxazol-6-yl)methyl)-N-methylacrylamide; (R)-N-((7-(1,2-dihydroxyethyl)-4-(4-(trifluoromethoxy)phenyl)benzo[d]oxazol-6-yl)methyl)-N-methylacrylamide; (S)—N-((7-(1,2-dihydroxyethyl)-4-(4-(trifluoromethyl)phenyl)benzo[d]oxazol-6-yl)methyl)acrylamide; (R)-N-((7-(1,2-dihydroxyethyl)-4-(4-(trifluoromethyl)phenyl)benzo[d]oxazol-6-yl)methyl)acrylamide; (S)—N-((7-(2-oxooxazolidin-5-yl)-4-(4-(trifluoromethoxy)phenyl)benzo[d]oxazol-6-yl)methyl)acrylamide; (R)—N-((7-(2-oxooxazolidin-5-yl)-4-(4-(trifluoromethoxy)phenyl)benzo[d]oxazol-6-yl)methyl)acrylamide; N-((7-(hydroxymethyl)-4-(4-(trifluoromethoxy)phenyl)benzo[d]oxazol-6-yl)methyl)acrylamide; N-((7-(hydroxymethyl)-4-(6-(trifluoromethoxy)pyridin-3-yl)benzo[d]oxazol-6-yl)methyl)acrylamide; Cyclobut-1-en-1-yl(3-(9-methyl-6-(4-(trifluoromethoxy)phenyl)-9H-purin-2-yl)azetidin-1-yl)methanone; (E)-9-methyl-2-(1-(prop-1-en-1-ylsulfonyl)azetidin-3-yl)-6-(4-(trifluoromethoxy)phenyl)-9H-purine; (E)-4-Hydroxy-1-(3-(9-methyl-6-(4-(trifluoromethoxy)phenyl)-9H-purin-2-yl)azetidin-1-yl)but-2-en-1-one 2-Fluoro-1-(3-(9-methyl-6-(4-(trifluoromethoxy)phenyl)-9H-purin-2-yl)azetidin-1-yl)prop-2-en-1-one; Bicyclo[1.1.0]butan-1-yl(3-(9-methyl-6-(4-(trifluoromethoxy)phenyl)-9H-purin-2-yl)azetidin-1-yl)methanone; (E)-2-methyl-1-(3-(9-methyl-6-(4-(trifluoromethoxy)phenyl)-9H-purin-2-yl)azetidin-1-yl)but-2-en-1-one; (E)-1-(3-(9-methyl-6-(4-(trifluoromethoxy)phenyl)-9H-purin-2-yl)azetidin-1-yl)but-2-en-1-one; (R)-1-(3-(9-methyl-6-(4-(trifluoromethoxy)phenyl)-9H-purin-2-yl)pyrrolidin-1-yl)prop-2-en-1-one; (S)-1-(3-(9-methyl-6-(4-(trifluoromethoxy)phenyl)-9H-purin-2-yl)pyrrolidin-1-yl)prop-2-en-1-one; 1-(4-(9-methyl-6-(4-(trifluoromethoxy)phenyl)-9H-purin-2-yl)piperazin-1-yl)prop-2-en-1-one; (E)-4-hydroxy-1-(4-(9-methyl-6-(4-(trifluoromethoxy)phenyl)-9H-purin-2-yl)piperazin-1-yl)but-2-en-1-one; 2-fluoro-1-(4-(9-methyl-6-(4-(trifluoromethoxy)phenyl)-9H-purin-2-yl)piperazin-1-yl)prop-2-en-1-one; N-(1-(9-methyl-6-(4-(trifluoromethoxy)phenyl)-9H-purin-2-yl)azetidin-3-yl)acrylamide; (E)-1-(4-hydroxybut-2-enoyl)-3-(9-methyl-6-(4-(trifluoromethoxy)phenyl)-9H-purin-2-yl)azetidine-3-carbonitrile; 1-((9-methyl-6-(4-(trifluoromethoxy)phenyl)-9H-purin-2-yl)methyl)-3-methylenepyrrolidin-2-one; N-((9-methyl-6-(4-(trifluoromethyl)piperidin-1-yl)-9H-purin-2-yl)methyl)acrylamide; N-((9-methyl-6-(4-(trifluoromethoxy)piperidin-1-yl)-9H-purin-2-yl)methyl)acrylamide; 1-(3-(9-(difluoromethyl)-6-(4-(trifluoromethoxy)phenyl)-9H-purin-2-yl)azetidin-1-yl)-2-fluoroprop-2-en-1-one; N-((9-methyl-2-(4-(trifluoromethoxy)phenyl)-9H-purin-6-yl)methyl)acrylamide; 6-(1-(2-fluoroacryloyl)azetidin-3-yl)-8-(4-(trifluoromethoxy)phenyl)pyrido[3,4-b]pyrazin-5(6H)-one; 6-(1-(cyclobut-1-ene-1-carbonyl)azetidin-3-yl)-8-(4-(trifluoromethoxy)phenyl)pyrido[3,4-b]pyrazin-5(6H)-one; 5-(1-(2-fluoroacryloyl)azetidin-3-yl)-3-methyl-7-(4-(trifluoromethoxy)phenyl)-3,5-dihydro-4H-imidazo[4,5-c]pyridin-4-one; (E)-5-(1-(4-hydroxybut-2-enoyl)azetidin-3-yl)-3-methyl-7-(4-(trifluoromethoxy)phenyl)-3,5-dihydro-4H-imidazo[4,5-c]pyridin-4-one; (R)-N-((7-(1-hydroxyethyl)-1-methyl-4-(4-(trifluoromethoxy)phenyl)-1H-benzo[d]imidazol-6-yl)methyl)acrylamide (S)-N-((7-(1-hydroxyethyl)-1-methyl-4-(4-(trifluoromethoxy)phenyl)-1H-benzo[d]imidazol-6-yl)methyl)acrylamide N-((7-((2-hydroxyethyl)amino)-1-methyl-4-(4-(trifluoromethoxy)phenyl)-1H-benzo[d]imidazol-6-yl)methyl)acrylamide; Methyl 2-(1-methyl-4-(4-(trifluoromethoxy)phenyl)-1H-benzo[d]imidazole-6-carboxamido)acrylate; N-(3-amino-3-oxoprop-1-en-2-yl)-1-methyl-4-(4-(trifluoromethoxy)phenyl)-1H-benzo[d]imidazole-6-carboxamide; N-((7-cyano-4-(2-fluoro-4-(trifluoromethoxy)phenyl)-1-methyl-1H-benzo[d]imidazol-6-yl)methyl)acrylamide; N-(2-(7-cyano-1-methyl-4-(4-(trifluoromethoxy)phenyl)-1H-benzo[d]imidazol-6-yl)ethyl)-N-methylacrylamide; 2-Fluoro-1-(3-(1-methyl-4-(4-(trifluoromethoxy)phenyl)-1H-benzo[d]imidazol-6-yl)azetidin-1-yl)prop-2-en-1-one; N-((8-(4-(trifluoromethyl)phenoxy)quinolin-6-yl)methyl)acrylamide; (S)—N-((5-(1,2-dihydroxyethyl)-8-(4-(trifluoromethyl)phenoxy)quinolin-6-yl)methyl)acrylamide; and (R)-N-((5-(1,2-dihydroxyethyl)-8-(4-(trifluoromethyl)phenoxy)quinolin-6-yl)methyl)acrylamide; or a pharmaceutically acceptable salt thereof. Also provided herein are any and all stereoisomers of the compounds presented herein, including, where applicable, their geometric isomers (e.g., cis / trans or E / Z isomers), enantiomers, diastereomers, tautomers, or mixtures in any ratio, including racemic mixtures.
[0300] In some embodiments, provided herein is a compound selected from the group consisting of: 2-Chloro-N-methyl-N-[[7-[4-(trifluoromethoxy)phenyl]thiazolo[5,4-d]pyrimidin-5-yl]methyl]acetamide N-[[4-cyano-7-[4-(trifluoromethoxy)phenyl]-2,3-dihydrobenzofuran-5-yl]methyl]prop-2-enamide N-[[7-(hydroxymethyl)-4-[6-(trifluoromethoxy)-3-pyridyl]-1,3-benzoxazol-6-yl]methyl]prop-2-enamide N-[[4-[4-(trifluoromethoxy)phenyl]-6,7-dihydro-5H-pyrano[2,3-d]pyrimidin-2-yl]methyl]prop-2-enamide N-[[5-hydroxymethyl-8-[4-(trifluoromethoxy)phenyl]imidazo[1,2-a]pyridin-6-yl]methyl]prop-2-enamide N-[[4-[4-(trifluoromethoxy)phenyl]-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-yl]methyl]prop-2-enamide N-[[4-[4-(trifluoromethoxy)phenyl]quinazolin-2-yl]methyl]prop-2-enamide N-[[7-[2-fluoro-4-(trifluoromethoxy)phenyl]-4-(hydroxymethyl)-2,3-dihydrobenzofuran-5-yl]methyl]prop-2-enamide N-[[7-[4-(trifluoromethoxy)phenyl]oxazolo[5,4-b]pyridin-5-yl]methyl]prop-2-enamide N-[[4-[4-(trifluoromethoxy)phenyl]furo[3,2-d]pyrimidin-2-yl]methyl]prop-2-enamide N-Methyl-N-[[7-[4-(trifluoromethoxy)phenyl]thiazolo[5,4-d]pyrimidin-5-yl]methyl]prop-2-enamide N-[[4-(hydroxymethyl)-7-[4-(trifluoromethoxy)phenyl]-2,3-dihydrobenzofuran-5-yl]methyl]prop-2-enamide N-[[4-[4-(trifluoromethoxy)phenyl]-6,7-dihydrofuro[3,2-d]pyrimidin-2-yl]methyl]prop-2-enamide 1-chloro-N-[[4-(hydroxymethyl)-7-[4-(trifluoromethoxy)phenyl]-2,3-dihydrobenzofuran-5-yl]methyl]methanesulfonamide 2-Chloro-N-[[7-[4-(trifluoromethoxy)phenyl]thiazolo[5,4-d]pyrimidin-5-yl]methyl]acetamide N-[[5-cyano-8-[4-(trifluoromethoxy)phenyl]-6-quinolyl]methyl]prop-2-enamide N-[(1R)-1-[4-(hydroxymethyl)-7-[4-(trifluoromethoxy)phenyl]-2,3-dihydrobenzofuran-5-yl]ethyl]prop-2-enamide N-[(1S)-1-[4-(hydroxymethyl)-7-[4-(trifluoromethoxy)phenyl]-2,3-dihydrobenzofuran-5-yl]ethyl]prop-2-enamide N-[[4-(hydroxymethyl)-7-[4-(trifluoromethoxy)phenyl]-2,3-dihydrobenzofuran-5-yl]methyl]ethenesulfonamide 2,3,3-Trideuterio-N-[[4-(hydroxymethyl)-7-[4-(trifluoromethoxy)phenyl]-2,3-dihydrobenzofuran-5-yl]methyl]prop-2-enamide N-[[7-[4-(trifluoromethoxy)phenyl]thiazolo[5,4-d]pyrimidin-5-yl]methyl]prop-2-enamide N-[[4-(hydroxymethyl)-7-(5-isopropoxythiazol-2-yl)-2,3-dihydrobenzofuran-5-yl]methyl]prop-2-enamide N-[[4-imidazol-1-yl-7-[4-(trifluoromethoxy)phenyl]-2,3-dihydrobenzofuran-5-yl]methyl]prop-2-enamide N-[[4-(hydroxymethyl)-7-[4-(pentafluoro-lambda-6-sulfanyl)phenyl]-2,3-dihydrobenzofuran-5-yl]methyl]prop-2-enamide 2-Chloro-N-[[4-(hydroxymethyl)-7-[4-(trifluoromethoxy)phenyl]-2,3-dihydrobenzofuran-5-yl]methyl]acetamide N-[[5-ethyl-8-[4-(trifluoromethoxy)phenyl]imidazo[1,2-a]pyridin-6-yl]methyl]prop-2-enamide N-[[4-cyano-3-methyl-7-[4-(trifluoromethoxy)phenyl]benzimidazol-5-yl]methyl]prop-2-enamide; N-[[5-[(1R)-1,2-dihydroxyethyl]-8-[4-(trifluoromethoxy)phenyl]quinoxalin-6-yl]methyl]prop-2-enamide; N-[[4-(hydroxymethyl)-3-methyl-7-[4-(trifluoromethoxy)phenyl]benzimidazol-5-yl]methyl]prop-2-enamide; N-[[3-methyl-4-[(1S)-1,2-dihydroxyethyl]-7-[4-(trifluoromethoxy)phenyl]benzimidazol-5-yl]methyl]prop-2-enamide; N-[[3-methyl-4-[(1R)-1,2-dihydroxyethyl]-7-[4-(trifluoromethoxy)phenyl]benzimidazol-5-yl]methyl]prop-2-enamide; N-[[3-methyl-4-[(1R)-1-hydroxyethyl]-7-[4-(trifluoromethoxy)phenyl]benzimidazol-5-yl]methyl]prop-2-enamide; N-[[3-methyl-4-[(1S)-1-hydroxyethyl]-7-[4-(trifluoromethoxy)phenyl]benzimidazol-5-yl]methyl]prop-2-enamide; N-[[3-methyl-4-(1H-pyrazol-4-ylmethyl)-7-[4-(trifluoromethoxy)phenyl]benzimidazol-5-yl]methyl]prop-2-enamide; N-[[2-methyl-7-[4-(trifluoromethoxy)phenyl]thiazolo[5,4-d]pyrimidin-5-yl]methyl]prop-2-enamide; N-[[5-hydroxymethyl-8-[4-(trifluoromethoxy)phenyl]imidazo[1,2-a]pyridin-6-yl]methyl]-N-methyl-prop-2-enamide; N-[[8-[4-(trifluoromethoxy)phenyl]imidazo[1,2-a]pyridin-6-yl]methyl]prop-2-enamide; N-Methyl-N-[[8-[4-(trifluoromethoxy)phenyl]imidazo[1,2-a]pyridin-6-yl]methyl]prop-2-enamide N-[[3-(difluoromethyl)-4-(hydroxymethyl)-7-[4-(trifluoromethoxy)phenyl]benzimidazol-5-yl]methyl]prop-2-enamide; (R)—N-((1-(difluoromethyl)-7-(1,2-dihydroxyethyl)-4-(4-(trifluoromethoxy)phenyl)-1H-benzo[d]imidazol-6-yl)methyl)acrylamide; (S)—N-((1-(difluoromethyl)-7-(1,2-dihydroxyethyl)-4-(4-(trifluoromethoxy)phenyl)-1H-benzo[d]imidazol-6-yl)methyl)acrylamide; N-[2-[4-cyano-3-methyl-7-[4-(trifluoromethoxy)phenyl]benzimidazol-5-yl]ethyl]prop-2-enamide; N-[[8-methyl-5-[4-(trifluoromethoxy)phenyl]-7-quinolyl]methyl]prop-2-enamide; N-[[8-(hydroxymethyl)-5-[4-(trifluoromethoxy)phenyl]-7-quinolyl]methyl]prop-2-enamide; (S)-N-((8-(1,2-dihydroxyethyl)-5-(4-(trifluoromethoxy)phenyl)quinolin-7-yl)methyl)acrylamide; (R)-N-((8-(1,2-dihydroxyethyl)-5-(4-(trifluoromethoxy)phenyl)quinolin-7-yl)methyl)acrylamide; (S)—N-((5-(1,2-dihydroxyethyl)-8-(4-(trifluoromethoxy)phenyl)quinolin-6-yl)methyl)acrylamide; (R)-N-((5-(1,2-dihydroxyethyl)-8-(4-(trifluoromethoxy)phenyl)quinolin-6-yl)methyl)acrylamide; N-[[5-(hydroxymethyl)-8-[4-(trifluoromethoxy)phenyl]-6-quinolyl]methyl]-N-methyl-prop-2-enamide; N-[[5-(hydroxymethyl)-8-[4-(trifluoromethoxy)phenyl]-6-quinolyl]methyl]prop-2-enamide; N-[[5-[(1S)-1,2-dihydroxyethyl]-8-[4-(trifluoromethoxy)phenyl]-6-quinolyl]methyl]-N-methyl-prop-2-enamide; N-[[5-[(1R)-1,2-dihydroxyethyl]-8-[4-(trifluoromethoxy)phenyl]-6-quinolyl]methyl]-N-methyl-prop-2-enamide; (S)—N-((4-(1,2-dihydroxyethyl)-7-(4-(trifluoromethoxy)phenyl)-2,3-dihydrobenzofuran-5-yl)methyl)acrylamide; (R)-N-((4-(1,2-dihydroxyethyl)-7-(4-(trifluoromethoxy)phenyl)-2,3-dihydrobenzofuran-5-yl)methyl)acrylamide; (S)—N-((4-(1,2-dihydroxyethyl)-7-(4-(trifluoromethoxy)phenyl)-2,3-dihydrobenzofuran-5-yl)methyl)-N-methylacrylamide; (R)-N-((4-(1,2-dihydroxyethyl)-7-(4-(trifluoromethoxy)phenyl)-2,3-dihydrobenzofuran-5-yl)methyl)-N-methylacrylamide; N-[[3-methyl-4-methylsulfonyl-7-[4-(trifluoromethoxy)phenyl]benzimidazol-5-yl]methyl]prop-2-enamide; N-[[4-(3-hydroxyprop-1-ynyl)-3-methyl-7-[4-(trifluoromethoxy)phenyl]benzimidazol-5-yl]methyl]prop-2-enamide; 2-Fluoro-1-[3-[4-(hydroxymethyl)-3-methyl-7-[4-(trifluoromethoxy)phenyl]benzimidazol-5-yl]azetidin-1-yl]prop-2-en-1-one; (S)—N-((1-methyl-7-(S-methylsulfonimidoyl)-4-(4-(trifluoromethoxy)phenyl)-1H-benzo[d]imidazo...
Claims
1. Compound of formula (II-AB'): or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof, wherein: L' is *-N(R 3 )-L-** or * indicates the point of attachment to Z, ** indicates X 1 is C or N, and X 1 is R 1 and together with the atoms to which they are attached, a 5- to 6-membered heteroaryl, a 5- to 6-membered heterocyclyl, a phenyl, or C fused to ring A. 5-6 Forming a cycloalkyl; X 1 and R 1 The 5- to 6-membered heteroaryl, 5- to 6-membered heterocyclyl, phenyl, and C 5-6 Cycloalkyl is, independently, one or more R t and optionally substituted with R t is independently, at each occurrence, halo, C 1-15 Alkyl, haloC 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3- to 15-membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d C.O.R. e , -CONR d R e , -SO 2 R d , -SO 2 N.R. d R e , -NR d SO 2 R e , and -NR d R e and R d and R e are each independently H or C 1-6 alkyl, R d Or R e The above C 1-6 The alkyl is optionally substituted with one or more substituents selected from halo, oxo, -OH and -CN; X 2 is N or CR s and R s H, halo, C 1-15 Alkyl, Hydroxyl C 1-6 Alkynyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3- to 15-membered heterocyclyl, -OH, -CN, C 1-15 Alkoxy, -NR d C.O.R. e , -CONR d R e , -SO 2 R d , -S(O)NHR d , -SO 2 N.R. d R e , -NR d SO 2 R e , and -NR d R e Selected from: R s The above C 1-15 Alkyl and C 1-15 Each alkoxy is independently one or more R t1 wherein R t1 is independently at each occurrence halo, oxo, —OH, —CN, 5- to 6-membered heteroaryl, or —NR d R e and R d and R e are each independently H or C 1-6 alkyl, R d Or R e The above C 1-6 The alkyl is optionally substituted with one or more substituents selected from halo, oxo, -OH and -CN; and R s The above C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl and 3- to 15-membered heterocyclyl each independently represent one or more R t2 and optionally substituted with R t2 is independently at each occurrence halo, oxo, —OH, —CN, and C 1-6 alkyl; and R d and R e are each independently H or C 1-6 alkyl, R d Or R e The above C 1-6 The alkyl is optionally substituted with one or more substituents selected from halo, oxo, -OH and -CN; X 3 is N or CH; B is, i) phenyl or 5- to 6-membered heteroaryl; the phenyl and 5- to 6-membered heteroaryl of B are each independently one or more R 2 is replaced by R 2 is independently, at each occurrence, halo; S(R y ) 5 and each R y is halo; or C optionally substituted with one or more halo 1-6 is alkoxy; or ii) Halo C 1-3 -O-phenyl substituted with alkyl (provided that B is haloC 1-3 When L' is -O-phenyl substituted with alkyl, L' is *-N(R 3 )-L-**, and Z is -C(O)CHCH 2 And X 1 is C and X 2 is CR s And X 3 is CH); or iii) C 1-3 Is it an alkyl-substituted bicyclopentane (where B is C)? 1-3 When L' is an alkyl-substituted bicyclopentane, L' is *-N(R 3 )-L-**, and Z is -C(O)CHCH 2 (provided that the iv) ethynyl or haloC 1-3 phenyl substituted with alkyl (provided that B is ethynyl or haloC 1-3 When L' is phenyl substituted with alkyl, L' is *-N(R 3 )-L-**, and Z is -C(O)CHCH 2 and R s is C substituted with one or more —OH 1-3 provided that it is alkyl; or v) Halo C 1-3 Alkyl or haloC 1-3 alkoxy-substituted piperidine, provided that B is haloC 1-3 Alkyl or haloC 1-3 When L' is an alkoxy-substituted piperidine, L' is *-N(R 3 )-L-**, and Z is -C(O)CHCH 2 (provided that: R 3 is H or C 1-6 is alkyl; Z is -OH, -NR d R e , C 1-6 Alkoxy, -C(O)R a or -S(O) 2 R b and R d and R e are each independently H or C 1-6 alkyl, R d Or R e The above C 1-6 The alkyl is optionally substituted with one or more substituents selected from halo, oxo, -OH and -CN; R a and R b each independently represents: i) deuterium, C 1-6 Alkyl, Hydroxyl C 1-6 Alkyl, halo and haloC 1-6 C optionally substituted with one or more substituents selected from alkyl 2-6 alkenyl; ii) C optionally substituted with one or more halo 1-6 alkyl; or iii) cyclobutenyl or bicyclobutanyl; L is methylene or ethylene, and the methylene of L is one C 1-6 optionally substituted with alkyl; Y is CH or C(CN), and n and m are each independently 1 or 2; However, subject to the following conditions: i) i-1) X 1 R 1 and together with the atom to which they are attached form a phenyl, i-2) X 2 Or X 3 is N, B in formula (II-AB') is phenyl, and R 2 Halo C 1-6 being alkoxyl; and ii) when n=1 and m=2, or n=2 and m=1, B is phenyl substituted with halomethyloxyl; and iii) the compound of formula (II-AB') is not any of the following: N-((8-(4-fluorophenyl)imidazo[1,2-a]pyrazin-6-yl)methyl)acrylamide; N-((8-(4-(trifluoromethoxy)phenyl)imidazo[1,2-a]pyrazin-6-yl)methyl)acrylamide; N-((7-fluoro-4-(4-(trifluoromethoxy)phenyl)quinazolin-2-yl)methyl)acrylamide; N-((8-(4-(difluoromethoxy)phenyl)imidazo[1,2-a]pyrazin-6-yl)methyl)acrylamide; 1-(4-(4-(4-methoxyphenyl)-1-methyl-1H-imidazo[4,5-c]pyridin-6-yl)piperidin-1-yl)ethan-1-one; 4-(4-methoxyphenyl)-1-methyl-6-(1-(methylsulfonyl)piperidin-4-yl)-1H-imidazo[4,5-c]pyridine; 6-(1-(ethylsulfonyl)piperidin-4-yl)-4-(4-methoxyphenyl)-1-methyl-1H-imidazo[4,5-c]pyridine; 6-(1-(ethylsulfonyl)piperidin-4-yl)-1-isopropyl-4-(4-methoxyphenyl)-1H-imidazo[4,5-c]pyridine; 4-(4-methoxyphenyl)-1-methyl-6-(1-((trifluoromethyl)sulfonyl)piperidin-4-yl)-1H-imidazo[4,5-c]pyridine; and N-((4-(4-fluorophenyl)-1,8-naphthyridin-2-yl)methyl)acetamide.
2. 10. The compound of claim 1, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof, wherein the compound is a compound of formula (II-A): or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof.
3. 10. The compound of claim 1, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof, wherein the compound is a compound of formula (II-B): or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof.
4. Z is -C(O)R a Or -S(O) 2 R b and R a and R b each independently represents: i) deuterium, C 1-6 Alkyl, Hydroxyl C 1-6 Alkyl, halo and haloC 1-6 C optionally substituted with one or more substituents selected from alkyl 2-6 alkenyl; ii) C optionally substituted with one or more halo 1-6 4. The compound of claim 1, wherein: iii) alkyl; or iii) cyclobutenyl or bicyclobutanyl, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof.
5. Z is -C(O)R a and R a Deuterium, C 1-6 Alkyl, Hydroxyl C 1-6 Alkyl, halo and haloC 1-6 C optionally substituted with one or more substituents selected from alkyl 2-6 5. The compound of claim 4, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof, which is alkenyl.
6. Z is -C(O)R a and R a is ethenyl optionally substituted with one or more substituents selected from deuterium and halo, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof.
7. Z is -C(O)R a and R a C optionally substituted with one or more halo 1-6 5. The compound of claim 4, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof, wherein R is an alkyl group.
8. Z 6. A compound according to claim 5, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof.
9. Z is -C(O)R a and R a is cyclobutenyl or bicyclobutanyl, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof.
10. 10. A compound according to any one of claims 1 to 9, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof, wherein B is one or more R 2 phenyl substituted with R 2 is independently, at each occurrence, halo; S(R y ) 5 and each R y is halo; or C optionally substituted with one or more halo 1-6 3. The compound, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof, which is alkoxy.
11. 11. A compound according to any one of claims 1 to 10, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof, wherein B is one or more R 2 phenyl substituted with R 2 is independently, at each occurrence, halomethoxy, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof.
12. B 12. A compound according to any one of claims 1 to 11, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof.
13. 10. A compound according to any one of claims 1 to 9, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof, wherein B is one or more R 2 is a 5-6 membered heteroaryl substituted with R 2 is independently, at each occurrence, halo; S(R y ) 5 and each R y is halo; or C optionally substituted with one or more halo 1-6 3. The compound, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof, which is alkoxy.
14. 10. A compound according to claim 1, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof, Z is -C(O)R a and R a is deuterium, C 1-6 Alkyl, halo and haloC 1-6 C optionally substituted with one or more substituents selected from alkyl 2-6 alkenyl; and B is one or more R 2 phenyl substituted with R 2 is C optionally substituted with one or more halo 1-6 3. The compound, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof, which is alkoxy.
15. 10. A compound according to claim 1, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof, Z is -C(O)R a and R a is C optionally substituted with one or more halo 1-6 is alkyl, B is one or more R 2 phenyl substituted with R 2 is C optionally substituted with one or more halo 1-6 3. The compound, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof, which is alkoxy.
16. A compound according to claim 2, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof, wherein the compound is a compound of formula (II-A-20): or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof.
17. A compound according to claim 3, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof, wherein the compound is a compound of formula (II-B-18) or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof.
18. R 3 is H, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof.
19. 19. A compound according to any one of claims 1 to 18, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof, X 1 is C or N; X 2 But, CR s and R s H, halo, C 1-15 Alkyl, Hydroxyl C 1-6 Alkynyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3- to 15-membered heterocyclyl, -OH, -CN, C 1-15 Alkoxy, -NR d C.O.R. e , -CONR d R e , -SO 2 R d , -S(O)NHR d , -SO 2 N.R. d R e , -NR d SO 2 R e , and -NR d R e and X 3 is N or CH, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof.
20. X 1 and X 3 is N, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof.
21. X 1 is C and X 3 is CH, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof.
22. X 2 is CR s and R s is C 1-15 Alkyl, 5-15 membered heteroaryl, -CN or C 1-15 22. The compound of any one of claims 1 to 21, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof, which is alkoxy.
23. X 1 is C; X 2 is N; and X 3 is N or CH, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof.
24. X 1 But, R 1 and together with the atom to which they are attached form a 5-6 membered heteroaryl fused to Ring A, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof.
25. 25. The compound of claim 24, wherein the 5-6 membered heteroaryl fused to Ring A is selected from the group consisting of:
26. X 1 But, R 1 and together with the atom to which they are attached form a 5-6 membered heterocyclyl fused to Ring A, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof.
27. 27. The compound of claim 26, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof, wherein the 5- to 6-membered heterocyclyl fused to ring A is or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof.
28. X 1 But, R 1 and together with the atom to which they are attached form a phenyl fused to ring A, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof.
29. X 1 But, R 1 and C fused to ring A together with the atoms to which they are attached 5-6 A compound according to any one of claims 1 to 19 and 21 to 23, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof, which forms a cycloalkyl.
30. A compound selected from any one of the compounds in Table 1, or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof:
31. 31. A pharmaceutical composition comprising: (i) a compound according to any one of claims 1 to 30, or a stereoisomer, tautomer, or pharma- ceutically acceptable salt thereof; and (ii) a pharma- ceutically acceptable carrier, diluent, or excipient.
32. 31. A compound according to any one of claims 1 to 30, or a stereoisomer, tautomer or pharma- ceutically acceptable salt thereof, for use in medical therapy.
33. Acoustic neuroma, acute leukemia, acute lymphocytic leukemia, acute myeloid leukemia (monocytic, myeloblastic, adenocarcinoma, angiosarcoma, astrocytoma, myelomonocytic and promyelocytic), acute T-cell leukemia, basal cell carcinoma, bile duct carcinoma, bladder cancer, brain cancer, breast cancer, bronchogenic carcinoma, cervical cancer, chondrosarcoma, chordoma, choriocarcinoma, chronic leukemia, chronic lymphocytic leukemia, chronic myeloid (granulocytic) leukemia, chronic myeloid leukemia, colon cancer, colorectal cancer, craniopharyngioma, cystadenocarcinoma, diffuse large B-cell lymphoma, proliferation abnormalities changes (dysplasia and metaplasia), embryonal carcinoma, endometrial cancer, endothelial sarcoma, ependymoma, epithelial carcinoma, erythroleukemia, esophageal cancer, estrogen receptor positive breast cancer, essential thrombocythemia, Ewing's sarcoma, fibrosarcoma, follicular lymphoma, testicular germ cell cancer, glioma, glioblastoma, gliosarcoma, heavy chain disease, hemangioblastoma, hepatocellular carcinoma, hormone insensitive prostate cancer, leiomyosarcoma, leukemia, liposarcoma, lung cancer, lymphangioendothelial sarcoma, lymphangiosarcoma, lymphoblastic leukemia, lymphoma (Hodgkin and non-Hodgkin); Malignant tumors and hyperproliferative disorders of the bladder, breast, colon, lung, ovary, pancreas, prostate, skin and uterus, lymphoid malignancies of T-cell or B-cell origin, medullary carcinoma, medulloblastoma, melanoma, meningioma, mesothelioma, multiple myeloma, myeloid leukemia, myeloma, myxosarcoma, neuroblastoma, NUT midline carcinoma (NMC), non-small cell lung cancer, oligodendroglioma, oral cancer, osteogenic sarcoma, ovarian cancer, pancreatic cancer, papillary adenocarcinoma, papillary carcinoma, pinealoma, erythrocytosis vera, prostate cancer, rectal cancer, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, sarcoma 31. The compound of any one of claims 1 to 30, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for use in the treatment and / or prevention of a disease or condition mediated by TEAD activity selected from the group consisting of: sebaceous carcinoma, seminoma, skin cancer, small cell lung carcinoma, solid tumors (carcinoma and sarcoma), small cell lung cancer, gastric cancer, squamous cell carcinoma, synovium, sweat gland carcinoma, thyroid cancer, Waldenstrom's macroglobulinemia, testicular tumor, uterine cancer and Wilms' tumor.
34. 31. A compound according to any one of claims 1 to 30, or a stereoisomer, tautomer or pharma- ceutically acceptable salt thereof, for use in modulating TEAD activity.
35. 31. The compound of any one of claims 1 to 30, or a stereoisomer, tautomer, or pharma- ceutically acceptable salt thereof, for use in the treatment and / or prevention of a disease or condition mediated by TEAD activity.
36. 31. Use of a compound according to any one of claims 1 to 30, or a stereoisomer, tautomer or pharma- ceutically acceptable salt thereof, for the preparation of a medicament for the treatment or prevention of a disease or condition mediated by TEAD activity.
37. 31. A method for treating cancer in a mammal comprising administering to said mammal a therapeutically effective amount of a compound according to any one of claims 1 to 30, or a stereoisomer, tautomer or pharma- ceutically acceptable salt thereof.
38. 31. A method for modulating a TEAD activity, comprising contacting a TEAD with a therapeutically effective amount of a compound of any one of claims 1 to 30, or a stereoisomer, tautomer, or pharma- ceutically acceptable salt thereof.
39. 31. A method for treating a disease or condition mediated by TEAD activity in a mammal, comprising administering to the mammal a therapeutically effective amount of a compound according to any one of claims 1 to 30, or a pharma- ceutically acceptable salt thereof.
40. 31. Use of a compound according to any one of claims 1 to 30, or a stereoisomer, tautomer or pharma- ceutically acceptable salt thereof, for modulating TEAD activity.
41. 31. Use of a compound according to any one of claims 1 to 30, or a stereoisomer, tautomer or pharma- ceutically acceptable salt thereof, for the treatment and / or prevention of a disease or condition mediated by TEAD activity.
42. A composition comprising: (i) one or more TEAD inhibitors or pharma- ceutically acceptable salts thereof; and (ii) one or more KRAS inhibitors or pharma- ceutically acceptable salts thereof; 31. A composition, wherein the one or more TEAD inhibitors is any one of the compounds according to any one of claims 1 to 30.
43. 43. The composition of claim 42, wherein the one or more KRAS inhibitors comprises a G12C KRAS inhibitor.
44. 1. A method of treating cancer in a subject in need thereof, comprising administering to the subject an effective amount of a combination comprising: (i) one or more TEAD inhibitors or pharma- ceutically acceptable salts thereof; and (ii) one or more KRAS inhibitors or pharma- ceutically acceptable salts thereof; The method, wherein the one or more TEAD inhibitors is any one of the compounds according to any one of claims 1 to 30.
45. 45. The method of claim 44, wherein the one or more KRAS inhibitors comprises a G12C KRAS inhibitor.
46. A kit comprising: (i) one or more TEAD inhibitors or pharma- ceutically acceptable salts thereof; (ii) one or more KRAS inhibitors or pharma- ceutically acceptable salts thereof; and (iii) instructions for administering the combination to treat cancer in a subject in need thereof; The one or more TEAD inhibitors are any one of the compounds according to any one of claims 1 to 30.
47. 47. The kit of claim 46, wherein the one or more KRAS inhibitors comprises a G12C KRAS inhibitor.
48. 31. Use of a compound according to any one of claims 1 to 30, or a stereoisomer, tautomer or pharma- ceutically acceptable salt thereof, for the preparation of a medicament for the treatment or prevention of a disease or condition mediated by KRAS activity.
49. 49. The use of claim 48, wherein the disease or condition mediated by KRAS activity is cancer.
50. 31. Use of a compound according to any one of claims 1 to 30, or a stereoisomer, tautomer or pharma- ceutically acceptable salt thereof, for modulating KRAS activity.
51. 31. Use of a compound according to any one of claims 1 to 30, or a stereoisomer, tautomer or pharma- ceutically acceptable salt thereof, for the treatment and / or prevention of a disease or condition mediated by KRAS activity.
52. 52. The use of claim 51, wherein the disease or condition mediated by KRAS activity is cancer.
53. 1. A method for reducing a subject's resistance to a treatment comprising a KRAS inhibitor, the method comprising administering a therapeutically effective amount of a TEAD inhibitor or a pharma- ceutically acceptable salt thereof.
54. Compound of formula (II-AB'): or a stereoisomer or tautomer thereof, or a pharma- ceutically acceptable salt thereof, comprising the formula: L' is *-N(R 3 )-L-** or * indicates the point of attachment to Z, ** indicates X 1 is C or N, and X 1 is R 1 and together with the atoms to which they are attached, a 5- to 6-membered heteroaryl, a 5- to 6-membered heterocyclyl, a phenyl, or C fused to ring A. 5-6 Forming a cycloalkyl; X 1 and R 1 The 5- to 6-membered heteroaryl, 5- to 6-membered heterocyclyl, phenyl, and C 5-6 Cycloalkyl is, independently, one or more R t and optionally substituted with R t is independently, at each occurrence, halo, C 1-15 Alkyl, haloC 1-15 Alkyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3- to 15-membered heterocyclyl, -OH, -CN, oxo, C 1-15 Alkoxy, -NR d C.O.R. e , -CONR d R e , -SO 2 R d , -SO 2 N.R. d R e , -NR d SO 2 R e , and -NR d R e and R d and R e are each independently H or C 1-6 alkyl, R d Or R e The above C 1-6 The alkyl is optionally substituted with one or more substituents selected from halo, oxo, -OH and -CN; X 2 is N or CR s and R s H, halo, C 1-15 Alkyl, Hydroxyl C 1-6 Alkynyl, C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl, 3- to 15-membered heterocyclyl, -OH, -CN, C 1-15 Alkoxy, -NR d C.O.R. e , -CONR d R e , -SO 2 R d , -S(O)NHR d , -SO 2 N.R. d R e , -NR d SO 2 R e , and -NR d R e Selected from: R s The above C 1-15 Alkyl and C 1-15 Each alkoxy is independently one or more R t1 wherein R t1 is independently at each occurrence halo, oxo, —OH, —CN, 5- to 6-membered heteroaryl, or —NR d R e and R d and R e are each independently H or C 1-6 alkyl, R d Or R e The above C 1-6 The alkyl is optionally substituted with one or more substituents selected from halo, oxo, -OH and -CN; and R s The above C 6-20 Aryl, 5-15 membered heteroaryl, C 3-20 Cycloalkyl and 3- to 15-membered heterocyclyl each independently represent one or more R t2 and optionally substituted with R t2 is independently at each occurrence halo, oxo, —OH, —CN, and C 1-6 alkyl; and R d and R e are each independently H or C 1-6 alkyl, R d Or R e The above C 1-6 The alkyl is optionally substituted with one or more substituents selected from halo, oxo, -OH and -CN; X 3 is N or CH; B is, i) phenyl or 5- to 6-membered heteroaryl; the phenyl and 5- to 6-membered heteroaryl of B are each independently one or more R 2 is replaced by R 2 is independently, at each occurrence, halo; S(R y ) 5 and each R y is halo; C optionally substituted with one or more halo 1-6 is alkoxy; or ii) Halo C 1-3 -O-phenyl substituted with alkyl (provided that B is haloC 1-3 When L' is -O-phenyl substituted with alkyl, L' is *-N(R 3 )-L-**, and Z is -C(O)CHCH 2 And X 1 is C and X 2 is CR s And X 3 is CH); or iii) C 1-3 Is it an alkyl-substituted bicyclopentane (where B is C)? 1-3 When L' is an alkyl-substituted bicyclopentane, L' is *-N(R 3 )-L-**, and Z is -C(O)CHCH 2 (provided that the iv) ethynyl or haloC 1-3 phenyl substituted with alkyl (provided that B is ethynyl or haloC 1-3 When L' is phenyl substituted with alkyl, L' is *-N(R 3 )-L-**, and Z is -C(O)CHCH 2 and R s is C substituted with one or more —OH 1-3 provided that it is alkyl; or v) Halo C 1-3 Alkyl or haloC 1-3 alkoxy-substituted piperidine, provided that B is haloC 1-3 Alkyl or haloC 1-3 When L' is an alkoxy-substituted piperidine, L' is *-N(R 3 )-L-**, and Z is -C(O)CHCH 2 (provided that: R 3 is H or C 1-6 is alkyl; Z is -OH, -NR d R e , C 1-6 Alkoxy, -C(O)R a or -S(O) 2 R b and R d and R e are each independently H or C 1-6 alkyl, R d Or R e The above C 1-6 The alkyl is optionally substituted with one or more substituents selected from halo, oxo, -OH and -CN; R a and R b each independently represents: i) deuterium, C 1-6 Alkyl, Hydroxyl C 1-6 Alkyl, halo and haloC 1-6 C optionally substituted with one or more substituents selected from alkyl 2-6 alkenyl; ii) C optionally substituted with one or more halo 1-6 alkyl; or iii) cyclobutenyl or bicyclobutanyl; L is methylene or ethylene, and the methylene of L is one C 1-6 optionally substituted with alkyl; Y is CH or C(CN), and n and m are each independently 1 or 2; However, subject to the following conditions: i) i-1) X 1 R 1 and together with the atom to which they are attached form a phenyl, i-2) X 2 Or X 3 is N, B in formula (II-AB') is phenyl, and R 2 Halo C 1-6 being alkoxyl; and ii) when n=1 and m=2, or n=2 and m=1, B is phenyl substituted with halomethyloxyl; and iii) the compound of formula (II-AB') is not any of the following: N-((8-(4-fluorophenyl)imidazo[1,2-a]pyrazin-6-yl)methyl)acrylamide; N-((8-(4-(trifluoromethoxy)phenyl)imidazo[1,2-a]pyrazin-6-yl)methyl)acrylamide; N-((7-fluoro-4-(4-(trifluoromethoxy)phenyl)quinazolin-2-yl)methyl)acrylamide; N-((8-(4-(difluoromethoxy)phenyl)imidazo[1,2-a]pyrazin-6-yl)methyl)acrylamide; 1-(4-(4-(4-methoxyphenyl)-1-methyl-1H-imidazo[4,5-c]pyridin-6-yl)piperidin-1-yl)ethan-1-one; 4-(4-methoxyphenyl)-1-methyl-6-(1-(methylsulfonyl)piperidin-4-yl)-1H-imidazo[4,5-c]pyridine; 6-(1-(ethylsulfonyl)piperidin-4-yl)-4-(4-methoxyphenyl)-1-methyl-1H-imidazo[4,5-c]pyridine; 6-(1-(ethylsulfonyl)piperidin-4-yl)-1-isopropyl-4-(4-methoxyphenyl)-1H-imidazo[4,5-c]pyridine; 4-(4-methoxyphenyl)-1-methyl-6-(1-((trifluoromethyl)sulfonyl)piperidin-4-yl)-1H-imidazo[4,5-c]pyridine; and N-((4-(4-fluorophenyl)-1,8-naphthyridin-2-yl)methyl)acetamide.
55. The invention as herein above described.
Citation Information
Patent Citations
Fused pyrazole derivatives, methods for their preparation, and their use in the treatment of cancer, inflammation, and immune disorders - Patents.com
JP2019503393A
2-Cyanoisoindoline derivatives for cancer treatment
JP2019508467A
α, β unsaturated amide compound
WO2017111076A1
α, β-unsaturated amide compound
WO2018235926A1
